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Eukaryotic protein translation elongation is tightly controlled by several 
regulation factors. Eukaryotic translation elongation factor 1B (eEF1B) is the GTP 
exchange factor for eukaryotic translation elongation factor 1A (eEF1A), which is a 
G-protein transporting aminoacyl-tRNA to the A site of the ribosome in a GTP 
dependent manner. The structure of the heavy complex composed of eEF1B and 
eEF1A (eEF1H) has been widely studied and several models have been proposed, 
but it is yet not clear how the subunits of the two proteins interact with each other. 
eEF1B is made up of three subunits, eEF1Bα, eEF1Bδ and eEF1Bγ, and each subunit 
has been found to be over expressed in different types of cancer. A copy number 
variant near the eEF1Bδ gene is associated with amyotrophic lateral sclerosis. The 
two isoforms of eEF1A, eEF1A1 and eEF1A2, are 92% identical, but only eEF1A1 
was found to interact with eEF1B subunits in yeast two hybrid (Y2H) experiments. 
The aims of this PhD project are to investigate the potential involvement of eEF1B in 
disease, as well as the relationship between eEF1B and eEF1A2. 
All three eEF1B subunits were present in almost all the cell types and mouse 
tissues tested. eEF1Bδ showed different variants, the heaviest of which is tissue 
specific and expressed only in brain and spinal cord. eEF1Bα and eEF1Bδ showed 
certain abnormalities in transformed cell lines, although in the breast cancer tissues 
tested no apparent change in eEF1B expression was found. Knockdown of eEF1B 
did not significantly affect NSC34 cell viability over short periods. In spinal cord 
sections from motor neurone disease (MND) patients, half of the cases showed a 
change of eEF1B protein expression compared to normal spinal cord, with either a 
higher level in glial cells, or a lower level in motor neurones. 
eEF1B and eEF1A2 were found to be co-expressed in mouse motor neurones, 
and proximity ligation assay also detected physical interactions between both eEF1A 
isoforms and eEF1B subunits in mammalian cells, contrary to the previous Y2H 
study. Experiments in a mouse model with no eEF1A2 expression also support this 
finding. In heart and skeletal muscle from wasted mice where eEF1A is absent the 




level, suggesting that eEF1A2 and eEF1B not only physically interact, but also show 
an interdependence in expression.  
Overall the results from cultured cells, mouse and human tissues in this study 
demonstrate the potential involvement of eEF1B in MND, and its interaction with 
eEF1A, which contributes to the understanding of the non-canonical functions of 




Chapter 1 Introduction 
1. 1 Protein translation 
Protein translation is a stage in gene expression when messenger RNA (mRNA) 
is decoded on the ribosome into specific polypeptides. Protein translation contains 
three steps: initiation, elongation and termination, each of which is precisely 
regulated by a number of factors. 
 
1.1.1 Initiation 
Eukaryotic translation begins with recognition of the initiation site and 
formation of the 48S initiation complex, which is a stepwise process and regulated 
by many initiation factors (eIFs). The first step of initiation is the formation of the 
43S preinitiation complex consisting of the small (40S) ribosomal subunit, initiator 
tRNA (Met-tRNAiMet), eIF2 and GTP. To make the 40S ribosomal subunit vacant, 
the ribosome must be dissociated, which is thought to be promoted by eIF3 and 
eIF1A. eIF2, with eIF2B as the guanine nucleotide exchange factor (GEF), binds 
Met-tRNAiMet and GTP jointly to form a ternary complex, which then binds the 40S 
subunit aided by eIF1, eIF1A and eIF3, thus the 43S preinitiation complex is formed. 
The next step is the preinitiation complex binding to the 5’ cap of the mRNA, 
which is mediated by eIF4F, eIF4B, eIF3. eIF4F is a heterotrimeric complex 
comprising three subunits: eIF4E, which is a cap binding protein; eIF4G, which 
serves as a scaffold for other components and contains binding sites for eIF4E, 
PABP, and, at least in mammalian cells, for eIF4A,  RNA and eIF3; and eIF4A, the 
ATP-dependent RNA helicase. The eIF4F/4A/4B complex cooperatively unwinds the 
cap-proximal region of mRNA, to allow the 43S complex to bind. 
After binding to the 5’ end of the mRNA, the 43S preinitiation complex starts 




of eIF1. eIF1 also induces conformational change of the 43S complex, from ‘closed’ 
to ‘open’ state, as suggested by Pestova and Kolupaeva (Pestova and Kolupaeva 
2002). Other factors including eIFA, eIF4A, eIF4B and eIF4F are also involved in 
the scanning, although they may have complementary roles. This “scanning mode” is 
the most common approach to recognise initiation sites in eukaryotic cells.  
In rare cases, a 5’ cap-independent mechanism is used whereby the 40S 
ribosomal subunit binds to an internal ribosome entry site (IRES) on the mRNA at or 
just upstream of the initiation codon directly without scanning from the 5’ end cap, 
independent of eIF4E. 
Once the initiation codon on the mRNA is recognised and its codon/anticodon 
interaction with the Met-tRNAiMet is established, another initiation factor, eIF5, 
activates the GTPase centre in eIF2. The GTP hydrolysis on eIF2 induces the release 
of eIF2 and possibly other initiation factors off the ribosomal complex, so that the 
large (60S) ribosomal subunit can bind the 40S to assemble a complete (80S) 
ribosome. A different GTPase initiation factor, eIF5B, is required for this last step in 
initiation, but the GTP hydrolysis occurs after the formation of the 80S ribosome, 
indicating that it serves as a final checkpoint for correct 80S ribosome assembly 
rather than having a mechanical role. 
 
1.1.2 Elongation 
During translation elongation, the aminoacyl-tRNA (aa-tRNA) is delivered to 
the A-site of the ribosome to join the peptide under formation. In eukaryotic cells, 
protein translation elongation is mediated by elongation factors (EFs), eEF1 and 
eEF2. eEF1 includes eEF1A, the GTP-binding protein, and eEF1B, the GEF for 
eEF1A, which will be discussed in detail in the following sections. eEF1 transports 
aa-tRNA and eEF2 promotes the GTP-dependent translocation of the peptide chain 




eEF1A, together with GTP as a complex, carries an aa-tRNA to the A-site of 
the ribosome. After decoding between the mRNA and the tRNA and conformational 
change in the decoding centre of the ribosome, only the cognate tRNA is permitted to 
enter the following steps and the GTP hydrolysis is activated. eEF1A•GDP is 
released and recycled to the GTP-binding form, and the cognate aa-tRNA is located 
in the A-site of the ribosome. The next step is to form a peptide bond between the 
amino acid and the peptidyl-tRNA, catalyzed by the peptidyl transferase center in the 
ribosome. The previous peptidyl-tRNA is deacylated and the previous aa-tRNA is 
bound to the nascent peptide chain, then both the deacylated tRNA and the peptidyl-
tRNA are translocated by eEF2 to the E-site and the P-site of the ribosome 
respectively, and the mRNA is also moved by three amino acid so that the next 
codon is presented near the A-site of the ribosome for the next cycle of the above 
process (Figure 1.1). 
Elongation factors are highly conserved among different species and may be 
involved in other cellular activities apart from protein synthesis, such as the cell 
cycle control, signal transduction, cytoskeleton regulation and stress response.  
 
1.1.3 Termination 
When the ribosome reaches a stop codon, translation termination is triggered. 
The completion of termination requires release factors (RFs). There exist two classes 
of RFs in both prokaryotes and eukaryotes. Class I are codon specific RFs which 
recognize a stop codon and promote peptide chain release; class II are non-specific 
RFs which stimulate the activity of class I RFs. In eukaryotic cells, each class of RFs 
contains only one eukaryotic RF (eRF): eRF1 belongs to class I, and eRF3, class II. 
eRF1 has an omnipotent decoding capacity of all three termination codons, UAA, 
UAG and UGA.  
Once a stop codon presented in the A site of the ribosome is decoded by eRF1, 




peptidyl transferase center of the ribosome, and the consequent release of the nascent 
peptide chain is triggered. eRF1 and eRF3 function as a complex, with eRF1 as a 
GTP-dissociation inhibitor, which promotes the GTP-binding to eRF3, and eRF3 
stimulates the activity of eRF1 and enhances the peptide release by eRF1 in the 
presence of GTP. 
Ultimately the completed polypeptide is released from the tRNA and the tRNA 
is released from the ribosome. 
 
1.1.4 Regulation of protein translation 
In eukaryotic cells, gene expression is strictly regulated at several different 
levels, such as modification of DNA, transcriptional regulation controlling the 
transcription of DNA to RNA, posttranscriptional regulation modulating the 
modification of the mRNA, and translational regulation monitoring the translation 
process of mRNA to protein.  
The regulation of protein translation steps is usually mediated by modifying 
translation factors. For example, eIF4E can be bound by inhibitory proteins and 
therefore hinders the binding of mRNA. Phosphorylation of eEF1 (discussed in detail 
in section 1.3.5) or eEF2 (Sivan, Kedersha et al. 2007) by certain kinases could 
upregulate or downregulate protein translation. Protein translation could also be 
regulated through modifications, including phosphorylation, ubiquitination and 
methylation, of certain protein components of the ribosome. 
The structure of the mRNA could affect translation efficiency as well. For 
example, mRNA with high secondary structures and thermal stability at the 5’ 
untranslated region (UTR) showed more dependence on initiation factors, therefore 
affected the ribosome recruitment as well as the scanning (De Benedetti and Graff, 
2004). The initiation factor dependence of the mRNA could also be affected by the 




Micro RNAs (miRNAs) are a group of shortRNA molecules found in 
eukaryotic cells. miRNAs have been identified to act as regulators of mRNA stability 
and translation, by repressing translation at the initiation or postinitiation step, or 
triggering the deadenylation and subsequent degradation of the mRNA (reviewed in 
Fabian, Sonenberg, et al. 2010). 
After translation, the nascent polypeptide is under posttranslational regulation. 
Proteins need to undergo certain modifications to be functionally activated, including 
addition of other proteins, methylation, glycosylation, removal of certain amino acids, 
or conformational change. Lipidation is crucial for locating the membrane proteins. 
Phosphorylation is a common mechanism to active or inactive a protein instantly, 










Figure 1.1 A schematic diagram of protein translation elongation in eukaryotic 
cells (adapted from Schneider-Poetsch, Usui et al. 2010). E, P and A. The E-, P- and 
A-site on the ribosome. Phe- and Met-. Two examples of aminoacyl-tRNA. eEF1A 
(1A) delivers aminoacyl-tRNA to the A-site of the ribosome based on the interaction 
between the mRNA codon exposed on the A-site and the anticodon on the tRNA, and 
is then released from the ribosome. eEF2 translocates the peptidyl-tRNA to the P-site 
and the deacylated tRNA to the E-site, so that the A-site of the ribosome is vacated 




1. 2 Eukaryotic translation elongation factor 1A 
eEF1A is equivalent to the bacterial elongation factor thermo unstable (EF-Tu) 
(Amons, Pluijms et al. 1983). eEF1A is a GTP binding protein, which transports 
aminoacyl-tRNA to the A site of ribosome in a GTP-dependent manner, catalysed by 
its GEF, eEF1B.  
eEF1A is encoded by various genes in different species. Lower eukaryotes 
such as S. cerevisiae contain at least two genes encoding for the same eEF1A protein, 
while mammals have two isoforms for eEF1A encoded by separate genes, eEF1A1 
and eEF1A2. The two eEF1A isoforms are 92% identical and share the same 
function in translation elongation (Ann, Moutsatsos et al. 1991), but they have very 
different expression patterns. It has been observed in mice that during early 
development eEF1A1 is expressed ubiquitously but starts to decrease in skeletal 
muscle, heart and neurons postnatally until eEF1A2 takes its place in these tissues 
and cells. As a result, in adult tissues eEF1A1 and eEF1A2 are exclusively expressed, 
and the tissues where eEF1A2 is expressed contains mostly cells fully differentiated 
and characterised by very little or no cell division (Lee, Francoeur et al. 1992; 
Khalyfa, Bourbeau et al. 2001; Newbery, Loh et al. 2007). 
eEF1A1 and eEF1A2 showed equal activities and GTP hydrolysis rates in 
translation assays in vivo and in vitro. Interestingly, when their affinities to GDP and 
GTP were examined, eEF1A1 bound GDP and GTP with about equal affinity, while 
eEF1A2 showed stronger affinity for GDP than to GTP (Kahns, Lund et al. 1998), 
hence eEF1A2 was thought to be more dependent on a GEF than eEF1A1 was. 
However a Y2H study found no interaction between eEF1A2 and any of the eEF1B 
subunit (Mansilla, Friis et al. 2002). 
eEF1A has non-canonical functions other than its roles in translation, including 
roles in cytoskeleton regulation, apoptosis, stress response and protein degradation 




oncogene as it is overexpressed inappropriately in a number of cancers (reviewed in 
Lee and Surh 2009). On the other hand, loss of eEF1A2 expression in the motor 




1.3 Eukaryotic Translation elongation factor 1B 
eEF1B is a macromolecular complex stimulating the GDP-GTP exchange on 
eEF1A. In lower eukaryotes eEF1B contains a guanine nucleotide exchange subunit 
eEF1Bα and a structural subunit eEF1Bγ, while higher eukaryotic cells have another 
guanine nucleotide exchange subunit eEF1Bδ. Other nomenclatures have been used 
for eEF1B components during a long period of research, and the nomenclature used 
in this thesis is the one proposed by Le Sourd et al in 2006 (Le Sourd, Boulben et al. 
2006), as listed in Table 1.1. 
 





EEF1B2 eEF1Bα eEF1β 24-28kD 
EEF1D eEF1Bδ eEF1Bβ, eEF1δ 32-36kD 
EEF1G eEF1Bγ eEF1γ 47-52kD 
 
1.3.1 eEF1Bα 
eEF1Bα is the lightest subunit of eEF1B complex, which is equivalent of 
bacterial elongation factor thermo stable (EF-Ts), and has guanine nucleotide 
exchange activity. The gene encoding eEF1Bα was mapped to human chromosome 2 
(EEF1B2). Other loci for eEF1Bα mapped to human chromosome 15 (EEF1B1), 5 
(EEF1B3) and X (EEF1B4) are most probably correspond to tissue specific 
intronless paralogues or pseudogenes (Chambers, Rouleau et al. 2001). 
eEF1Bα is conserved among eukaryotic species. The C-terminal domain of 
eEF1Bα is considered to be necessary and sufficient for its GEF activity (Perez, 
Kriek et al. 1998), and responsible for the interaction between eEF1Bα and eEF1A, 
while the N-terminal domain is involved in its binding to the N-terminal domain of 
eEF1Bγ (van Damme, Amons et al. 1991). 




The main function of eEF1Bα is to mediate the nucleotide exchange for eEF1A. 
It has been found essential for cell growth in yeast (Hiraga, Suzuki et al. 1993), and 
mutation of yeast eEF1Bα enhances translation fidelity with a lower translational 
efficiency (Carr-Schmid, Valente et al. 1999).  It is assumed that eEF1Bα helps 
nucleotide exchange in eEF1A by disrupting interactions between GDP with the P-
loop and switch regions of eEF1A (Pittman, Valente et al. 2006). 
 
1.3.2 eEF1Bδ 
eEF1Bδ is the metazoan-specific subunit of eEF1B. The human eEF1Bδ gene 
is mapped to chromosome 8 which is transcribed to into two mRNAs by alternative 
splicing.  
The C-terminus of eEF1Bδ is homologous with eEF1Bα (Guerrucci, Monnier 
et al. 1999) and contains the nucleotide exchange activity. However, a study found 
that eEF1Bδ dissociated GDP from eEF1A•[3H]GDP in vitro at the same rate as 
eEF1Bα did only in the first minute of the reaction, then the nucleotide exchange rate 
in the system with eEF1Bδ became the same as the one without any GEF. In addition, 
while the presence of eEF1Bγ stimulated the nucleotide exchange activity of eEF1Bα, 
it did not affect the GDP dissociation catalyzed by eEF1Bδ (Bec, Kerjan et al. 1994). 
 The N-terminal domain of eEF1Bδ has a leucine zipper motif (Morales, 
Cormier et al. 1992), indicating possible binding of other proteins, but this motif is 
not involved in the polymerization of eEF1Bδ monomers (Sheu and Traugh 1997), 
and the N-terminal domain is not sufficient for the dimerization of eEF1Bδ (Mansilla, 
Friis et al. 2002).  
eEF1Bδ has been found to exist as different isoforms resulting from alternative 
splicing. Two isoforms with close MW have been discovered in Xenopus laevis 
oocytes (Mulner-Lorillon, Minella et al. 1994; Minella, Mulner-Lorillon et al. 1996), 




mRNAs, differing by the existence of a 78-base stretch inserted in the open reading 
frame (ORF), in front of the leucine zipper-encoding sequence. As a result, the two 
isoforms of eEF1Bδ protein have similar MWs and migration patterns on SDS-
PAGE, showing two bands on Western blots that are close to each other.  
Recent studies have identified another isoform for eEF1Bδ protein, which is 
around 70-80kD, namely eEF1BδL. The mRNA encoding eEF1BδL contains an 
extra exon, exon 3, which is skipped in the mRNA transcripts of other isoforms. Up 
to now little is known about the significance of eEF1BδL, except that it is tissue 
specific, expressed only in brain, spinal cord and testis (Kaitsuka, Tomizawa et al. 
2011), which is in line with the results obtained by our lab (Miriam Portela, PhD 
thesis, 2008). It was also demonstrated that the expression of eEF1BδL in brain 
started from embryonic day 15 (Kaitsuka, Tomizawa et al. 2011). However, when 
the expression pattern of eEF1Bδ protein was examined in different cell lines, 
Kaitsuka and colleagues reported the expression of eEF1BδL in HeLa and Hek293 
cell lines, while in our lab the same antibody detected eEF1BδL expression only in 
neuronal cell lines such as NSC34, SHSy5Y and Lan5, but not HeLa or Hek293 
(Miriam Portela, PhD thesis, 2008). 
 
1.3.3 eEF1Bγ 
eEF1Bγ is the eukaryotic specific subunit of eEF1B, the gene of which has 
been mapped to human chromosome 11. The N-terminal domain of eEF1Bγ contains 
a homologue to the theta class of glutathione S-transferases (GSTs) (Jeppesen, Ortiz 
et al. 2003), which will be discussed later. 
The role of eEF1Bγ in translation elongation is not well understood yet. 
eEF1Bγ is usually found tightly associated with eEF1Bα and it can be isolated from 
eEF1Bα only under strong denaturing conditions. Research on Artemia showed that 




eEF1Bα alone, indicating that eEF1Bγ is possibly a catalyst for eEF1Bα. eEF1Bγ is 
also likely to be involved in directing other subunits in the eEF1B complex (Janssen 
and Moller 1988) and to play a role in scaffolding for the eEF1B complex  (Le Sourd, 
Boulben et al. 2006) as it is highly associated with membrane and cytoskeleton 
structures which is further discussed in section 1.4.2 of this thesis.  
 
1.3.4 The eEF1B Complex 
Although the components of eEF1B are now clear, and eEF1B is considered to 
form a reversible macro complex with eEF1A (eEF1H) to mediate the guanine 
nucleotide exchange on eEF1A, yet how the three subunits of eEF1B combine 
together and how they interact with eEF1A remain unknown. The components of 
eEF1H have been studied in various species by different groups and several 
structural models have been proposed, as shown in Figure 1.2. However, there is 
much inconsistency among these models. 
The first structure model proposed was by G Bec and colleagues, based on in 
vitro reconstitution experiments using different combinations of the subunits purified 
from rabbit liver, as well as published information about eEF1H subunits from 
Artemia by other groups (Bec, Kerjan et al. 1994). They suggested a protomer 
composed of valyl-tRNA and eEF1H, which were associated through eEF1Bδ. Two 
such protomers could bind to each other via the leucine zipper motif on the N-
terminus of two eEF1Bδ subunits (Figure 1.2 A).   
Later in the same year a paper studying Artemia had different findings (Janssen, 
van Damme et al. 1994), and suggested a structure model wherein eEF1Bγ binds to 
both eEF1Bα and eEF1Bδ, each of which binds to a eEF1A subunit (Figure 1.2 B). 
O Minella et al. proposed a model (Figure 1.2 C) for Xenopus eEF1H based on 
results from the analysis of native complexes instead of reconstitution experiments 




The model proposed by GT Sheu and colleagues suggests the existence of 
eEF1Bγ dimers (Sheu and Traugh 1999). The major difference between this model 
and others is that each eEF1Bγ subunit binds to one eEF1Bα or eEF1Bδ subunit, not 
both (Figure 1.2 D). 
Another model (Figure 1.2 F) was proposed by Jiang et al (Jiang, Wolfe et al. 
2005) according to three-dimensional research. This model, without information of 
the binding regions on each subunit, is in line with the one proposed by Bec et al in 
1994, supporting the hypothesis of eEF1Bδ dimer being a core in the complex. 
While eEF1A has two isoforms, none of the models above has taken the two 
isoforms of eEF1A into account. Mansilla and colleagues identified an interaction 
between eEF1B and eEF1A1 but not eEF1A2 based on a series of Y2H experiments, 
and therefore suggested a model of eEF1H containing eEF1A1 but not eEF1A2 
(Mansilla, Friis et al. 2002). The model (Figure 1.2 E) is similar to the one proposed 
by Janssen et al, except that it suggests the potential of dimerizing of eEF1B via the 
eFE1Bδ subunit. 
Although the above models are different from each other, which is very likely 
to be caused by the different techniques used in different groups, there are some 
points that seem to be less controversial among all the models. Firstly, it is believed 
that eEF1Bα and eEF1Bγ are tightly associated and can only be separated under 
denaturing conditions (Bec and Waller 1989). Secondly, eEF1Bα and eEF1Bδ 
showed no affinity for each other. Finally, the binding sites of eEF1Bα and eEF1Bδ 
to eEF1Bγ locate on the N-terminus of the three proteins, while the C-terminus of 





Figure 1.2 Schematic models of eEF1B interacting with eEF1A and/or ValRS proposed 
by Bec, Kerjan et al. 1994 (A), Janssen, van Damme et al. 1994 (B), Minella, Mulner-
Lorillon et al. 1998 (C), Sheu and Traugh 1999 (D), Mansilla, Friis et al. 2002 (E) and 
Jiang, Wolfe et al. 2005 (F). α, δ, γ, 1A1 and ValRS represent eEF1Bα, eEF1Bδ, eEF1Bγ, 
eEF1A1 and ValRS respectively. N and C represent N-terminus and C-terminus of the 
























































1.3.5 Regulation of eEF1B by phosphorylation 
Phosphorylation by protein kinases is a major way to modulate protein and 
cellular activities, and eEF1B subunits have been shown to be phosphorylated in vivo 
and in vitro by different protein kinases, mainly on the serine or threonine residues. 
eEF1Bα and eEF1Bδ, together with ValRS and eEF1A, are phosphorylated by 
protein kinase C (PKC) in response to the stimulation of hormones such as 4P-
phorbol 12-myristate 13-acetate (PMA) in rabbit reticulocytes; this stimulated 
elongation activity up to threefold both in vitro and in vivo (Venema, Peters et al. 
1991). It is then found that this phosphorylation by PKC of eEF1Bα and eEF1Bδ 
increased the rate of nucleotide exchange and of Phe-tRNA binding to ribosomes, 
and thus stimulated elongation activity (Peters, Chang et al. 1995).  
Insulin stimulation resulted in phosphorylation of eEF1A, eEF1Bα and eEF1Bδ, 
but not eEF1Bγ, by multipotential S6 kinase, leading to 2 to 2.5 fold stimulation of 
elongation activity in 3T3 cells (Chang and Traugh 1997; Chang and Traugh 1998). 
Furthermore, HeLa cells treated with paclitaxel showed an elevated phosphorylation 
on eEF1Bγ while the protein level was not affected (Prado, Casado et al. 2007). 
eEF1Bγ can be phosphorylated in vitro by Darkener of apricot (DOA) kinase in 
Drosophila. DOA is a member of the LAMMER family, a protein kinase family in 
higher eukaryotes characterized by a EHLAMMERILG motif (Yun, Farkas et al. 
1994), which is essential for their kinase activity (Savaldi-Goldstein, Sessa et al. 
2000). The phosphorylation site for DOA is located on S294 in the C-terminus of 
eEF1Bγ, which is considered essential for its activity (Fan, Schlierf et al. 2010). 
eEF1Bδ and eEF1Bγ have been found to be substrates for cyclin-dependent 
kinases (CDK) 1 during the maturation of Xenopus oocytes (Belle, Derancourt et al. 
1989; Mulner-Lorillon, Poulhe et al. 1989; Janssen, Morales et al. 1991). In vitro 




(Kawaguchi, Kato et al. 2003) and T230 (Mulner-Lorillon, Cormier et al. 1992) 
respectively. This phosphorylation does not affect the guanine nucleotide exchange 
rate for the complex, but decreases the elongation rate of valine while increasing the 
synthesis rate of serine and phenylalanine (Monnier, Belle et al. 2001). The 
phosophorylation of S133 of eEF1Bδ by CDK1 during mitosis in HeLa cells, 
however, results in induction of the affinity of eEF1Bδ to eEF1A, leading to a lower 
guanine nucleotide change activity and subsequently slower translation (Sivan, 
Aviner et al. 2011). 
eEF1Bα from Artemia can be phosphorylated on S89 by a casein kinase (CKII) 
-like protein kinase, and the phosphorylation inhibits the guanine nucleotide 
exchange activity of  eEF1Bα (Janssen, Maessen et al. 1988).   
eEF1Bα from Artemia, wheat germ embryos and rabbit is phosphorylated by 
CKII (Palen, Huang et al. 1990; Palen, Venema et al. 1994; Chen and Traugh 1995). 
The sites for CKII phosphorylation of recombinant rabbit eEF1Bα expressed in E. 
coli have been identified as S106 and S112 (Chen and Traugh 1995). CKII also 
phosphorylates eEF1Bδ (Palen, Venema et al. 1994), on S162 of tagged eEF1Bδ in 
HeLa cells, and phosphorylation of endogenous eEF1Bδ was also detected by the 
phosphor-specific S162 antibody (Gyenis, Duncan et al. 2011). In the native eEF1H 
complex eEF1Bα and eEF1Bδ are phosphorylated by CKII only in the presence of 
GDP (Palen, Venema et al. 1994), suggesting that the phosphorylation of eEF1Bα 
and eEF1Bδ by CKII happens when eEF1A•GDP is associated with eEF1B complex. 
In cells infected with viruses, eEF1Bδ can be phosphorylated by viral protein 
kinases, suggesting that the modification of eEF1Bδ by viral protein kinases may be 
a way for viruses to regulate their protein synthesis and replication. The viral 
proteins kinases leading to eEF1Bδ phosphorylation include UL13 encoded by herpes 
simplex virus 1 (HSV-1) (Kawaguchi, Van Sant et al. 1998), UL97 of human 
cytomegalovirus (Kawaguchi, Matsumura et al. 1999), and BGLF4 of Epstein-Barr 




viral protein kinases share the same phosphorylation site with cellular kinase CDK1 
(Kawaguchi and Kato 2003).  
 
 
Kinases Effect on translation 
Subunits phosphorylated 
(sites if known) 
PKC Upregulation eEF1Bα 
eEF1Bδ 
CDK1 Possible downregulation eEF1Bδ  (S133) 
eEF1Bγ  (T230) 
CKII No effect eEF1Bα  (S106, S112) 
eEF1Bδ  (S162) 





DOA kinase Unknown eEF1Bγ  (S294) 
Table 1.2. Phosphorylation of eEF1B subunits by cellular protein kinases and their 




1.4 The functions of eEF1B  
1.4.1 eEF1B and the cell cycle control 
The cell cycle is controlled mainly through CDKs (reviewed in Murray 2004), 
which are regulated by cyclical proteolysis of cyclins by phosphorylation cascades. 
As discussed in section 1.3.5 eEF1B subunits are regulated by kinases that are 
involved in the cell cycle, including CDK1 and PKC, and the phosphorylation of 
eEF1B subunits by some kinases coincide with the reduced protein synthesis activity 
during mitosis. In addition, other lines of evidences also suggest that eEF1B plays a 
role in cell cycle control.  
The two proteins, CF51 and CF32, which were found to be enriched in the 
cleavage furrow (CF) isolated from dividing sea urchin eggs have been identified as 
eEF1A and eEF1Bα respectively, and eEF1Bα regulates the actin bundling activity 
of eEF1A, which is important to maintain the structure of the contractile ring during 
cytokinesis (Fujimoto and Mabuchi 2010). 
During the first mitotic cell cycle in sea urchin embryos, the subcellular 
location of eEF1Bδ changes in a cell cycle specific manner although the total 
expression level does not change. At the time of nuclear envelope breakdown during 
mitosis, a fraction of eEF1Bδ concentrates around the nucleus and later forms two 
large spheres around the mitotic spindle poles, suggesting a link between eEF1Bδ 
and cell cycle regulation (Boulben, Monnier et al. 2003). In HeLa cells undergoing 
mitosis, the two shorter isoforms of endogenous eEF1Bδ protein change their 
intensities around the M-phase, with a shift of the lower to the upper band (Sivan, 
Aviner et al. 2011), indicating a cell cycle dependent alternative splicing of eEF1Bδ 
mRNA.  
Human squamous carcinoma cells SCC-35 exposed to ionizing radiation 




role of eEF1Bδ in cell cycle dependent response to DNA damage (Jung, Kondratyev 




1.4.2 eEF1B and the cytoskeleton 
The cytoskeleton in eukaryotic cells includes actin filaments, microtubules and 
intermediate filaments, each of which has been found to be associated with different 
subunits of eEF1B, suggesting the roles of eEF1B and the regulation of cytoskeleton 
may be closely related. 
A 17 kD fragment of Dictyostelium discoideum eEF1Bα was found to associate 
with actin in vitro, and recombinant Dictyostelium discoideum eEF1Bα expressed in 
E. coli stimulates the assembly of actin (Furukawa, Jinks et al. 2001), whereas 
eEF1Bα and actin extracted from sea urchin eggs show no affinity to each other 
(Fujimoto and Mabuchi 2010). One group suggested that eEF1Bα balances the roles 
of eEF1A between translation and actin organization by competing with actin for the 
binding site on eEF1A (Pittman, Kandl et al. 2009), while another group found that 
eEF1Bα disrupts the eEF1A-induced actin bundling by promoting guanine 
nucleotide change on eEF1A (Fujimoto and Mabuchi 2010). Nevertheless, the 
observation that eEF1Bα disrupts eFE1A-induced actin bundling may to some extent 
explain the observation that eEF1Bα stimulates the rate of actin assembly in a 
concentration dependent negative manner (Furukawa, Jinks et al. 2001). However, 
the same report found that unlike eEF1Bα alone, the intact eEF1Bα:eEF1Bγ complex 
stimulated actin assembly in a concentration dependent manner (Furukawa, Jinks et 
al. 2001), indicating eEF1Bγ is likely to play a role in actin assembly. 
Microtubules are also found associated with eEF1B. eEF1Bα and eEF1Bγ are 
often associated with tubulin in Artemia, and under non-denaturing conditions 
eEF1Bγ coprecipitated with tubulin (Janssen and Moller 1988).  
Kinectin is a microtubule-dependent membrane anchor, and eEF1Bδ has been 
found to interact with kinectin both in vivo and in vitro. Overexpression of kinectin 
fragments in vivo disrupts the subcellular localization of eEF1Bδ but not the ER 




(Ong, Er et al. 2003). Interruption of kinectin binding to eEF1Bδ decreases the 
expression of membrane protein but enhances cytosolic protein expression, showing 
that the binding of eEF1B to certain cytoskeleton components regulates protein 
synthesis. The other two subunits of eEF1B have been found not to interact with 
kinectin in Y2H and coIP experiments (Ong, Lin et al. 2006). 
During mitosis of fertilized sea urchin eggs, eEF1Bδ showed a localization 
change as described earlier in last section. It is found that eEF1Bδ is co-localized 
with the astral microtubules but not the spindle microtubules at metaphase, anaphase 
and telophase, and the distribution of eEF1Bδ during mitosis proved to be dependent 
on microtubules (Boulben, Monnier et al. 2003). 
eEF1Bγ is usually considered as a scaffold subunit for the eEF1B complex, as 
it has no guanine nucleotide exchange activity, and the deletion of eEF1Bγ in S. 
cerevisiae does not affect protein synthesis or translation fidelity in vivo (Olarewaju, 
Ortiz et al. 2004). However, disruption of eEF1Bγ binding to keratin, which is an 
intermediate filament of the cytoskeleton, leads to decreased protein translation in 
human epithelial cells (Kim, Wong et al. 2006; Kim, Kellner et al. 2007).  
 
1.4.3 eEF1B and the stress response 
Stress conditions include radiation, temperature changes, exposure to drugs or 
toxins, oxidative stress, hypoxia and nutrient limitation. Cells exposed to stress 
conditions express stress response genes in order to adapt to the circumstances. 
Translation factors have been reported to be involved in response to different types 
of stress conditions, and the roles of initiation factors in stress response is reviewed 




Proteomic studies identified eEF1Bα and eEF1Bδ as potential candidates that 
respond to heat shock and may be involved in heat shock signalling pathways in RIF-
1 cells whether they are thermotolerant or not (Kim, Song et al. 2002).  
eEF1Bα is down regulated in MCF, HCT116 and H460 cell lines exposed to 
ionizing radiation (IR) (Byun, Han et al. 2009). The down regulation of eEF1Bα has 
been also observed at both mRNA and protein levels in rice after heat shock (Lin, 
Chang et al. 2005). The RNA-binding protein TIAR suppresses translation in RKO 
cells in response to low levels of short-wavelength UV (UVC), by binding to the 3’ 
UTR of the mRNAs of eEF1Bα, as well as eIF4A, eIF4E, but not eEF1Bδ or eEF1Bγ 
(Mazan-Mamczarz, Lal et al. 2006).  
In S. cerevisiae exposure to H2O2 also causes down regulation of eEF1Bα 
(Godon, Lagniel et al. 1998). Moreover, H2O2 in S. cerevisiae leads to protein S-
thiolation of eEF1Bα in response to oxidative stress (Shenton and Grant 2003), and 
loss of eEF1Bα results in great resistance to CdSO4 (Olarewaju, Ortiz et al. 2004).  
Unlike eEF1Bα, which is down regulated in response to ionizing radiation, in 
SCC-35 cells exposed to the same radiation eEF1Bδ has been found upregulated 
(Jung, Kondratyev et al. 1994). eEF1Bδ is also upregulated in 3T3 cells transformed 
by cadmium (Joseph, Lei et al. 2002), and in mouse hippocampal HT22 cells treated 
with ochratoxin A (OTA) (Yoon, Cong et al. 2009). Furthermore, eEF1Bδ is over 
expressed in human melanoma cell line MeWo exhibiting chemoresistance towards 
antineoplastic drugs, such as vindesine, cisplatin, fotemstine and etoposide (Sinha, 
Kohl et al. 2000). 
While the significance of a tissue specific isoform of eEF1Bδ is unclear, a 
recent study (Kaitsuka, Tomizawa et al. 2011) found that tissue-specific alternative 
splicing is probably a way to coordinate the roles of eEF1Bδ in translation and in 
heat shock response. Heat shock in Hek293 cells leads to the upregulation of 
eEF1BδL and downregulation of the shorter eEF1Bδ isoforms, and eEF1BδL has 




induced by heat shock transcription factor (HSF) 1. Again as mentioned earlier, it 
should be pointed out that the cell lines used in this research, HeLa and HEK293 
cells, did not show eEF1BδL expression in this thesis although the same antibody 
was used. Nevertheless, eEF1A1 has been reported to be involved in the activation 
HSF1 upon heat shock (Kugel and Goodrich 2006; Shamovsky, Ivannikov et al. 
2006). HSF1 exists as monomers and is inactive in cells under normal conditions, but 
is trimerized and activated in response to heat shock. Activated HSF1 is localized in 
the nucleus and binds to HSEs in the promoters of genes upregulated in heat shock 
response, inducing the expression of heat-shock proteins (HSPs) and other 
cytoprotective proteins. The association of eEF1A with HSF1 has been identified in 
mammalian cell extracts, which was enhanced by heat shock. It is suggested that 
eEF1A1, together with heat shock RNA (HSR) 1, regulates the trimerization and 
trigger the activation of HSF1 (Shamovsky, Ivannikov et al. 2006). eEF1A2, the 
eEF1A isoform in motor neurons, does not have the same function as eEF1A1 in the 
heat shock response (Lowri Griffiths, PhD thesis, 2011). On the other hand, 
eEF1BδL, even though its expression may not be restricted in motor neurons only, 
induces the expression of HSE-containing genes in cooperation with HSF1 but not 
via the activation of HSF1 (Kaitsuka, Tomizawa et al. 2011). These findings are in 
line with previous report of the poor heat shock response in motor neurons due to 
failure of HSF1 activation (Batulan, Shinder et al. 2003).  
The third subunit, eEF1Bγ, plays an important role in the oxidative stress 
response. The N-terminus of eEF1Bγ has a similar structure to the theta-class of 
GSTs (Koonin, Mushegian et al. 1994), which is important for cellular detoxification 
of reactive oxygen species (ROS). Whether the GST-like domain of eEF1Bγ contains 
full GST activity is still to be determined. Rice recombinant eEF1Bγ and the eEF1B 
complex both show a low GST activity (Kobayashi, Kidou et al. 2001). eEF1B from 
Leishmania major is able to conjugate a variety of electrophilic substrates to 
trypanothione which is a substrate similar to glutathione (Vickers, Wyllie et al. 2004). 




lipophilic compounds. Overexpression of eEF1Bγ in parasite Trypanosoma cruzi 
leads to the resistance of clomipramine and antidepressant drug (Billaut-Mulot, 
Fernandez-Gomez et al. 1997).  
In S. cerevisiae eEF1Bγ is encoded by two genes, TEF3 and TEF4 (Kinzy, 
Ripmaster et al. 1994). Deletion of both genes does not affect cell viability, but 
resultes in the resistance to oxidative stress of CdSO4 and H2O2 in S. cerevisiae 
(Olarewaju, Ortiz et al. 2004). Further studies found that strains lacking eEF1Bγ 
show an increased level of oxidized proteins, and defects in protein turnover and the 
vacuolar functions in response to oxidative damage (Esposito and Kinzy 2010). 
Moreover, TEF3-encoded protein regulates methionine sulfoxide reductase A (msrA), 
which plays an important role in the adaptive response of yeast to oxidative stress, by 
binding to its promoter (Hanbauer, Boja et al. 2003).  
1.4.4 eEF1B and diseases 
1.4.4.1 eEF1B and cancer 
Protein synthesis is crucial for cells to maintain normal activity. Alteration of 
the expression level of certain proteins, including activation or upregulation of 
oncogenes and/or inactivation or downregulation of tumour suppressor genes, is a 
common feature of transformation and tumourigenesis. There are many reports on 
the changed expression level of the initiation factors (reviewed in Silvera, Formenti 
et al. 2010) and eEF1A in cancers (reviewed in Lamberti, Caraglia et al. 2004; Lee 
and Surh 2009). Similarly, the enhanced expression of at least one of eEF1B subunits 
in various cancers has also been reported. 
eEF1Bα 
eEF1Bα mRNA is found to be 20 times higher in transformed cultured rat 
kidney cells than normal rat tissue (Sanders, Maassen et al. 1992). Another report of 
eEF1Bα overexpression in cancer is in breast cancer. eEF1Bα mRNA in breast 




non-transformed breast epithelial cell line MCF-10A, demonstrated by Northern blot 
analysis. The same study also shows by RT-PCR a significant increase of eEF1Bα 
mRNA in breast cancer tissue over that in normal or fibroadenoma tissues, with a 
eEF1Bα/GAPDH ratio of 0.45 in cancer tissues and 0.12 in controls, although no 
difference was observed between different tumour grades (Al-Maghrebi, Anim et al. 
2005).  
eEF1Bα protein showed 1.33 fold upregulation in the high (PC3M-LN4) over 
low (PC3M)  metastatic prostate cancer cells (Everley, Krijgsveld et al. 2004). 
eEF1Bδ 
Compared to the other two subunits, the study of eEF1Bδ expression in cancer 
is more extensive.  
A study examining 10 human cancer cell lines derived from different tissues 
revealed that compared to their corresponding control cell lines, eEF1Bδ mRNA is 
overexpressed in primary ductal carcinoma cell line HCC1395, breast carcinoma cell 
lines T-47D, MCF-7, MDA-MB-361 and MDA-MB-453, but not in breast carcinoma 
cell line DU 4475 (Joseph, O'Kernick et al. 2004). Other studies also reported 
eEF1Bδ overexpression in cell lines derived from breast cancer (Jacob, Kandpal et al. 
1996). Overexpression of eEF1Bδ protein has been identified in medulloblastoma 
cell line DAOY (Peyrl, Krapfenbauer et al. 2003), as well as in four non-small lung 
cancer cells lines compared to normal bronchial epithelial cells (Liu, Chen et al. 
2004). 
Upregulation of eEF1Bδ mRNA has been observed in a number of cancer 
tissues. eEF1Bδ showed expression change between gastric carcinoma tissues and 
normal tissues (Zeng, Liao et al. 2007). Overexpression of eEF1Bδ mRNA was 
found to be significantly associated with worse overall and progression-free survival 
among all 64 patients with medulloblastoma (De Bortoli, Castellino et al. 2006). 




with poorer prognosis. In 38 out of 52 cases of oesophageal carcinoma the 
expression level of eEF1Bδ is significantly associated with lymph node metastases 
and advanced disease stages (Ogawa, Utsunomiya et al. 2004). In moderately to 
poorly differentiated hepatocellular carcinoma the overexpression of eEF1Bδ is 
coordinate with the tumour grading (Shuda, Kondoh et al. 2000). Colon cancer 
tissues from advanced stages express a higher level of eEF1Bδ compared to normal 
mucosa (Roblick, Hirschberg et al. 2004). 
Further evidence for the involvement of eEF1Bδ in cancer came from the 
studies on transformation and tumourigenesis of cultured non-carcinoma cells. 
eEF1Bδ is overexpressed in Balb/c-3T3 cells (Joseph, Lei et al. 2002) and human 
bronchial epithelial cells (16HBE) (Lei, Wang et al. 2010) transformed by Cadmium, 
and the carcigenic potential of Cadmium can be reversed by blocking eEF1Bδ with 
antisense mRNA, suggesting that eEF1Bδ is one of the genes that account for the 
transformation and carcinogenesis induced by Cadmium. Furthermore, NIH3T3 cells 
transfected with eEF1Bδ are able to form transformed foci and subcutaneous 
tumours in nude mice (Joseph, Lei et al. 2002), and blocking eEF1Bδ expression by 
antisense mRNA also reduces cell transformation (Lei, Chen et al. 2002).  
eEF1Bδ is a negative regulator for the ubiquitin ligase SIAH-1, inhibiting the 
ubiquitation and degradation of its substrates (Wu, Shi et al. 2011). Since some 
targets of SIAH-1 have proved to be oncogenic and anti-apoptotic (Matsuzawa and 
Reed 2001; Yoshibayashi, Okabe et al. 2007), this is in line with the tumourigenic 
potential of eEF1Bδ. 
eEF1Bγ 
In the breast cancer cell lines T47D and MDA-MA-231 where eEF1Bα is 
overexpressed, eEF1Bγ mRNA is also 2.9-fold higher than in non-transformed cell 
line MCF-10A (Al-Maghrebi, Anim et al. 2005). However, while this study found no 
change of eEF1Bγ in MCF-7 cell line, another group reported eEF1Bγ 




2004). Similarly, in the same study, eEF1Bγ mRNA expression in breast cancer 
tissues is about as 3.6 times much as in normal tissues (Joseph, O'Kernick et al. 
2004).    
Furthermore, eEF1Bγ mRNA overexpression has been observed in other types 
of cancer tissues. eEF1Bγ mRNA showed an overexpression in 25 out of 29 
colorectal carcinomas (Chi, Jones et al. 1992), 13 out of 25 colorectal adenomas 
(Ender, Lynch et al. 1993), and 7 out of 9 pancreatic adenocarcinomas (Lew, Jones et 
al. 1992) over their corresponding normal tissues. 
Upregulation of eEF1Bγ mRNA was found in 22 of 30 gastric carcinomas 
compared to corresponding normal tissues, with no relationship between the level of 
overexpression and tumour grades or the depths of invasion (Mimori, Mori et al. 
1995). However, a study in hepatocellular carcinoma found that the overexpression 
of eEF1Bγ correlated with carcinoma grading (Shuda, Kondoh et al. 2000). Another 
study in oesophageal carcinoma found that 5 out of 36 cases showed eEF1Bγ mRNA 
overexpression at a level of two-fold or more than normal tissues. All of the 5 cases 
were at the most advanced stage IV, and disclosed severe lymph node metastases, 
showing a relevance between eEF1Bγ overexpression and cancer grade (Mimori, 
Mori et al. 1996).  
On the other hand, overexpression of eEF1Bγ protein in cancers has also been 
found. A study on tissues from patients with colorectal adenocarcinoma found 
eEF1Bγ overexpression in 17 of 29 patients. The overexpression was only found in 
Dukes Stage B, C and D, but not Dukes Stage A cases. However this result should be 
treated with caution because the Western blot in this study showed only eEF1Bγ, and 
the subsequent quantification was not corrected to a loading control (Mathur, Cleary 
et al. 1998). 
The mechanism for overexpression of eEF1Bγ is unknown. A study on 
colorectal carcinoma identified a single base change (L158->S) in one case but not in 




carcinomas was not caused by gene amplification or rearrangement (Lew, Jones et al. 
1992; Frazier, Inamdar et al. 1998). 
 
1.4.4.2 eEF1B and motor neuron diseases 
Motor neuron disease (MND) is a general term used to designate a variety of 
neurodegenerative diseases, characterized by fatally progressive muscular weakness, 
atrophy, and paralysis due to the loss of motor neurons. Current studies of translation 
elongation factors associated with neurodegenerative diseases are mainly focused on 
initiation factors and eEF1A. Mutations of each of the five subunits of translation 
initiation factor eIF2B have been identified in patients with leukoencephalopathy 
with vanishing white matter (VWM) and childhood ataxia with central nervous 
system hypomyelination (CACH) (reviewed in Scheper, van der Knaap et al. 2007; 
Pavitt and Proud 2009). Absence of eEF1A2 in mice leads to a wasted phenotype 
(described in detail in section 1.5). 
So far not much is known about whether eEF1B is involved in MND like other 
translation factors. Information on eEF1B in MND to date is from several studies on 
amyotrophic lateral sclerosis (ALS), the most common form of MND. A study of the 
role of copy number variations (CNVs) in ALS reported eEF1Bδ as a potential ALS 
candidate (Wain, Pedroso et al. 2009). ALS is a fatal disease, characterized by the 
selective death of motor neurons in the spinal cord, brainstem and cortex. It has been 
found that CNVs may influence the risk of sporadic ALS (Cronin, Blauw et al. 2008). 
Both region-based and gene-based association analyses discovered that the gene 
encoding eEF1Bδ is covered in a CNV region that is associated with ALS. In 575 
ALS cases examined, CNV overlapped with the EEF1D gene by at least 1 base pair; 
in 7 cases there were losses and in 3 gains.  
A study of Down syndrome, which is caused by an extra copy of human 
chromosome 21 (hChr21) that leads to brain developmental dysregulations in 




that eEF1Bγ, together with several other genes encoding for translational regulators, 
is likely to participate in the pathway of defective neuron differentiation  in the late 
differentiated stage (Wang, Kadota et al. 2004). Microarray results identified a lower 






1.5 The wasted mouse, a model for MND 
Studies on MND are mostly carried out using mouse models, each carrying 
specific gene mutation(s) to model a certain type of human MND. Mice are 
commonly used as models for human diseases because of the advantages including 
that they share the same mammalian genes with human and the mouse genome is 
better understood (reviewed in Hafezparast, Ahmad-Annuar et al. 2002). In spite of 
the fact that it is impossible to replicate all the details of a certain human disease in a 
mouse model because of the different life span and physiology, and in some cases the 
mouse model may fail to show the exact phenotype as in human with the same 
mutations, which could be due to different biochemical pathways (Phaneuf, D., N. 
Wakamatsu, et al. 1996), the mouse model is an important and useful approach to 
understand the causes and pathology of MND. 
There are two types of MND mouse models for human MND (reviewed in 
Green and Tolwani 1999): those that develop spontaneously and those that are 
experimentally induced. The mouse model used in this project, the wasted mutant, 
occurred spontaneously. 
Wasted mutation arose spontaneously in the inbred mouse colony HRS/J at the 
Jackson laboratory in 1972 (Shultz, Sweet et al. 1982). The mutation has been 
reported to be a 15kb deletion of the promoter and first noncoding exon of the mouse 
Eef1a2 gene and thus abolishes the transcription of the gene (Chambers, Peters et al. 
1998).  
In wild type mice, eEF1A1 declines in heart, muscle and neurons postnatally, 
and by 21 days after birth eEF1A1 is shut down and replaced by eEF1A2 in these 
tissues and cells. In wasted mice, the reduction of eEF1A1 in brain, spinal cord, heart 
and muscle happens on schedule, regardless of the absence of eEF1A2 in these 
tissues (Khalyfa, Bourbeau et al. 2001), and causes death to the mice by 27 days. 




neurologic and immunologic abnormalities, while wild type (+/+) and heterozygote 
(wst/+) littermates are phenotypically normal. At 21 days after birth, wasted mice 
develop tremors, ataxia, weakness of hind limbs, weight loss, gait abnormalities, 
spleen and thymus atrophy, and progressive paralysis and die by about 28 days 
(Shultz, Sweet et al. 1982).  
Loss of eEF1A2 in wasted mice causes lesions in central nerve system. 
Homozygous wasted mice show prominent vacuolar degeneration of motor neurons 
within anterior horns of the spinal cord and the brainstem (Woloschak, Rodriguez et 
al. 1987; Lutsep and Rodriguez 1989). In the spinal motor neurons from wasted mice, 
most of the nuclear envelope (NE) undergoes deformity, and the nuclei are 
translocated away from the centre (Ueda, Tezuka et al. 2004). The pathology in 
spinal cord of wasted mice seems to happen in a cascade, first at the cervical level 
and then progressing caudally. The vacuolation of motor neurons and reactive gliosis 
in spinal cord from homozygote wasted mice were seen at the cervical but not at the 
lumbar level (Newbery, Gillingwater et al. 2005). Unlike thymus, motor neurons in 
wasted mice die by mechanisms other than apoptosis and necrosis (Ueda, Tezuka et 
al. 2004). Furthermore, wasted mice showed retraction of synapses from motor 
endplates in muscle (Newbery, Gillingwater et al. 2005), and develop progressive 
muscle wasting which leads to the loss of body weight, and atrophy of the spleen and 
thymus due to extensive apoptosis (Potter, Bernstein et al. 1998). Our lab has 
demonstrated that expression of eEF1A2 in neuronal and muscle tissues in wasted 




1.6 Proximity Ligation Assay 
In this thesis protein interactions were detected using in situ proximity ligation 
assay (PLA). PLA is a novel technique which is based on the antibody-mediated 
recognition of target antigens in close proximity (Fredriksson, Gullberg et al. 2002). 
A pair of oligonucleotide labeled secondary antibodies (PLA probes) generates a 
signal only when the two PLA probes bind in close proximity, either to the same 
primary antibody or two primary antibodies that have bound to the sample in close 
proximity. A schematic diagram of detecting the interaction between two proteins is 
shown in Figure 1.3. The signal from each detected pair of PLA probes is visualized 
as an individual fluorescent spot. These PLA signals can be quantified and assigned 
to a specific subcellular location based on microscopy images. 
PLA was first described as a sensitive method for protein measurements in 
solution (Fredriksson, Gullberg et al. 2002). It was then modified for different 
biological applications including detection and quantification of protein-protein 
interactions (Soderberg, Gullberg et al. 2006), protein-DNA or -RNA interactions 
(Gustafsdottir, Schlingemann et al. 2007), protein expression and protein 
phosphorylation (Jarvius, Paulsson et al. 2007). Compared to other techniques used 
to investigate protein-protein interactions, PLA has the advantages of investigating 
endogenous protein interactions in situ, either on tissues or cultured cells directly. It 
is very sensitive and able to detect transient protein-protein interactions at single-
molecule resolution. Finally it is a fast and simple method to visualize protein-
protein interactions and could give information on the distribution of interacting 















Figure 1.3. Schematic presentation of the principle of PLA. A and B. Target protein 1 
(green) and protein 2 (yellow) are recognized by two primary antibodys (dark gray/green 
and light gray/yellow, respectively), which are then bound by a pair of PLA probes (dark 
gray and light gray, respectively). The two DNA strands (black line in B) attached to the 
probes serve to template the hybridization of circularization oligonucleotides, which are 
joined by ligation into a circular DNA molecule (circular black line in B). C.  The circular 
DNA molecule is amplified by rolling-circle amplification (RCA) primed by one of the 
PLA probes, producing a long single-stranded DNA molecule (gray line). D. The RCA 
products are detected by hybridization of fluorescence labeled oligonucleotides (red dots) 





1.7 Project aims 
eEF1B subunits have been shown in various studies to have multiple functions 
and to be potentially related to diseases. Most of the studies on the roles of eEF1B in 
cancer are at mRNA level, and little is known about the potential involvement of 
eEF1B in motor neurone disease. On the other hand, although the components of 
eEF1B are identified, further information is needed regarding whether the two GEF 
in the eEF1B complex have the same function, and whether the two eEF1A isoforms 
interact with eEF1B in the same way. 
The aims of this project are to investigate the roles of eEF1B in cancer, motor 
neuron diseases, as well as to understand the relationship between eEF1B subunits 
and eEF1A.  
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Solutions and buffers 






solution (Vector Laboratories) 
5 ml dH2O 
2 drops of buffer Stock Solution 
2 drops of DAB Stock Solution 
2 drops of the Hydrogen Peroxide Solution 
Blocking buffer for Western blots 
5% (w/v) Marvel dried skimmed milk 
0.2 % (v/v) Tween 20,  PBS 
Citric acid solution for antigen 
retrieval in immunohistochemistry 
0.1 M citric acid pH 6.0 
dH2O up to 1 liter 
Duolink II wash buffer A 
One pouch of Duolink II wash Buffer A powder 
dissolved in 1L dH2O 
Duolink II wash buffer B 
One pouch of Duolink II wash Buffer B powder 
dissolved in 1L dH2O 
Duolink Wash buffer SSC (2x) 
1 pouch of Duolink Wash buffer SSC powder 
dissolved in 1L dH2O 
Duolink Wash buffer TBS-T (2x) 
1 pouch of Duolink Wash buffer TBS-T powder 
dissolved in 1L dH2O 
ECL solution (GE Healthcare) 
Detection reagent 1and detection reagent 2 at 
the 1:1ratio 
Freezing medium for liquid nitrogen 
stocks 
10% (v/v) newborn calf serum 
90% (v/v) DMSO 
Laemmli loading buffer (2x) 
60mM Tris.HCl pH 6.8 
0.1% Bromophenol blue 
10% glycerol 
2% SDS 
dH2O up to 1L 
Laemmli running buffer (10x) 
250mM Tris HCl pH 8.3 
1.9M Glycine 
10% SDS 
dH2O up to 1L 
Table 2.1. List of solutions and buffers required for performing experiments in the 
thesis.
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Lithium carbonate solution 67.7 mM lithium carbonate in 1L dH2O 
Membranes stripping buffer 
10% (v/v) SDS 
0.5 M Tris-HCl pH 6.8 
0.8 % (v/v) β-mercaptoethanol 
dH2O up to 100 ml 
4% Neutral buffered formalin (NBF) 
108ml 37% formaldehyde 
4g monobasic sodium phosphate (NaH2PO4) 
6.5g disodium hydrogen phosphate (Na2HPO4) 
dH2O up to 1L 
Orange G DNA loading buffer 
30% (v/v) glycerol 
100 mg Orange G 
dH2O up to 50ml 
3% Peroxidase blocking solution 
40 ml of 30% (v/v) hydrogen peroxide solution 
dH2O up to 400 ml 
Made fresh 
Phosphate Buffered Saline (PBS) 
1 PBS tablet (Sigma) 
100 ml dH2O 
Autoclaved, stored at 4oC 
PBS-tween-20 (PBS-T) As above and 0.1% (v/v) Tween-20 (Sigma) 
Radioimmuno- precipitation assay 
(RIPA) buffer 
50 mM Tris-HCl pH 7.5 
150 mM sodium chloride 
1% (v/v) NP-40 
0.5 % (w/v) sodium deoxycholate 
0.1% (v/v) SDS 
1 mini-complete protease tablet (Roche) 
dH2O up to 10 ml 
Stored at -20oC after tablets were added 
0.32M Sucrose 
10.9g Sucrose in 100ml dH2O 
1 mini-complete protease tablet (Roche) in 10ml 
Transfer buffer (10x) 
30.3g Tris 
144.1g  glycine 
dH2O up to 1 liter 
TBE (Tris-Borate-EDTA) 90 mM Tris-Borate, 2 mM EDTA pH 8.0 
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2.1.2 Cell lines 
All the cell lines used in this study are listed in Table 2.2.  
 
 
Cell Line Species Cell Type Maintenance Medium Source 
NIH-3T3 Mouse Embryo fibroblast DMEM+10% NBCS ATCC 
A1 8.6 Mouse 
Fibroblast; 








A2 9.6 Mouse 
Fibroblast; 








A549 Human Lung carcinoma epithelial DMEM +10% FBS ATCC 
HCT116 Human Colon carcinoma epithelial DMEM+10% NBCS ATCC 
Hek293 Human Transformed embryonic kidney cells DMEM +10% FBS ATCC 
HeLa Human Cervical cancer epithelial DMEM+10% FBS ATCC 
MCF-7 Human Breast adenocarcinoma cells DMEM +10% FBS ATCC 
MDA-MB-231 Human Breast carcinoma cells DMEM +10% FBS ATCC 
MDA-MB-451 Human Breast carcinoma cells DMEM +10% FBS ATCC 
NSC34 Mouse Motor neuron neuroblastoma hybrid DMEM+10% FBS ATCC 
PC3 Human Prostate cancer cells RPMI+10% NBCS ATCC 
Rat 2 Rat Embryo fibroblast DMEM +10% FBS ATCC 
T47D Human Breast cancer cells DMEM +10% FBS ATCC 
 
 
Table 2.2. Panel of cell lines used in different tissue culture applications. 




All mice were maintained in accordance with Home Office regulations in the 
small animal Biomedical Research Facility (BRF) at Western General Hospital. The 
mice were exposed to 12 hour light/12 hour dark cycles with ad libitum access to 
food and water. Wasted mice are on a mixed although predominantly C3H/HeH and 
C57BL/6J background. 
2.1.4 Antibodies 
All the antibodies used for the Western blot, IHC and PLA experiments in this 
thesis, together with their working concentrations for each type of application are 
listed in Table 2.3. 
2.1.5 Slides 
For tissues slides, mouse tissues were dissected from mice and immediately 
transferred to 4% Neutral buffered formalin (NBF) and kept in NBF for 2 days.  
Alternatively, for IHC of cultured cells, cells were washed twice with 
Dulbecco's phosphate buffered saline (DPBS, supplied by Gibco), trypsinized and 
centrifuged as described in section 2.2.1. The cell pellet was resuspended in 25ml of 
culture medium and transferred to a 50ml tube. The suspension was incubated at 
37°C in a 5% CO2 incubator for 10 minutes before centrifugation at 400×g and 4°C 
for 5 minutes. The supernatant was then removed and the cells were resuspended in 
50ml of ice cold DPBS. The last two steps were repeated. Finally the cell pellet 
collected was resuspended in 10ml of 4% NBF for 60 minutes. 
Fixed tissues or cells were sent to the Pathology Histology service (University 
of Edinburgh) for processing. Paraffin embedded tissues or cells were cut using a 
microtone (Leitz 1512) into 4µm sections and mounted on Superfrost plus slides 
(Thermo Scientific). 
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A breast cancer tissue array was obtained from AccuMax Array, containing 12 
cancer cases of infiltrating ductal carcinoma, as well as 12 corresponding normal 
tissues from each patient. MND sections were obtained from the London 
Neurodegenerative Diseases Brain Bank and the pathological information is listed in 
Table 2.4.  
 
Name/Target Company Species Application And Dilution 
Anti-goat biotin Dako Rabbit IHC 1:500 
Anti-mouse biotin  Dako Goat IHC 1:500 
Anti-rabbit biotin Dako Goat IHC 1:500 
Anti-goat HRP  Dako Rabbit WB  1:2000 
Anti-mouse HRP  Dako Rabbit WB  1:2000 
HRP goat anti-rabbit  Dako Goat WB  1:2000 
Alexa Fluor anti-rabbit 594 (red) Invitrogen Donkey IF 1:800 
Alexa Fluor anti‐sheep 488 (green) Invitrogen Donkey IF 1:800 





eEF1Bδ ProteinTech Group Rabbit 
WB 1:2000 
IHC 1: 800 
IF/PLA 1:200 
PLA 1:200 
eEF1Bδ GeneTex Rabbit WB 1:1000 
eEF1Bγ Abcam Mouse WB 1:1000 
eEF1Bγ Sigma Rabbit WB 1:800 
eEF1Bγ Bethyl Rabbit IHC 1:30 PLA 1:40 
eEF1A2-1 Custom (Helen Newbery1) Sheep 
WB  1:200 
IHC 1:25 
IF  1:25 
PLA  1:20 
GAPDH Chemicon Mouse WB  1:40000 
TK1 Olink Chicken PLA 1:10 
α-Tubulin Sigma-Aldrich Mouse IF 1:2500 
γ-Tubulin Sigma-Aldrich Mouse WB 1:10000 
V5 LSBio Sheep PLA 1:120 
1. Dr Helen Newbery is a Postdoctoral researcher working in Professor Cathy Abbott’s group. 
Table 2.3. List of antibodies and conditions for performing WB, IHC, IF and PLA.






 Age Sex Region Pathological Diagnose 
A1 59 F Thoracic MND 
A2 68 F Cervical MND 
A3 39 F Cervical MND 
A4 63 M Cervical MND 
A5 74 F Cervical MND 
A6 67 M Cervical MND 
A7 74 M NS MND 
A8 62 M NS MND 
B1 77 M Cervical MND 
B2 78 F NS MND 
B3 55 M Cervical MND 
B4 50 M Cervical MND 
B5 71 M Thoracic MND 
B6 45 M Cervical MND 
B7 63 F Cervical MND 
B8 70 F Cervical MND 
C1 55 M Cervical MND 
C2 84 M Cervical MND 
C3 49 M NS MND 
C4 72 M Thoracic MND 
C5 78 M NS MND 
C6 81 F Cervical MND 
C7 80 F Cervical MND 
C8 81 F Cervical MND 
D1 68 F Cervical MND 
D2 61 M Thoracic MND 
D3 44 F Cervical MND 
D4 57 F Thoracic MND 
D5 56 M Cervical MND with upper and lower MN damage (possibly familial) 
Table 2.4. Informations of the MND patients and pathological diagnose as supplied by 
the  London Neurodegenerative Diseases Brain Bank. MN. Motor neuron. AD. 
Alzheimer's disease. NS. Not specified. 
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D6 72 M Cervical MND with TDP-43 positive glial inclusion in M cervical spine 
D7 92 M Thoracic MND mild/moderate aging changes 
D8 85 F Cervical MND and AD 
E1 42 M Cervical MND mild and focal neurofibrillary tangles 
E2 39 M Cervical MND with upper and lower MN damage 
E3 59 M Cervical MND with diffuse inv cervical spine, P62 positive inclusions 
E4 71 M Cervical MND with extra-motor pathology 
E5 62 M Cervical MND frontotemporal lobar degeneration AD Braak IV 
E6 87 F Cervical MND possible AD Braak IV 
E7 67 F Cervical MND with extra MN inclusions 
E8 63 M Thoracic MND ubiquitin positive intracytoplasmic inclusions 
F1 42 M Cervical MND with subcortical ubiquitin inclusions 
F2 55 M Cervical MND with mild AD changes 
F3 83 M Cervical MND and AD 
F4 70 M Cervical MND extramotor p62 positive cytoplasmic neuronal & intranuclear inclusions 
F5 87 M Cervical MND with upper and lower MN damage 
F6 74 M Cervical MND AD type neurofibrillary changes Braak I 
F7 73 M Cervical MND with upper and lower MN damage 
F8 68 M Cervical MND early AD Braak III 
G1 57 M NS MND oligodendroglial p62 immunoreactivities 
G2 66 M Thoracic MND mild tau pathology in limbic Braak I 
G3 75 M Cervical MND with additional inclusions in hippocampus 
G4 66 M NS MND evidence of small blood vessel dilation 
G5 57 F Cervical MND dementia early stage 
A 40 M Lumbar Control 
B N/A M Cervical Control 
C 64 M NS Control 
D 79 F NS Control 
E 87 F Cervical Control 
F 54 M NS Control 
G 95 M Cervical Control 
H 61 M Lumbar Control 
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I 55 F Cervical Control 
J 62 M Cervical Control 
K 80 M NS Control 
L 92 F Cervical Control (Braak I-II) 
M 89 F Cervical Control (some hypoxic changes) 
N 90 F Cervical Control (Mild AD changes Braak II) 
O 78 M NS Control (metastatic carcinoma deposits) 
P 81 M NS Control (old cerebral infarct) 
Q 68 M Cervical Control – hypoxia 
R 57 M NS Control (mild ischaemia) 
S 64 F Cervical Control (morphological abnormality) 
T 86 F   Control (cerebral infarct) 
 
2.1.6 DNA primers 
A list of the primers used throughout this thesis is shown in Table 2.5.  Primers 
were designed with the Primer3 programme (Rozen and Skaletsky 2000) and 
confirmed by Blasting the sequences with NCBI's BLAST. Primers were all ordered 
from Sigma-Aldrich.  
Upon arrival, all the primers were dissolved in dH2O to a final concentration of 
100µM and stored at -20°C for later experiments. Fresh working solutions of 5µM 
were made before amplification reactions each time. 
2.1.7 siRNAs 
siRNAs for eEF1Bα, eEF1Bδ and eEF1Bγ were commercially available from 
Ambion. Custom siRNAs for eEF1BδL and eEF1A2 were produced by Sigma-
Aldrich and Invitrogen respectively. To design specific siRNAs targeting eEF1BδL, 
the sequence of the exon 3 of eEF1Bδ gene was copied into the BLOCK-iT RNAi 
designer software (Invitrogen), and the siRNAs were chosen by their ranking given 
by the software. siRNAs were resuspended to a concentration of 20µM and aliquoted 
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before storage at -80°C. A non-targeting scrambled siRNA supplied by Invitrogen 
was used as a negative control for RNAi experiments. 
The siRNAs used for RNAi experiments in this thesis are listed in table 2.6. 
 
Name Target Species Sequence  5’ to 3’ 
BqPCR5F eEF1Bα Mouse GAAGCCTTGGGATGATGAGA 
BqPCR6R eEF1Bα Mouse TATTCCAGCATCCGTTCC 
DqPCR3F eEF1Bδ Mouse AGCTTGTGCCTGTTGGCTAT 
DqPCR3R eEF1Bδ Mouse CTCTGCACATGCTCCTCAAA 
GapdhQPCR2F GAPDH Mouse GGGTGTGAACCACGAGAAAT 
GapdhQPCR2F GAPDH Mouse ACTGTGGTCATGAGCCCTTC 
GqPCR1F eEF1Bγ Mouse CCTCATCGCTGCTCAGTACA 





Name Target Sequence 5’-3’ Source 
1A2 siRNA11 Mouse eEF1A2 UUAACGGACACAUUCUUCACAUUGA Invitrogen 
1A2 siRNA21 Mouse eEF1A2 CAAUCUUGUACACAUCCUGCAGAGG Invitrogen 
Bα siRNA1 Mouse eEF1Bα CCAUCCUACUAGACGUGAAtt Ambion 
Bα siRNA2 Mouse eEF1Bα CAUCAAGUCGUAUGAAAAtt Ambion 
D siRNA1 Mouse eEF1Bδ CACCAGCAGAGGACGAUGAtt Ambion 
D siRNA2 Mouse eEF1Bδ GGACGAUAGUGCUCGUGAAtt Ambion 
DL siRNA1 Mouse eEF1BδL AUCAAACAGGGCCUCAUAGAAGCCC Sigma-Aldrich 
DL siRNA2 Mouse eEF1BδL CGUAGGAAACAAGAGAGCUGGGUCA Sigma-Aldrich 
G siRNA1 Mouse eEF1Bγ GGUGGACUAUGAGUCGUAUtt Ambion 
G siRNA2 Mouse eEF1Bγ CCUCAUCACUGGGAUGUUUtt Ambion 
1. Designed by Dr Lowri Griffiths. 
Table 2.5. Primer sequences used for different PCR applications.  
Table 2.6. List of siRNA sequences used in this thesis, as well as their reference names, 
sources and targets.  
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2.2 Cell culture 
2.2.1 Cell culture maintenance 
For experiments and maintaining cultures, cell lines were grown in Cell Start 
T25, T75 or T175 flasks (Greiner Bio-One) unless stated otherwise. Each cell line 
was grown in the corresponding medium listed in Table 2.2, and kept at 37°C in a 
5% CO2 incubator. When cells reached 80 to 90% confluence, the medium was 
aspirated and cells were washed twice with prewarmed DPBS and incubated in a 1:1 
mix of trypsin:versene (Invitrogen) for about 5 minutes until most cells were 
detached from the flask. A small amount of prewarmed culture media was added and 
the suspension was centrifuged at 1200 rpm for 5 minutes. The supernatant was then 
aspirated and the cell pellet was resuspended in 5 ml of fresh prewarmed culture 
medium and split into a new flask 1 in 5 or 1 in 10 depending on the volumes of 
future culture. For T25, T75 or T175 flasks 10 ml, 25 ml or 50 ml of culture medium 
was added respectively. Cells were usually split approximately every 3 to 7 days and 
kept until they reached passage number 20 or for NSC34 cells passage number 15.  
 
2.2.2 Cell counting 
To count the number of cells, cultured cells were washed with DPBS, 
trypsinized and the pellet was collected as described in section 2.2.1. The cell pellet 
was resuspended in 10ml of the culture media, and 100µl of the suspension was 
mixed with 9.9 ml of Isoton. Cells were then counted automatically using a Coulter 
Counter Z2 series (Beckman coulter). 
Alternatively, cells were counted using a haemocytometer (Weber Scientific 
International, England). Briefly, cultured cells were collected and resuspended as 
described in section 2.2.1. 1ml of the cell suspension was diluted in 4ml of culture 
medium in a 10ml falcon and mixed. The haemocytometer was prepared by placing 
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the special coverslip properly on the surface of the counting chamber. A drop of the 
cell suspension was then applied to the edge of the coverslip and sucked into the void 
so that the chamber was completely filled with the diluted cell suspension. The 
chamber was then examined under a light microscope (Leica) and the number of 
cells in the chamber was counted.  The cell concentration was calculated by dividing 
the mean of the numbers from each large square by 10-4cm2.  
 
2.2.3 Cryopreservation of cells 
To obtain liquid nitrogen stocks of the cells, cultured cells were trypsinised and 
centrifuged as described in 2.2.1. The pellets were then resuspended in 10ml of 90% 
FBS or NBS depending on the cell line (Table 2.2) and 10% DMSO. The suspension 
was transferred into 1ml screw top CryoTube vials (Nunc), and frozen at -20°C 
overnight, -70°C freezer for three days, and then kept in a liquid nitrogen tank for 
longer storage. 
 
2.2.4 RNAi  
RNAi experiments in this thesis were performed following the standard 
protocol supplied with the siLentFect Lipid Reagent (Bio-Rad). Cells with no 
siLentFect reagent, cells with no siRNA and cells with a non-targeting scrambled 
siRNA were used as negative controls. Each knockdown experiment was performed 
in triplicate. 
An appropriate number of cells were cultured in 12-well plates in 
corresponding medium so that they reached about 50% confluence overnight. The 
following day, twenty minutes prior to transfection, the culture medium in each well 
was replaced by 500µl of fresh medium. For each well to be transfected, 50µl of 
serum-free medium containing 0.7µl of siRNA was mixed with another 50µl serum-
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free medium containing 1.5µl of siLentFect and mixed by pipetting. The mixture was 
incubated for 20 minutes at room temperature before being added to each well with 
growing cells. The plate was shaken back and forth to mix the solution and then 
incubated at 37°C in a 5% CO2 incubator. The medium was changed 24 hours after 
transfection, and the cells were cultured for another 48 hours before being subjected 
to further experiments. 
For RNAi in a 96-well plate, each well contained 100µl plating medium, 0.1µl 
siRNA, 10µl serum-free medium for siRNA and 10µl for siLentFect instead. 
 
2.2.5 MTT assay  
The MTT assay was used to determine the viability of cultured cells after 
RNAi using the MTT Cell Proliferation Assay Kit (Cayman Chemical Company). 
The reagents were prepared prior to the MTT experiment as follows: the Cell-Based 
Assay Buffer Tablet was dissolved in 100ml of dH2O; the 125mg vial of MTT 
Reagent was dissolved in 25ml of Assay Buffer and made into smaller aliquots. 
Cells were seeded in a 96 well plate at a density of 5x102-105 cells per well in 
100µm of culture medium, and grown at 37°C in a 5% CO2 incubator for 24 hours 
before the RNAi procedure described in section 2.2.4. 72 hours after RNAi, the 
medium was changed, and 10µl of MTT Reagent was added to each well and mixed 
for one minute on a shaker. The cells were incubated for 3 hours at 37°C in a 5% 
CO2 incubator before the formazan produced was visible at the bottom of each well. 
Subsequently, the culture medium in each well was carefully aspirated avoiding any 
disruption of the cell monolayer. Next, 100µl of the Crystal Dissolving Solution was 
added to each well and the formazan crystals were dissolved and the solution in the 
wells became purple. Finally, the absorbance of each sample was measured at 570nm 
using a Synergy HT Multi-Mode Microplate Reader (BioTek) and analysed by Gen5 
Data Analysis Software (BioTek). 
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Each knockdown was performed in triplicate. Cells with no siLentFect reagent, 
cells with no siRNA and cells with a non-targeting scrambled siRNA were used as 
negative controls for RNAi. Cells with no MTT Reagent and wells with dH2O only 
were used as negative controls for the MTT assay. 
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2.3 Protein-related methods 
2.3.1 Protein extraction from cells 
Protein extracts were made when cells reached 80 to 90% confluence. To make 
a cell lysate, the cell culture medium was aspirated off and the cells were washed 
twice with DPBS, then a small amount of ice cold RIPA buffer was added, just 
enough to cover the bottom of the flask or the well. Cells were then incubated in 
RIPA buffer at 4°C for 20 minutes. Subsequently, cells were detached from the flask 
or the well, and the cells that remained loosely attached were scraped from the wall 
of the container. Cells were then transferred into a micro-centrifuge tube and 
centrifuged at 13,000 rpm for 30 minutes at 4°C. The supernatant was collected and 
stored at -20°C for further study.  
The protein concentration of the lysates prepared was measured using a Nano 
Drop 1000 (Thermo Scientific). 
2.3.2 Protein extraction from tissues 
Mouse tissues were dissected and flash frozen in liquid nitrogen before storage 
at -70°C. To produce protein lysates, tissues were placed in 0.32M sucrose solution 
in tubes from the Precellys ceramic kit or steel kit for heart and muscle tissues, and 
homogenised in a Precellys 24 Homogeniser. Samples were moved to fresh tubes and 
stored at -20°C. 
 
2.3.3 Western Blotting 
2.3.3.1 Sample preparation 
 Protein extracts obtained from 2.3.1 or 2.3.2 were mixed at 1:1 with 2× 
Laemmli loading buffer (Table 2.1) and 1:10 with 1M DTT. The mixtures were then 
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heated in a boiling water bath at 100°C for 5 min in order to denature the proteins 
and disrupt protein-protein interactions. Samples were then ready for electrophoresis 
or stored at -20°C for later examination. 
 
2.3.3.2 SDS-PAGE electrophoresis 
Separating gels of 10% or 12% depending on the size of the protein of interest 
were prepared as follows: 
 10% 12% 
30% acrylamide 10.4 ml 12.8 ml 
1.5 M Tris-HCl pH 8.8 8 ml 8ml 
dH2O 13.4 ml 11ml 
20% SDS 160 µl 160µl 
25% AMPS 20 µl 20µl 
TEMED 80 µl 80µl 
 
The gel solution was well mixed and poured between two glass plates (Bio-
Rad) until the gel was 1 to 2cm from the top edge. The remaining space was filled 
with dH2O and then the gel was left at room temperature for approximately 30 
minutes to set. The water was then removed and replaced with 4% stacking gel 
prepared as follows: 
 
30% acrylamide 1.45 ml 
0.5 M Tris-HCl pH 6.8 2.5 ml 
dH2O 5.95 ml 
20% SDS 50µl 
25% AMPS 50 µl 
TEMED 5 µl 
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After the stacking gel was poured into the space between the plates, a comb of 
either 10 or 15 slots (Bio-Rad) was put on the top and the gel was left at room 
temperature for approximately 15 minutes to set. When the gel was ready, the gel 
apparatus (Bio-Rad) was assembled and filled up with approximately 500ml of 1x 
Laemmli running buffer. The combs were then removed and protein samples 
prepared in Section 2.3.3.1 were loaded into individual wells, as well as a protein 
size marker (Fullrange rainbow, GE Healthcare) in the first well. The gel was run at 
100V long enough to allow the samples to run through the stacking gel, and then run 
at 120V until the blue dye in the samples reached the bottom edge of the gel. 
 
2.3.3.3 Western blot transfer 
After electrophoretic separation, the gel was removed from the plates and 
placed in 1x transfer buffer together with Whitman filter paper (6cm by 8cm) and 
sponges. For each gel, a piece of Hybond-P PVDF transfer membrane (Amersham, 
GE Healthcare) was cut (6cm by 8cm) and pre-wet in methanol before being put in 
the transfer buffer. A sponge, two pieces of filter paper, the gel, the transfer 
membrane, another two pieces of filter paper and a sponge were assembled strictly in 
the above order in a plastic blotter soaked in the transfer buffer. The assembled blot 
was placed in a tank filled with transfer buffer, a magnetic stirrer and a frozen ice 
pack. The transfer was run at 100V/400A in a 4°C cold room for 60 minutes and then 
the blotting apparatus was dissembled and the membrane was placed in blocking 
buffer. The blocking process was either overnight at 4°C or 1 hour at room 
temperature. 
 
2.3.3.4 Immunostaining  
After blocking, the membrane was probed with a primary antibody diluted in 
5% (w/v) powdered milk in PBS-T to an appropriate concentration as described in 
Chapter 2 Materials and Methods 
51 
 
Table 2.3. The membrane was then incubated at room temperature for 1.5 hours with 
gentle shaking, and then washed for 5 minutes ×4 with PBS-T before being probed 
with an appropriate HRP conjugated secondary antibody for 1 hour at room 
temperature under gentle shaking. The membrane was washed for 5 minutes ×4 with 
PBS-T, followed by visualization using the ECL Western blotting detection kit 
(Amersham, GE Healthcare). 
2.3.3.5 Densitometric analysis 
Selected pictures of the Western blots were scanned into a computer for 
quantification. The intensity of the bands on the blot were quantified using the 
GelQuant.NET software (version 1.6.5) provided by biochemlabsolutions.com.  
 
2.3.3.6 Re-probing the membranes 
To re-probe a membrane with a different antibody, the membrane was washed 
with PBS-T (5 minutes×3) and incubated in stripping buffer for 30 minutes. The 
membrane was then washed with PBS-T, incubated with blocking buffer and probed 
with a different antibody following the same procedure described in section 2.3.3.4. 
 
2.3.3.7 Relative quantification of protein expression 
To compare the protein expression levels in wild type and wasted mouse 
tissues, samples for each tissue and genotype were taken from three individual 
animals. The intensity of the band for the target protein was normalised to that of the 
loading control (GAPDH or tubulin) in each sample and the mean of the three 
samples was taken for the comparison.  
The standard deviation (SD) and the standard error of the mean (SEM) were 
calculated and student’s t-test was performed in Excel (Microsoft). 
 
Chapter 2 Materials and Methods 
52 
 
2.3.4 Immunohistochemisty (IHC) 
2.3.4.1 Antigen retrieval and antibody probing 
Slides of cultured cells, human or mouse tissues obtained from section 2.1.5 
were deparaffinised twice in xylene for 5 minutes, and rehydrated twice in absolute 
ethanol, twice in 75% ethanol and finally water. Slides were then immersed in 0.01M 
citrate buffer (pH 6.0) and microwaved for 15 minutes for antigen retrieval. Slides 
were cooled and washed with running tap water for 5 minutes, then with PBS for 5 
minutes, before being loaded onto Shandon Sequenzas (Thermo Scientific).  
Subsequently, slides were immersed in peroxidase blocking solution for 5 
minutes and washed with PBS. Slides were then blocked for 30 minutes at room 
temperature in 100µl serum (diluted 1:5 in PBS) of the same species in which the 
secondary antibody was raised. Primary antibody diluted to an appropriate 
concentration in PBS was added onto the slides, and slides were washed 3 times with 
PBS after 30 minutes incubation of the primary antibody. The slides were then 
incubated with 100µl of appropriate biotinylated secondary antibody (Dako 
Cytomation) diluted 1:500 in PBS for 30 minutes. Slides were washed 3 times with 
PBS afterwards, and 3 drops of Vectastatin R.T.U. Elite® ABC Reagent (Vector 
Laboratories) were added onto each slide. Slides were incubated at room temperature 
for 30 minutes, and washed in PBS for 5 minutes.  
Slides treated with no primary antibody were used as negative controls. 
 
2.3.4.2 Detection  
To visualise the protein expression, slides were treated with pre-mixed DAB 
solution for approximately one minute. Slides were then counterstained in 
haematoxylin, washed under running tap water, stained with lithium carbonate, 
washed again under running tap water, dehydrated twice in 70% ethanol and twice in 
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absolute ethanol. Finally slides were cleared twice in xylene and mounted using 
pertex (CellPath). 
The slides were viewed under an Olympus BX60 light microscope (Olympus) 
and pictures were captured using Cell^D software (Olympus). Alternatively, the 
slides were viewed under a Nikon AZ100 multi-purpose zoom microscope and 
pictures were captured and analyzed using IPLab software (version 3.9.5 r4 for Mac, 
BD Biosciences). 
 
2.3.5 Immunofluorescense (IF)  
IF was used to visualize the expression of two different proteins in the same 
sample. The experiment was performed following the same procedure as in IHC 
described in sections 2.3.4.1 until the step of antigen retrieval was done. The slides 
were then blocked for 30 minutes with donkey serum (given by Dr Shaun Mackie, 
MMC, University of Edinburgh), which was diluted 1:10 in PBS. Primary antibodies 
raised in different species against the two proteins of interest were diluted to an 
appropriate concentration and added onto the slides. The slides were washed with 
PBS after 30 minute incubation with primary antibodies. Next, two fluorescent 
secondary antibodies (HRP conjugated rabbit antibody 594 and HRP conjugated 
sheep antibody 488, red and green respectively) were added to the slides, and the 
slides were incubated in the dark at room temperature for 30 minutes before being 
washed in PBS for 5 minutes. The slides were sealed with coverslips using 
Vectashield hard set mounting medium with DAPI (Vector). 
The IF results were observed under a Zeiss Axioskop 2 fluorescence 
microscope using appropriate filters, and pictures were captured using Smart Capture 
2 software.  
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2.3.6 Proximity Ligation Assay (PLA) using the Duolink in situ PLA Kit 
PLA was performed using reagents and directions supplied in the Duolink in 
situ PLA kit, Duolink II Probemaker kit or DuolinkII Fluorescence kit (Olink 
Bioscience). All the incubation processes were performed in a pre-warmed humidity 
chamber at 37°C unless stated otherwise. 
Negative controls for the PLA experiments included a sample with only one 
primary antibody to one of the target proteins, and a sample with a pair of primary 
antibodies raised against one target protein, and a protein that was not expected to 
interact with the target protein (based on function and/or subcellular localisation). 
 
2.3.6.1 Probing 
Slides of fixed mouse tissue or cells obtained from section 2.1.5 were subjected 
to deparaffinization, rehydration and antigen retrieval as described in section 2.3.4.1. 
A hydrophobic slide marker, PAP pen (BioGenex), was used to draw a hydrophobic 
circle around the tissue section on each slide so that the area of reaction was no 
larger than 1cm2. The Duolink Blocking stock and the Antibody Diluent stock were 
diluted 1:5 in dH2O respectively. 40µl of the Blocking solution was added to each 
slide. After 30 minutes incubation, the Blocking Solution was tapped off the slides 
and two primary antibodies diluted in the Antibody Diluent were added onto the 
slides and the slides were incubated for 30 minutes. Next, the slides were washed in 
1x TBST for 5 minutes x 2. The slides were then incubated for 2 hours with two PLA 
probes (anti-rabbit and anti-sheep) diluted in the Antibody Diluent.  
 
2.3.6.2 Hybridization 
Duolink Hybridization stock was diluted 1:5 in dH2O and mixed well. The 
slides were washed with 1x TBS-T for 2 x 5 minute under gentle shaking, and 40µl 
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of the hybridization solution was added on each reaction area. The slides were then 
incubated for 15 minutes. 
 
2.3.6.3 Ligation 
After hybridization, the remaining solution was tapped off the slides and the 
slides were washed in 1x TBS-T for 1 minute under gentle agitation. The ligation 
reagent was prepared by diluting the Duolink Ligation stock 1:5 in dH2O and mixing 
with the Duolink Ligase. For each reaction 1µl Ligase was added to 39µl Ligation 
solution. 40µl of the mixture was added to each reaction area, and the slides were 
incubated for 15 minutes. 
 
2.3.6.3 Amplification 
The Ligation-Ligase solution was removed from the slides and the slides were 
washed using 1x TBS-T for 2x 2 minutes. A solution made by diluted Amplification 
stock (1:5 in dH2O) and Polymerase (diluted 1:80 in the Amplification solution and 
vortexed) was added to the slides (40µl per reaction area). The slides were incubated 
for 90 minutes.  
 
2.3.6.4 Preparation for imaging 
The slides were then washed in 1x TBS-T for 2x 2 minutes under gentle 
shaking, and 40µl of the Duolink Detection solution 613 (stock diluted 1:5 in dH2O) 
was added to each reaction area. Slides were incubated for 60 minutes.  
The slides were then washed in the following reagents in a dark room: 2x SSC 
for 2 minutes, 1x SSC for 2 minutes, 0.2x SSC for 2 minutes, 0.02x SSC for 2 
minutes, and 70% ethanol for 1 minute. The slides were left to dry in a dark room. 
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Finally the slides were mounted with a coverslip using a minimal volume of Duolink 
Mounting Medium containing DAPI. 
 
2.3.6.5 Imaging 
PLA signals were visualized by a Zeiss Axioskop 2 fluorescent microscope 
with appropriate filters, and pictures were captured using Smart Capture 2 software.  
 
2.3.7 PLA using the Duolink II Probemaker kit 
2.3.7.1 Antibody conjugation 
Conjugation of the antibody and an oligonucleotide was performed to make a 
custom PLA probe. The process followed the protocol supplied with Duolink II 
Probemaker kit (Olink Bioscience). Briefly, 2µl Conjugation Buffer was added to 
20µl antibody and then mixed gently with a pipette. The mixture was added to the 
vial of activated oligonucleotide (Duolink II Plus or Minus for each antibody) and 
incubated at room temperature overnight. 2µl of the Stop Buffer was added to 
terminate the reaction, and the solution was incubated at room temperature for 30 
minutes. Finally, 24µl of Storage Solution was added to the conjugated probe for 
storage. 
2.3.7.2 Probing 
Slides were treated as described in section 2.3.6.1 with conjugated probes 
instead of PLA probes, but with one drop of the Block Solution from Duolink II 
Probemaker kit instead of diluted blocking solution. 
2.3.7.3 Detection 
In this thesis Duolink II Detection Reagents Red was used, which contained 
reagents for ligation and amplification.  
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After probing, the solution was tapped off the slides and the slides were 
washed twice in 1x Wash Buffer for 5 minutes under gentle agitation. 40µl of a 
solution for the oligo ligation containing the Ligation solution (Ligation stock diluted 
1:5 in dH2O) and the Ligase (diluted 1:40 in the Ligation solution immediately 
before addition to the samples, and vortexed to mix) was added to each reaction area, 
and the slides were incubated for 30 minutes. 
Subsequently, the Ligation-Ligase solution was removed from the slides and 
the slides were washed using 1x Wash Buffer A for 2 minutes x 2. A solution made 
by diluted Amplification stock (1:5 in dH2O) and Polymerase (diluted 1:80 in the 
Amplification solution before addition to the samples, and vortexed to mix) was 
added to the slides (40µl per reaction area). All the diluting steps were performed in 
dark because of the light sensitivity of the reagents. The slides were incubated for 
100 minutes.  
2.3.7.4 Preparation for imaging 
The slides were then washed twice in 1x Wash Buffer B for 10 minutes under 
gentle shaking, and then in 0.01x Wash Buffer B for 1 minute. The slides were left to 
dry in a dark room. Finally the slides were mounted with a coverslip using a minimal 
volume of Duolink II Mounting Medium with DAPI. 
2.3.7.5 Imaging 
PLA signals were visualized by a Zeiss Axioskop 2 fluorescent microscope 
with appropriate filters, and pictures were captured using Smart Capture 2 software.  
 
2.3.8 PLA using the DuoLink II Fluorescence kit 
The PLA experiments using this kit were performed with commercially 
supplied PLA probes, and followed the same steps as described in 2.3.6.1, 2.3.7.3, 
2.3.7.4 and finally 2.3.7.5. 
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2.4 Molecular biology methods 
2.4.1 PCR sample preparation 
2.4.1.1 RNA extraction 
To extract RNA from cultured cells, cell pellets were collected as described in 
section 2.2.1 and total RNA was extracted following the protocol for cultured cells 
supplied with the RNeasy Mini Kit (Qiagen).  
To extract RNA from frozen tissues, mouse tissue samples of less than 30 mg 
were used following the protocol for animal tissues supplied with RNeasy Mini Kit 
(Qiagen). 
During extraction, RNA was treated for 15 minutes with DNase I (Qiagen) to 
minimise any DNA contamination. RNA concentration (ng/µl) in samples was 
assessed using a NanoDrop 1000 device (Thermo Scientific). 
 
2.4.1.2 cDNA synthesis 
In order to synthesize cDNA from mRNA, the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) was used following the standard protocol 
supplied. Each reaction contained the following composition: 
10 x Reaction Buffer 2.0µl 
25x Deoxynucleotide Mix (100mM) 0.8µl 
10x RT Random primers 2.0µl 
RNase inhibitor 1.0µl 
Reverse transcriptase 1.0µl 
RNA sample 10µl 
dH2O 3.2µl 
     
The following condition was used to perform reverse transcription cycles: 
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Step 1 25oC 10 minutes 
Step 2 37oC  120 minutes 
Step 3 85oC 5 seconds 
Step 4 4oC 5 minutes 
The cDNA produced was kept at 4oC for short term or -20oC for long term 
storage. Samples with no RNA and samples with no reverse transcriptase were used 
as negative controls and were subjected to the same procedure as the other samples. 
 
2.4.2 PCR reactions 
2.4.2.1 PCR with Taq Polymerase 
In a regular PCR amplification, each reaction was prepared as follows: 
PCR Buffer 1µl 
2.5 mM Deoxynucleotide Mix 2µl 
Forward primer (0.25µM) 2.5µl 
Reverse primer (0.25µM) 2.5µl 
Sigma Taq buffer 2.5µl 
Taq DNA polymerase 0.5µl 
dH2O 14µl 
Template DNA 1µl 
 
The following conditions were programmed on an MJ Research PTC-255 DNA 
Thermal Cycler (MJ Research, USA) to perform the following DNA amplification 
cycles: 
Step 1 x1 95oC 3 minutes 
Step 2 x35 94oC  30 seconds 
  54-57oC 30 seconds 
  72oC 30 seconds 
Step 3 x1 72oC 10 minutes 
Step 4 x1 4oC 5 minutes 
 




2.4.2.1 Quantitative PCR (qPCR, Real Time PCR) 
qPCR was performed with a standard curve method for the quantification of 
gene expression. Primers of each gene were designed to amplify a product of 100-
180bp with no secondary structure and with low primer dimer formation. To avoid 
amplification of genomic DNA, primers were designed across splice junctions. The 
accumulation of PCR product was detected by a fluorescent SYBR Green dye 
(Finnzymes). 
For each reaction, the mixture was made up as follows: 
2x DyNAmo Flash Master mix 10µl 
Forward primer (0.25µM) 2µl 
Reverse primer (0.25µM) 2µl 
Template cDNA 2µl 
dH2O 4µl 
 
Samples with no template cDNA, samples with no Reverse Transcriptase 
sample, as well as a sample of dH2O only were used as negative controls.  
The following programme was used on MyiQ Thermal Cycler (Bio-Rad) to 
perform DNA amplification cycles: 
Step 1 x1 95oC 6 minutes 
Step 2 x40 95oC  10 seconds 
  60oC 20 seconds 
  72oC 20 seconds –data collection 
Step 3 x1 95oC 1 minute 
Step 4 x1 60oC 1 minute 
Step5 x80 60oC 10 seconds –data collection (temperature 
increased by 0.5oC  per cycle to produce 
the melt curve) 
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A series of diluted cDNA (1:10, 1:100, 1:1000 and 1:10000 respectively) was 
used to conduct a standard curve for each pair of primers. Results with efficiencies 
between 90-105% were used for further analysis. Samples were always in triplicate 
and the mean was taken for the analysis.  
To compare the gene expression in the tissues from wild type and wasted mice, 
the Ct value of the target gene (Cttgt) was normalised against the Ct value of the 
reference gene (Ctref) using the following fomula: 
∆Ct = Cttgt - Ctref 
The ∆Ct values from wild type (∆Ctwt) and wasted (∆Ctwst) mouse samples 
were then used to calculate the ratio of the gene expression in wasted to wild type 
mouse samples using the following formula:  
Comparative expression = 2- (∆Ctwst - ∆Ctwt) 
 
2.4.3 DNA electrophoresis 
DNA electrophoresis was performed to confirm the specificity of the PCR 
products.  Agarose gels were made by dissolving the agarose powder in 0.5x TBE 
buffer to reach a concentration of 1.5 to 2% (w/v) depending on the expected size of 
the PCR products. Agarose solution was microwaved for at least 2 minutes and 
cooled under running tap water. SYBR Safe DNA gel stain (Invitrogen) was added to 
the solution at a final concentration of 1% (v/v). The mixture was then poured into a 
plastic tray with combs, and left to set at room temperature. Orange G loading buffer 
at 10% (v/v) of the total sample volume was added to the DNA samples and mixed. 
The tray with the agarose gel was placed in an electrophoresis tank filled with 0.5x 
TBE buffer and the comb was removed. The mixed DNA samples were loaded into 
the wells, with a 100bp-1kb DNA ladder (New England BioLabs) loaded into one 
well as a molecular weight marker. The gel was run at 100 V for 30 to 90 minutes 
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until the orange line was approximately 0.5 cm from the edge of the gel. Gels were 
then removed from the tank and visualized under UVIdoc Gel Documentation 
System (UVItec). 
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Chapter 3 Expression of eEF1B subunits in diseases 
3.1 Introduction 
Protein synthesis is a crucial process in cells tightly controlled by a group of 
translation factors. Alteration in the expression of specific translation factors in 
tumourigenesis has been recognised. The roles of initiation factors (eIFs) in 
tumourigenesis have been extensively studied (reviewed in Silvera, Formenti et al. 
2010). eEF1A, especially eEF1A2, has also been found to be oncogenic (reviewed in 
Lee and Surh 2009).  
Increase of eEF1B expression in different cancers was also demonstrated 
(reviewed in section 1.4.4.1), and most of the studies focused on the change at the 
mRNA level. A study examining ten human cancer cell lines using real time PCR has 
observed overexpresson of eEF1Bδ and eEF1Bγ mRNA in breast cancer cell lines 
compared to normal human primary breast cell lines. eEF1Bδ showed an 
overexpresson (2- to 10-fold) in cell lines T47D, MCF-7, MDA-MB-361, and MDA-
MB-453, while eEF1Bγ showed an overexpresson (2- to 10-fold) in T47D and MCF-
7 cells (Joseph, O'Kernick et al. 2004). Another study using Northern blot analysis 
found increased levels of eEF1Bα and eEF1Bγ mRNA in T47D and MDA-MA-231 
cell lines, but not MCF-7 compared to non-transformed breast epithelial cell line 
MCF-10A. The study also demonstrated a significant increase of eEF1Bα and 
eEF1Bγ mRNA levels in breast cancer tissues over those in normal or fibroadenoma 
tissues (Al-Maghrebi, Anim et al. 2005). It is unknown whether the overexpresson of 
eEF1B subunits happens also at the protein level.  
The regulation of translation factors in neuronal cells is associated with 
neuronal defects. Translational control is important for long-lasting synaptic 
plasticity and memory by regulating the translation of certain RNAs in response to 
different synaptic stimulation, including titanic stimulation, treatment with brain-
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derived neurotrophic factor (BDNF) (reviewed in Wang and Tiedge 2004; Costa-
Mattioli, Sossin et al. 2009). Mutations of each of the five subunits of translation 
initiation factor eIF2B can cause leukoenocephalopathy with vanishing white matter 
(VWM) and childhood ataxia with central nervous system hypomyelination (CACH) 
(reviewed in Scheper, van der Knaap et al. 2007; Pavitt and Proud 2009). Absence of 
eEF1A2 causes a wasted phenotype in mice (Chambers, Peters et al. 1998; Abbott, 
Newbery et al. 2009) as described in section 1.5. 
So far not much is known about the involvement of eEF1B in MND. A study in 
the role of copy number variations (CNVs) in amyotrophic lateral sclerosis (ALS) 
reported eEF1Bδ as a potential ALS candidate (Wain, Pedroso et al. 2009). ALS is a 
fatal neurodegenerative disease characterized by the selective death of motor neurons 
in the spinal cord, brainstem and cortex. Using both region-based and gene-based 
association analyses, Wain and colleagues found that the gene encoding eEF1Bδ was 
covered in a CNV region that was associated with ALS. In 575 ALS cases examined, 
CNV overlapped with the EEF1D gene by at least 1 base pair; in 7 cases there were 
losses and in 3 gains. Microarray results have identified a lower level of eEF1Bγ, but 
not eEF1Bδ, in ALS patients than controls (Bakay, Wang et al. 2006). 
In this study the expression of eEF1B in breast cancer and MND cases were 
examined in order to further establish the relationship between eEF1B and diseases. 




3.2.1 eEF1B in normal and transformed cell lines 
Twelve cell lines were examined for the expression of eEF1B subunits at the 
protein level. Three of the cell lines are untransformed cell lines, including NIH3T3, 
Rat2 and Hek293 cell lines. Others are cancer cell lines originating from different 
human tissues. The species and cell types in detail are shown in Table 2.2. 
eEF1Bα was detected in all cell lines except in MCF-7, and showed a lower 
expression in Rat2, HeLa and T47D cell lines. An extra band lighter than the normal 
eEF1Bα band (about 20 kD, indicated by Arrow A in Figure 3.1 A) was detected in 
HeLa, HCT116, PC3, T47D, MDA-MB-231, and MDA-MB-453 cells, but not in 
others (Figure 3.1 A).  
eEF1Bδ appeared as two bands that were very close to each other, representing 
two isoforms of eEF1Bδ. Like eEF1Bα, there was no visible band in MCF7 cells, but 
the loading control shows that there was less protein in this track compared with 
most other cell lines. eEF1Bδ was weaker in Rat2, PC3, T47D cells. Extra bands 
lighter than normal eEF1Bδ were observed in T47D, HeLa and MDA-MB-453 cells 
(about 24 kD, indicated by Arrow B in Figure 3.1 B). In MCF7 cells where no 
eEF1Bα or eEF1Bδ was detected, longer exposure time of the blots also failed to 
show any band of eEF1Bα or eEF1Bδ (data not shown). Although in the blot shown 
in Figure 3.1 no eEF1Bδ band of normal size was shown in HeLa cells, in a separate 
Western blot on the same HeLa cell extract eEF1Bδ showed the normal sized bands 
as well as the lower band (data not shown). 
The expression patterns of eEF1Bγ in all cell lines tested were similar, with no 
obvious differences observed except that in MCF7 it was weaker (Figure 3.1 C).  
Since the cell lines tested are from different tissues and species, the results 
were not quantified to compare the expression level of eEF1B in cancer cell lines and 
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in untransformed cell lines, but it can be seen that compared to untransformed cell 
lines, eEF1Bα and eEF1Bδ have different expression patterns in certain cancer cell 
lines. 




























Figure 3.1. WB analysis of eEF1B subunits expression in untransformed 
cell lines (NIH3T3, Rat2 and Hek 293) and transformed cell lines (A549, 
HeLa, HCT116, LNCap, PC3, T47D, MCF7, MDA-MB-231 and MDA- 
MB-453). GAPDH was used as a loading control. Arrow A indicates the 
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3.2.2 eEF1Bα and eEF1Bδ in breast cancer tissues 
Since eEF1Bα and eEF1Bδ showed some changes in transformed cell lines, the 
expression of these two isoforms was then examined in a panel of breast cancer 
tissues.  
The breast consists of branching duct systems extending from the nipple and 
leading to the terminal duct lobular unit (TDLU), which branches into a cluster of 
small acini to form a lobule. The ducts and acini are lined by two layers of cells, a 
luminal layer of epithelial cells and a discontinuous basal layer of myoepithelial cells. 
The majority of breast stroma is composed of dense fibrous tissues and adipose 
tissues. 
In breast tissue eEF1Bα and eEF1Bδ were present in the cytoplasm of 
epithelial cells and myoepithelial cells, as well as in stromal cells (Figure 3.2 a-i and 
Figure 3.3 a-i). 
The expression of eEF1Bα in breast cancer tissues showed no prominent 
difference from normal tissues (Figure 3.2). In all 24 cases, only one (Figure 3.2 F) 
showed an apparent higher expression of eEF1Bα than normal tissue (Figure 3.2 f). 
In some cases the overall staining of eEF1Bα appeared stronger in cancer tissues 
than their corresponding normal tissues, but it was possibly because the sections 
derived from normal tissues contains mainly adipose tissue or fibrous interlobular 
tissues (Figure 3.2 b, c, d, e, h and k). In other cases the staining in cancer and 
normal tissues showed no significant difference.  
eEF1Bδ expression in breast cancer tissues (Figure 3.3) was similar to eEF1Bα, 
showing no significant difference between cancer and normal tissues. Apparent 
higher expression in cancer tissues was seen only in 2 cases out of 24 (Figure 3.3 A 
and K). Some cases of normal tissue contained mainly interlobular tissues (Figure 
3.3 b, c, d, e, h and k), as with those for eEF1Bα. There were several sections that 
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showed no staining for eEF1Bδ (Figure 3.3 E, J, i and j), which was most likely an 
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Figure 3.3 continued. 
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3.2.3 Knockdown of eEF1B in NSC34 cells 
All the RNAi experiments in this thesis were carried out in NSC34 cells. 
NSC34 is a hybrid cell line produced by fusion of motor neuron enriched, embryonic 
mouse spinal cord cells with mouse neuroblastoma, and expresss motor neuron 
properties (Cashman, Durham et al. 1992). NSC34 cells express the shorter isoforms 
as well as the tissue-specific isoform of eEF1Bδ, so the loss of shorter and longer 
isoforms could be studied respectively.  
 
3.2.3.1 Validation of siRNAs 
In order to validate the siRNAs, the cells transfected with each siRNA were 
collected and expression levels of corresponding proteins were examined using 
Western blotting. Different siRNA concentrations and cell harvest times after 
transfection were tested for optimisation (data not shown). In this study cells were 
harvested 72 hours after transfection using siRNAs at a concentration of 10nM. For 
each gene, two different siRNAs targeting different sequences were used and each 
knockdown was performed in triplicate. A non-targeting siRNA was used as a 
negative control. 
Commercial pre-designed siRNAs targeting each eEF1B subunit were shown 
to be specific and efficient under the experimental condition of this study. Two 
eEF1Bα siRNAs knocked down eEF1Bα protein in NSC34 cells with similar 
efficiency, respectively by 51% and 49% on average (Figure 3.4 A2). Similar results 
were gained by the two eEF1Bγ siRNAs, both of which knocked down eEF1Bγ by 
70% on average (Figure 3.4 D2). Both eEF1Bδ siRNAs knocked down eEF1Bδ in 
NSC34 cells, although siRNAa is more efficient than siRNAb. While eEF1Bδ 
siRNAa knocked down almost all eEF1Bδ protein, siRNAb knocked down eEF1Bδ 
proteins by 63% and eEF1BδL by 40% (Figure 3.4 B2).  




Since the commercial eEF1Bδ siRNAs knockded down all isoforms, siRNAs 
targeting eEF1Bδ exon 3, which is only transcribed in eEF1BδL, were designed to 
knockdown eEF1BδL. As shown in Figure 3.4 C, eEF1BδL siRNAs were also 
proved to be specific and efficient, which knockded down almost all eEF1BδL 
expression while other eEF1Bδ isoforms were not affected. However, because the 
track of negative control on the Western blot seemed to be affected with probably an 
air bubble since the band shown was slightly smaller than the correct size, the result 
of this knockdown was not quantified. 
 
3.2.3.2 Decrease of eEF1B did not affect cell viability 72 hours after transfection 
To demonstrate the effect of eEF1B knockdown on cell viability, an MTT 
assay was performed on NSC34 cells 72 hours after transfection. Absorbance at 
570nm were recorded and normalised with cells-only control, representing relative 
cell viability. As shown in Figure 3.5, the viability of cells transfected with each 
siRNA appeared slightly lower, but showed no statistical difference from controls. 
 






















GAPDH  37kD 
eEF1BδL 70kD 
eEF1Bδ 32-36kD 





Figure 3.4. siRNAs targeting eEF1B subunits knocked down eEF1Bα 
(A1), eEF1Bδ (B1), eEF1BδL (C) and eEF1Bγ (D1)  in NSC34 cells 
respectively, with quantifications of the relative expression levels of 
eEF1Bα (A2) eEF1Bδ (B2) and eEF1Bγ (D2). 1. Cells only. 2. Mock. 3. 
Non-targeting siRNAs. 4-6. Three samples treated with siRNAa. 7-9. 
Three samples treated with siRNAb. 
A2 
B2 
Chapter 3. Expression of eEF1B subunits in diseases 
79 
 
Figure 3.5. NSC34 cell viability after eEF1B subunits knockdown. 1. 
Cells only. 2. Mock. 3. Non-targetting siRNA. 4. eEF1Bα siRNAa. 5. 
eEF1Bα siRNAb. 6. eEF1Bδ siRNAa. 7. eEF1Bδ siRNAb. 8. eEF1BδL 
siRNAa. 9. eEF1BδL siRNAb. 10. eEF1Bγ siRNAa. 11. eEF1Bγ siRNAb. 




























Figure 3.4. continued. 
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3.2.4 eEF1B in MND 
3.2.4.1 eEF1B expression in the spinal cord of wasted mice 
In mouse spinal cord sections, eEF1B subunits were almost ubiquitously 
expressed in the cytoplasm of all types of cell (Figure 3.6 A, B, C1 and C2), except a 
few cells with no apparent positive staining (solid arrows in Figure 3.6).   
Wasted is a mouse model for MND which has no expression of eEF1A2, and is 
characterized by a wasted phenotype. The expression of eEF1B subunits in spinal 
cord from wasted mice was examined (Figure 3.6 a, b, c1 and c2) and compared with 
wild type spinal cord. In wasted mouse spinal cord the expression level of eEF1Bα 
appeared slightly lower than wild type mouse spinal cord, although there were a few 
cells that showed strong cytoplasmic staining (hollow arrows in Figure 3.6 a). 
Compared to wild type spinal cord, wasted mouse spinal cord showed a weaker 
staining for eEF1Bδ in some neurons and slightly stronger staining in others (Figure 
3.6 b). Similarly, compared to wild type, in wasted spinal cord eEF1Bγ was also 
weaker in motor neurons, and relatively stronger in several cells (hollow arrows in 
Figure 3.6 c1). When the total eEF1Bγ protein level was examined using Western 
blotting, however, there was no apparent difference between wild type and wasted 
type spinal cord (section 5.2.1 and 5.2.2.1 of this thesis). This can be explained by 
the uneven expression of eEF1Bγ in wasted spinal cord, which was weaker than wild 
type in some cells but stronger in others (Figure 3.6 C2 and c2) therefore the Western 
blot experiment did not identify any difference overall. Moreover, the cells with 
stronger staining also showed nuclear staining, unlike other cells. Some other cells in 
the wasted mouse spinal cord showed stronger staining of eEF1B than in wild type. 
The reason for the strong staining is not clear, but might perhaps suggest the 
existence of intracellular inclusion bodies. 
















Figure 3.6. IHC analysis of eEF1Bα (A and a), eEF1Bδ (B and b) and eEF1Bγ (C1, 
C2, c1 and c2) expression in wild type (A to C) and wasted (a to c) mouse spinal 
cord. Solid arrows indicate cells with no apparent staining. Hollow arrows indicate cells 
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3.2.4.2 eEF1B expression in the spinal cord of MND patients 
IHC analysis of eEF1B expression was also performed in human spinal cord 
sections, including 20 controls and 53 MND cases. Due to the restriction of patient 
sections, only eEF1Bα and eEF1Bδ were examined for this study. Unlike in wasted 
mice, the change of eEF1B expression in spinal cord sections from MND patients are 
more complicated.  
In the sections from normal spinal cord, eEF1Bα and eEF1Bδ had similar 
expression patterns, and both were detected in neurons and some of the glial cells 
(Right panels in Figure 3.7 and 3.8). All neurons showed strong staining, most of 
which was cytoplasmic while others showed both cytoplasmic and nuclear staining. 
Axonal staining was also visible in some of the controls. One of the controls 
presented no motor neurons (Figure 3.7 a5), and eEF1Bα showed weak staining in 
one control (Figure 3.7 d4) due to a poor section. eEF1Bα and eEF1Bδ were seen 
only in a subset (1/3 to 1/2) of the glial cells in normal spinal cord.  
The staining for eEF1Bα and eEF1Bδ in some spinal cord sections of MND 
patients showed an apparent difference from the controls (Left panels in Figure 3.7 
and 3.8). It can be seen by eye that compared to the control sections, some MND 
cases showed a weaker staining for eEF1Bα (Figure 3.7 A1, A4 and B3) and/or 
eEF1Bδ in neurons (Figure 3.8 A1, B2 and C3), while some showed more glial 
staining (Figure 3.7 B2, Figure 3.8 A2, D1, D3 and D4). Furthermore, MND cases 
showed less axonal staining than controls, probably because of the loss of MN in 
some cases, yet since the cases and controls are from different donors it is hard to 
draw any conclusion at this stage.  
Another significance of the results in MND cases is that some of the glial cells 
with eEF1Bα or eEF1Bδ staining appeared to be star-shaped or have branched 
processes, especially those in the white matter (Figure 3.7 B2, Figure 3.8 A2, C4, C5, 
D1, D3 and D4), which was almost absent in the controls. Although specific glial 




markers are needed for identification, the distinctive morphology suggests that they 
were likely to represent certain type(s) of glial cells, such as astrocytes or microglia. 









Figure 3.7. eEF1Bα in spinal cord sections from MND patients and controls. 
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Figure 3.7. continued. 
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Figure 3.7. continued. 
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Figure 3.8. eEF1Bδ in spinal cord sections from MND patients and 
controls. Left panel. Representative MND cases. Right panel. Controls. 
Scale bar, 200µm. 
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Figure 3.8 continued. 
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Figure 3.8 continued. 
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In order to compare the expression between controls and MND patients, 
quantification of the IHC results was attempted. 
At first IPLab (version 3.9.5 r4 for Mac, BD Biosciences) imaging software 
was used to quantify the intensity of staining and different parameters were 
calculated and compared. To validate the method, a group of representative sections 
was examined before applying the method to the entire population. Four sections that 
showed apparent different expression patterns of eEF1Bδ were chosen for this pilot 
study, including two controls and two MND cases (Figure 3.9). One of the two 
controls had strong staining in motor neurons and moderate staining in glia (Figure 
3.9 a1), while the other showed moderate staining in neurons and glia (Figure 3.9 a2). 
In both control sections about one third of the glial cells appeared to be stained. One 
of the two MND cases chosen showed an apparent weaker staining in neurons 
(Figure 3.9 A1) and the other showed an increased number of glial cells stained for 
eEF1Bδ (Figure 3.9 A2). 
The result obtained is listed in Table 3.1. Although it can be seen by eye that 
both control sections showed a stronger staining in motor neurons, the overall 
intensity quantified (Sum) was not in accordance with this observation, neither was 
the average intensity per area (Mean). The same situation was found with glial 
staining. To avoid the variability that was possibly caused by different runs of the 
IHC experiment procedure, staining intensities of two cell types within one section 
were also compared. MN/Glia (sum/area) represents the ratio of staining intensity of 
motor neurons to glial cells per area. The numbers for the two MND cases are 
slightly lower than controls, meaning a lower intensity in motor neurons and/or 
higher intensity in glial cells. Yet the numbers were very close and the difference 
was not significant. Additionally, when the numbers of cells stained in each selected 
area were counted, the result was not in line with the apparent increase of glial cells 
stained observed by eye in Figure 3.9 A2. This was likely because the imaging 
system did not distinguish between brown and blue staining and hence might have 




   




Figure 3.9. Immunohistochemical analysis of eEF1Bδ expression in representative spinal cord sections. A1 and 









 Cell type Sum Area 











MN 2208020 10711 32 206 69000 
1.036 ± 0.02 16 ± 0.98 
Glia 1.6×106 ± 407649 8310 ± 2120 380 ± 96 197 ± 3 4257 ± 255 
a2 
MN 4291599 25207 232 170 18498 
0.999 ± 0.01 4 ± 0.3 
Glia 3.0×106 ± 310541 17342 ± 1681 637 ± 65 170 ± 2 4694 ± 398 
A1 
MN 2512142 13316 144 189 17445 
0.997 ± 0.004 5 ± 0.4 
Glia 2.7×106 ± 515931 14062 ± 2664 764 ± 97 189 ± 1 3454 ± 237 
A2 
MN 4031494 23032 213 175 18927 
0.966 ± 0.02 5 ± 0.3 
Glia 2.1×106 ± 291747 11618 ± 1601 597 ± 73 181 ± 4 3516 ± 175 
Table 3.1. Comparison of eEF1Bδ expression in representative spinal cord sections. a1 and a2. control sections. A1 and A2. MND sections. 
Sum. Overall intensity counted. Area. The total area of brown staining. MN. Motor neuron. The neuron staining was examined in anterior horn. 
The glia staining was examined in four or five independent areas of same extent in anterior horn and in white matter, and the mean±SEM is shown.  
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Therefore the staining in controls and MND cases was scored by eye (twice), 
including the staining intensity in motor neurons and glial cells respectively, the 
approximate ratio of glial cells stained, as well as whether there were branched glial 
cells stained. A summary is listed in Table 3.2 and original images of each section 
are listed in Appendix 1 and 2. 
Compared to control sections, the staining for eEF1Bα in several MND cases 
showed certain differences. Some cases showed a lowered level of overall expression 
(Green in Table 3.2 eEF1Bα). Some showed an increased number of glial cells that 
were stained (Red in Table 3.2 eEF1Bα), and also in 4 cases some of the glial cells 
stained for eEF1Bα showed a branched morphology (Blue in Table 3.2 eEF1Bα). 
The rest of the cases did not show visible difference from control sections. 
As to eEF1Bδ expression, the difference between MND and normal spinal cord 
was more striking. Like eEF1Bα, eEF1Bδ in some cases also showed a lower level in 
both neurons and glial cells (Green in Table 3.2 eEF1Bδ). However, there were 
another 10 cases that showed a lower expression in motor neurons but not in glial 
cells (Purple in Table 3.2 eEF1Bδ). In the rest of the cases, 16 showed more 
branched glial cells stained with eEF1Bδ antibody (Red in Table 3.2 eEF1Bδ), 
including 11 cases with more glial cells stained overall (Blue in Table 3.2 eEF1Bδ).  
Furthermore, the expression patterns of the two proteins were not coordinated 
in all the sections examined. For example, some of the control sections showed an 
apparent low level of eEF1Bδ but a moderate level of eEF1Bα in motor neurons, and 
a high level of eEF1Bδ and moderate level of eEF1Bα in glial cells (Table 3.2 c3). 
Another control section had lower expression of eEF1Bα than eEF1Bδ in glial cells 
(Table 3.2 b2). Similarly in some MND cases the expression patterns of eEF1Bα and 
eEF1Bδ in the spinal cord from the same patients were different. In some of the cases 
where eEF1Bδ was increased in glial cells the expression of eEF1Bα showed no 
apparent difference from control (Table 3.2 C4, C5, C7, D2 and F7), or even lower 
(Table 3.2 C8, D4 and F6). In some cases of eEF1Bδ staining many branched glial 




cells were stained, which were hardly seen in corresponding sections with eEF1Bα 










Staining Intensity Total glia 
stained 
Branched 
glia stained (MN) (glial) (MN) (glial) 
a1 Control H M + Only a few H M/H +  
a2 Control M M ++  M/H M/H ++  
a3 Control M M +  M M +  
a4 Control VH M +  VH H ++  
a5 Control No MN M/H ++  M M/H ++  
b1 Control M/H M +  M/H M/H ++ Only a few 
b2 Control M/H L +  M/H M/H +  
b3 Control M/H M +  M M +  
b4 Control M M/H + Only a few M/H M/H +  
b5 Control M M +  M/H M +  
c1 Control H H ++  M/H M/H ++  
c2 Control M/H M ++ Y M M ++  
c3 Control M M ++ Y VL/M H ++ Y 
c4 Control M M ++  M M +  
c5 Control M M/L +  H H ++ Y 
d1 Control H M +  M M +  
d2 Control M/H M +  M M +  
d3 Control H M ++  M M +  
d4 Control M M +  M M +  
d5 Control H M ++  M/H M/H ++  





  eEF1Bα eEF1Bδ 




Staining Intensity Total glia 
stained
Branched 
glia stained (MN) (glial) (MN) (glial) 
A1 MND L L +  VL M ++  
A2 MND M M/H ++ Only a few M/L Only H in +++ Y 
A3 MND M/H L/M +  Poor section Poor section +  
A4 MND M L +  M M +  
A5 MND M/H H ++ Only a few VL VL, some H +  
A6 MND M M ++ Only a few L M ++  
A7 MND M L/M ++  L/M L +  
A8 MND M L/M +  M L/M +  
B1 MND M/H L/M +  M/H L/M +  
B2 MND H M/H +++ Y L/M L/M +  
B3 MND H M ++ Only a few M L-M/H ++ Only a few 
B4 MND L/M L/M +  M M/H ++  
B5 MND H L/M +  H H ++  
B6 MND L L only a few  M/H M/H ++  
B7 MND M/H M ++  M/H M ++  
B8 MND H M/H +++ Only a few M M ++  
C1 MND M M ++  M L ++  
C2 MND M/H L, H in some ++  L/M M ++ Only a few 
C3 MND M L ++  L M ++  
C4 MND H M +  M M/H ++ Y 
C5 MND H M/H ++  M/H H ++ Y 
C6 MND M M ++ Y M M ++ Y 
C7 MND M/H L/M ++ Only a few M M/H ++ Y 
C8 MND M/H L +  M/H M/H +++ Y 
D1 MND M M ++  M M +++ Y 





  eEF1Bα eEF1Bδ 




Staining Intensity Total glia 
stained
Branched 
glia stained (MN) (glial) (MN) (glial) 
D3 MND M/H M +++ Y M M/H +++ Y 
D4 MND M L +  M/H H +++ Y 
D5 MND H M +  M/H M +  
D6 MND H M ++  L/M L/M +  
D7 MND M/H M ++  L/M L, H in some +  
D8 MND M M/H ++  VL VL +  
E1 MND M L +  VL Few but H +  
E2 MND M L +  VL L +  
E3 MND H L/M +  L/M H ++ Y 
E4 MND M L/M +  M M ++  
E5 MND H M ++ Only a few M/H M ++  
E6 MND M M ++  M M ++  
E7 MND L/M L +  M M ++  
E8 MND M/H M/H +++ Only a few M(not many M ++  
F1 MND M/H M ++  M/H M ++  
F2 MND M M ++ Only a few L/M M ++  
F3 MND M/H M/H ++  L/M/H M ++  
F4 MND M L, H in some ++  M L, H in some ++ Only a few 
F5 MND L L a few  L M ++  
F6 MND L/M L +  H H +++ Y 
F7 MND M/H M/H ++  M/H H +++ Y 
F8 MND M/H M +  M/H M/H ++ Only a few 
G1 MND M M +  L M/H ++  
G2 MND M/H M +++ Y M/H H +++ Y 
G3 MND M/H M ++ Only a few M M/H +++ Y 
G4 MND M/H L +  M H +++ Y 
G5 MND M L/M + Only a few M/H M/H +++ Y 
Table 3.2 continued 
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3.3 Discussion 
Considerable evidence suggests that protein synthesis plays an important role 
in tumourigenesis, and many of the regulatory factors involved in protein translation 
were found to be potential oncogenes. All three subunits of eEF1B showed 
overexpression in various cancers respectively, including breast cancer (Al-Maghrebi, 
Anim et al. 2005), lung cancer (Liu, Chen et al. 2004), oesophageal cancer (Mimori, 
Mori et al. 1996; Ogawa, Utsunomiya et al. 2004), colon cancer (Chi, Jones et al. 
1992; Ender, Lynch et al. 1993; Mathur, Cleary et al. 1998). Overexpression of 
eEF1Bδ induced transformation of cultured cells and subcutaneous tumours in nude 
mice (Joseph, Lei et al. 2002). 
The studies to date on eEF1B expression in cancer are extensive but not 
systematic. Previous studies in breast cancer cell lines have identified an increase of 
all three eEF1B subunits at the mRNA level respectively, although one of the two 
studies observed eEF1Bγ overexpresson in the MCF-7 cell line while the other one 
did not. This inconsistency is perhaps a result of different experimental methods 
(Real Time PCR and Northern blot) and/or cell strains used in different labs. Here in 
this thesis the expression of eEF1B subunits in different cell lines, including four 
breast cancer cell lines, was examined at a protein level. Unlike the previous reports 
comparing the expression levels of eEF1B subunits between cell lines or tissues, the 
results in this thesis were not quantified due to the lack of a negative control from 
corresponding tissue and species for each type of cancer cell line.  
The two subunits of eEF1B which carry the GEF ability, eEF1Bα and eEF1Bδ, 
showed an altered expression pattern in some of the cell lines. Extra bands lighter 
than normal for eEF1Bα and eEF1Bδ were observed in several cancer cell lines 
while in non-transformed cell lines there was only a single band for eEF1Bα and two 
for eEF1Bδ representing different variants. Since all cell lysates were prepared in 
buffer containing protease inhibitors, it seemed unlikely that the shorter bands were 




caused by protein degradation. Still more careful characterization will be necessary. 
These lower bands were seen in some cancer cell lines but not in others, which was 
probably due to the different origins of the cell lines. 
Nevertheless, it seems the lower bands for each subunit existed in different cell 
lines. eEF1Bα showed the lower band in HeLa, HCT116, PC3, T47D, MDA-MB-
231 and MDA-MB-453, while eEF1Bδ, in T47D and MDA-MB-453. In all cell lines 
tested eEF1Bγ showed one single band. Moreover, compared with other two subunits, 
eEF1Bδ had a lower expression level in PC3 cell line. The unbalanced expression 
pattern of eEF1B subunits was also demonstrated at both mRNA and protein levels 
in human cardioesophageal carcinoma (Veremieva, Khoruzhenko et al. 2010). 
Although the three subunits are considered to form a complex and each has been 
reported respectively to show an altered expression in cancer, the non-coordinated 
changes observed in cancer cells and tissues indicate that the involvement of each 
subunit in carcinogenesis may be regulated at the level of individual subunits.  
Although the reports in breast cancer cell lines and tissues discovered 
overexpresson of eEF1B mRNA, in this study when the expression of eEF1Bα and 
eEF1Bδ proteins in breast cancer tissues were examined using IHC and compared 
with corresponding non-neoplastic tissues, no significant difference was observed. 
Only a few samples (2 out of 24 cases) showed a stronger staining for eEF1Bα or 
eEF1Bδ protein. This is likely due to the fact that some tissues contain mainly 
adipose tissue or fibrous interlobular tissues, and therefore were hardly stained. It is 
also worth noting that the control tissues were taken from the same patients as of the 
cancer tissues, and some control tissues showed apparent invasive carcinoma (Figure 
3.2 j and 3.3 h), which is possible responsible for the similar staining between breast 
cancer tissues and corresponding control tissues. Since the sample size in this study 
is relatively small and some sections contained predominantly adipose tissue, a larger 
sample size is required for further study, and no conclusion can be drawn at this 
stage from these preliminary data without suitable negative controls. The research on 
the other elongation factor eEF1A2 had different findings. While  cultured breast 




cancer cells showed a higher level of eEF1A2 mRNA, breast cancer tissues also 
showed apparent overexpression at the protein level of eEF1A2 (Joseph, O'Kernick 
et al. 2004; Tomlinson, Newbery et al. 2005). This is probably because as a tissue-
specific protein, eEF1A2 is normally not expressed in breast, so its high expression 
level in breast cancer tissues is more significant. 
The effect of eEF1B downregulation was also investigated in this thesis. 
Previous reports on the loss of eEF1B were carried out on yeast strains. Yeast eEF1B 
consists of two subunits, eEF1Bα (the GEF), and eEF1Bγ with no GTP exchange 
activity. Therefore it is not surprising that the absence of eEF1Bα is lethal in S. 
cerevisiae as the conversion of GDP to GTP on eEF1A is greatly dependent on its 
GEF (Hiraga, Suzuki et al. 1993). However, mammalian cells are more complicated. 
Unlike yeast eEF1B, the mammalian eEF1B complex has two subunits that have 
GTP exchange activity (van Damme, Amons et al. 1990), which raises the question 
of whether the two subunits play the same role in translation elongation and other 
cellular functions. The preliminary study in this thesis examined mammalian cell line 
NSC34 with knockdown of each eEF1B subunit.  
The siRNAs used were all efficient and specific to knock down targeting 
proteins, although the efficiency may vary. However, the resulting loss of expression 
seemed not to affect cell viability within the time period of this study. One possible 
explanation is, as stated above, that eEF1B complex has two subunits that have GTP 
exchange activity. Although human eEF1Bδ failed to correct the growth defect 
caused by loss of eEF1Bα in S. cerevisiae (Carr-Schmid, Valente et al. 1999), this 
does not exclude the possibility that in mammalian cells, the effect of one subunit 
knockdown could be compensated for by the existence of the other and therefore 
does not significantly reduce cell growth at least in the short term. Furthermore, 
NSC34 cells express both isoforms of eEF1A. The way the two isoforms function 
with eEF1Bα and eEF1Bδ is not yet clear, and is in fact rather complicated, as 
discussed in detail in chapter 5 of this thesis.  




eEF1Bγ, the third eEF1B subunit, contains no nucleotide exchange activity. 
Even though it is often found tightly associated with eEF1Bα, it seems not directly 
involved in the GTP exchange function of the complex. A study found that 
knockdown of eEF1Bγ reduced protein synthesis by about 22% in HeLa cells (Kim, 
Kellner et al. 2007),  yet disruption of both genes encoding eEF1Bγ in S. cerevisiae 
did not affect protein translation or cell viability (Kinzy, Ripmaster et al. 1994), the 
second of which is in line with our observation in NSC34 cells.  
The expression of eEF1B was also examined in spinal cord from mice and 
humans in health and with neuronal disease. Wasted mice are characterised by the 
deletion of eEF1A2, which is the only form of eEF1A in motor neurons in normal 
spinal cord. In wasted mice, the expression of eEF1B subunits in some neurons was 
lower than in wild type, yet to different extents for the different subunits. The down-
regulation may reflect the poor condition of motor neurons in wasted mice due to 
eEF1A absence, or possibly a direct result of eEF1A2 loss in these cells, which is 
further discussed in the following chapters of this thesis.  
On the other hand, eEF1B expression in human spinal cord also showed 
differences between normal and MND sections, especially eEF1Bδ. The first 
difference observed was the glial staining in the sections. In the controls only about 
1/3 to 1/2 of glial cells showed visible eEF1B staining, while MND cases appeared to 
show more glial cells which expressed eEF1Bδ. This is in accordance with the 
pattern of glial activation which happens in response of central nerve system (CNS) 
injury or disease. 
There are mainly two types of glial cells involved in glial activation, microglia 
and astrocytes. Microglia are small glial cells that are characterised as macrophages 
in CNS which are considered to serve as innate immune system in CNS monitoring 
the pathology of neurons (Glezer, Simard et al. 2007). In healthy matured CNS, 
microglia have a ramified morphology with processes branching off the small soma. 
Upon activation, microglia undergo morphological change, with processes 




withdrawal and an amoeboid appearance (Saijo and Glass 2011). Microglial 
activation can be identified by the increased expression of marker such as ionized 
Calcium-binding adapter molecule 1 (Iba1) (Ito, Tanaka et al. 2001) and macrosialin 
(CD68 or ED-1) (Bauer, Sminia et al. 1994). 
Astrocytes have a star-shaped morphology. In gray matter astrocytes have short 
and highly branched processes, and in white matter, long fibre-like processes.  
Astrocytes have many roles in the CNS, such as providing trophic support for 
neurons (Pellerin and Magistretti 2004), maintaining the extracellular ionic 
environment and pH for neurons, regulating synapses (Slezak and Pfrieger 2003; 
Santello and Volterra 2009), contacting with blood vessels and mediating CNS blood 
flow in response to changes of neuronal activity (Schummers, Yu et al. 2008), and 
involvement in CNS metabolism (Sofroniew and Vinters 2010). Astrocytes are 
activated in response to CNS injury and diseases, characterised by a significant 
increase in expression of glial fibrillary acid protein (GFAP) and the marker 
aldehyde dehydrogenase 1 family, member L1 (ALDH1L1) (Cahoy, Emery et al. 
2008). Moreover, astrocytes were found to contribute to microglial activation 
(Ovanesov, Ayhan et al. 2008).  
The branched glial cells that were hardly seen in controls but appeared in some 
MND cases were likely to be astrocytes or microglia according to their morphology, 
and presumably most of them were astrocytes since microglia withdraw their 
branched processes and acquire a round morphology when activated in injured CNS. 
However, due to the restriction of the spinal cord sections from patients, the sections 
were not examined for the expression of glial markers, such as CD68 for microglia 
and GFAP for astrocytes which are overexpressed in microgliosis or astrogliosis 
respectively. Further study is needed to demonstrate whether the upregulation of 
eEF1Bδ in MND cases happened in activated glial cells, which can be addressed by 
double immunofluorescent staining the sections with eEF1Bδ antibody together with 
a glial marker. Besides, upon CNS injury some of the astrocytes start to proliferate, 
(Buffo, Rite et al. 2008), which may also contributed to the number increase of 




stained astrocytes. Nevertheless the expression of eEF1Bδ protein in glial cells of 
some MND patients showed a similar pattern to reactive gliosis, with more glial cells 
showing eEF1Bδ staining. 
In addition, in the spinal cord sections which showed more glial staining for 
eEF1Bδ, a diffuse morphology of glial cells was observed in several cases (Appendix 
2 F7, G2, G3, G4 and G5). Reactive astrogliosis is a finely gradated continuum of a 
progressive process which varies with the severity of the injury or disease in the CNS. 
According to the classification of reactive astrogliosis proposed by Sofroniew and 
Vinters, severe diffuse reactive astrogliosis shows upregulation of GFAP and other 
genes, with hypertrophy of cell body and processes, together with astrocyte 
proliferation and broader process extension which leads to overlapping of 
neighbouring astrocyte processes and consequently diffused individual cell domains 
(Sofroniew and Vinters 2010). Although the pathological diagnosis information is 
not detailed in the severity of MND for each patient (the information of all the 
patients is listed in table 2.4), the observation of diffuse star-shaped glial cells that 
showed eEF1Bδ staining in some MND cases supports the hypothesis that the 
increase of eEF1Bδ expression could be at least partly explained by reactive 
astrogliosis. It is important to note that the control case that also showed overlapping 
glial processes and a stronger expression of eEF1Bα and eEF1Bδ (Figure 3.7 c3 and 
3.8 c3) was from a donor without MND but showed some hypoxic change, which 
triggers reactive astrogliosis as well (Miller, Bartley et al. 2005; Fang, Li et al. 2008). 
The other type of change was a lower expression level of eEF1B, mainly for 
eEF1Bδ, in motor neurons (in about 20% of the cases) instead of much change in 
glial cells. This downregulation in motor neurons is similar to what was observed in 
spinal cord sections from wasted mice, which again could have several possible 
reasons. The expression of eEF1A2 in these cases (IHC performed by Dr. Newbery 
in our group) was compared with eEF1Bδ. Representative cases with a lower 
expression of eEF1A2 and/or eEF1Bδ were chosen, including 2 controls and 4 MND 
cases, and the same regions of each case were compared. It appeared that the 




expression patterns of eEF1A2 and eEF1Bδ were not always coordinated (Appendix 
3). Some cases showed lower level of both proteins overall, but the expression in 
each motor neuron was not coordinated (Appendix 3 E1 and G1). However, caution 
must be applied when comparing the expression in individual cells because the two 
sections from each case were not necessarily identical. Nevertheless these data 
suggest that eEF1A2 is unlikely the direct reason for the downregulation of eEF1Bδ 
in motor neurons of the human MND cases examined.  
Interestingly, even though eEF1Bα expression in MND spinal cord showed a 
similar pattern to eEF1Bδ, in some of the cases where eEF1Bδ is upregulated in glial 
cells the expression of eEF1Bα showed no apparent difference from controls. This is 
the same case as in wasted mouse spinal cord sections. Therefore it is likely that the 
two subunits are regulated through different pathways. More discussion on this issue 
is in Chapter 5 in this thesis.  
These preliminary findings suggest the possible involvement of eEF1B 
subunits in neuronal diseases. For future investigation of the role of eEF1B in health 
and diseases, a larger sample size of cancer specimens originating from different 
tissues will be necessary, and protein overexpresson experiments in cultured cells as 
a complement of knockdown experiments will be helpful. Probably a different 
method to demonstrate cell viability after eEF1B knockdown is needed to determine 
the effect of loss of each eEF1B subunit. Since eEF1B subunits, especially eEF1Bδ, 
showed potential relevance to reactive gliosis, it would be of interest to perform 
immunoflourescence experiments staining the spinal cord sections from MND 
patients with eEF1Bδ and glial markers such as GFAP and CD68 to demonstrate 
whether the increase of eEF1Bδ expression indeed happened in activated astrocytes 
and/or microglia. 
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Chapter 4 eEF1A2 and eEF1B are physically associated 
4.1 Introduction 
During the process of eukaryotic protein translation elongation, eEF1A delivers 
aminoacyl-tRNA to the A site of the ribosome, aided by its GTP exchange factor, 
eEF1B. In mammals eEF1B is composed of three subunits: eEF1Bα, eEF1Bδ and   
eEF1Bγ, and was shown to form a ‘heavy’ complex (eEF1H) with eEF1A (Janssen, 
van Damme et al. 1994). The structure of eEF1H has been broadly studied and 
several two-dimensional models mapping the structure of eEF1H have been 
proposed in the last twenty years (reviewed in section1.4 in this thesis). However, 
while eEF1A has two isoforms in mammals as well as in Xenopus (Newbery, 
Stancheva et al. 2011), one of which, eEF1A2, is tissue-specific and expressed only 
in certain cells and tissues (Lee, Francoeur et al. 1992; Chambers, Peters et al. 1998; 
Kahns, Lund et al. 1998; Khalyfa, Bourbeau et al. 2001; Newbery, Loh et al. 2007), 
most of the models proposed to date did not give information pertaining to eEF1A2. 
One of the studies that took eEF1A2 into account was a series of yeast two-
hybrid (Y2H) analyses, where the cDNAs of both isoforms of eEF1A and all three 
eEF1B subunits, were cloned into Y2H expression vectors respectively to map the 
interaction pattern among the proteins. It was found that in contrast with eEF1A1, 
eEF1A2 has little or no affinity for eEF1Bα and eEF1Bδ (Mansilla, Friis et al. 2002), 
the two eEF1B subunits that have GTP exchange activity. It is perplexing as the two 
isoforms of eEF1A were thought to have similar abilities to bind to eEF1B, 
particularly eEF1Bα. The amino acid sequences of the two isoforms of human 
eEF1A are 92% identical. Comparative three-dimensional models of human eEF1A1 
and eEF1A2 on the basis of the crystal structure of homologous eEF1A from yeast 
mapped all the non-identical residues on one side of the molecule, while the binding 
sites for eEF1Bα were mapped on the other side, as shown in Figure 4.1 (Soares, 
Barlow et al. 2009). In addition, unlike eEF1A1 which binds GTP more strongly than 




GDP, eEF1A2 showed more affinity to GDP than GTP (Kahns, Lund et al. 1998), 
therefore eEF1A2 was thought to be more dependent on GEF than eEF1A1 was.  
One explanation proposed for the different affinities of the two isoforms of 
eEF1A to eEF1B was the potential existence of a different GEF, other than the 
eEF1B subunits presented in the Y2H experiments (Mansilla, Friis et al. 2002), for 
eEF1A2. For instance, multiple chromosomal isoforms of human eEF1Bα have been 
identified, one of which transcribes a brain- and muscle-specific cDNA (Pizzuti, 
Gennarelli et al. 1993). This expression pattern is in accordance with that of eEF1A2 
and thus might act as the GEF specifically for eEF1A2. Yet this gene was later found 
to be intronless, absent from mice, and a result of retrotransposition (Chambers, 
Rouleau et al. 2001). Other than eEF1Bα, eEF1Bδ exists in different isoforms, with 
the longest isoform, eEF1BδL, expressed in a tissue-specific manner, found in brain, 
spinal cord and testis only (Kaitsuka, Tomizawa et al. 2011), which is overlapping 
with the expression pattern of eEF1A2. This tissue-specific isoform of eEF1Bδ was 
not included in the Y2H experiments mentioned above. Compared to the ubiquitous 
eEF1Bδ, eEF1BδL has an extra exon that is transcribed and encodes a 367-amino-
acid long N-terminus, which contains a putative nuclear localization signal at amino 
acids 86-93 (Kaitsuka, Tomizawa et al. 2011). So far little is known about this tissue-
specific isoform and it is not clear if there is any other binding site in eEF1BδL apart 
from the leucine zipper motif that exists in both isoforms. The possible interaction of 
eEF1A2 with eEF1BδL should not be ruled out. The question of whether eEF1A2 is 
associated with eEF1B as eEF1A1 does remains unanswered; further study of 
endogenous proteins is required to understand the relationships between eEF1A2 and 
eEF1B. 
Different techniques were involved in previous studies on the structure of 
eEF1H, including reconstitution of purified subunits (Bec, Kerjan et al. 1994), 
polyacrylamide gel electrophoresis and limited proteolysis (Janssen, van Damme et 
al. 1994), analysis of the isolated, native complex (Minella, Mulner-Lorillon et al. 
1998), in vitro phosphorylation (Sheu and Traugh 1999), Y2H (Mansilla, Friis et al. 




2002), and electron micrographs of protein fractions from gel filtration high-
performance liquid chromatography (HPLC) (Jiang, Wolfe et al. 2005). All of the 
techniques, in vivo or in vitro, were performed with isolated, pull-down or exogenous 
proteins, without revealing the transient interactions of endogenous proteins 
happening within cells. In this study Proximity Ligation Assay (PLA) was used to 
investigate the interactions among endogenous eEF1H components in situ.  
PLA is based on dual binding by a pair of probes to the two proteins of interest 
via two specific antibodies raised in different species, in order to generate DNA 
strands, which then are amplified and serve as surrogate markers for the detected 
protein molecules (Fredriksson, Gullberg et al. 2002; Soderberg, Leuchowius et al. 
2008) (reviewed in detail in section 1.6). Compared to other techniques listed above, 
PLA has the advantage of investigating endogenous protein interactions in situ, 
either on tissues or cultured cells directly. It could give information on the 
distribution of interacting proteins between individual cells. PLA could also be 
modified to detect interactions between proteins and specific DNA or RNA 
sequences (Gustafsdottir, Schlingemann et al. 2007), which will not be discussed in 
this thesis. 
The aim of this project is to use in situ PLA technique to establish the potential 
interactions between eEF1A2 isoforms and eEF1B subunits in mammalian cells, and 
thus to further investigate the structure of eEF1H. 






Figure 4.1. Models of human eEF1A1 and eEF1A2 based on yeast eEF1A. 
Two equivalent views rotated by 180° about the y-axis of the surface 
representation of the crystal structure of yeast eEF1A (magenta, top panel), and 
the 3D models of eEF1A1 (blue, middle panel) and eEF1A2 (red, bottom panel). 
Locations of exposed variant side-chains are mapped onto the surface of the two 
human eEF1A models (green) and labelled on the eEF1A2 model, with the variant 
residue from eEF1A1 shown on the right hand side of the label. The C-terminal 
eEF1Bα-binding site (cyan) and GDP-binding site (yellow) are mapped on the 
crystal structure of yeast eEF1A. The locations highlighted in red are mutations 
that inhibit actin-bundling without altering translation in vivo. There are no 
variants in proximity to those residues implicated to be involved in translational 
fidelity (green). The two variants, Gln164Glu and Glu168Asp, found in close 
proximity to Arg166, a conservative mutation for the equivalent residue in yeast 
that was shown to reduce dependence on eEF1B (orange), both retain their main-
chain H-bonds with Arg166 (taken from Soares, Barlow et al. 2009). 
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4.2 Result 
4.2.1 Colocalization of eEF1A2 with eEF1Bα and eEF1Bδ in mouse spinal cord  
4.2.1.1. Colocalization of eEF1A2, eEF1Bα and eEF1Bδ in spinal cord sections 
At the time of this project, commercial eEF1A antibodies available recognized 
both isoforms, therefore a eEF1A2 specific polyclonal antibody generated in our lab 
was used in this and all the following studies. The specificity of this antibody has 
been demonstrated earlier by our lab (Newbery, Loh et al. 2007), and in this study 
the antibody was also tested in spinal cord sections from healthy mice, as well as 
wasted mice. Wasted mice have no expression of eEF1A2 (explained in section 1.5), 
which meant they could be used as a negative control for the antibody. As expected, 
in wasted spinal cord sections no positive staining was observed (Figure 4.2 A), and 
in normal spinal cord sections, positive staining was observed only in the motor 
neurons (Figure 4.2 B). Mouse spinal cord also expresses eEF1Bα and eEF1Bδ 
almost ubiquitously in all types of cell, although to different extents in different types 
of cells (Figure 4.2 B and C). 
Immunofluorescence results show the same. A direct view of the colocalization 
of eEF1A2 and eEF1Bα or eEF1Bδ in motor neuron cytoplasm in spinal cord is 
indicated by the yellow colour. In the cytoplasm of other cells only eEF1B subunits 






Figure 4.2. The expression of eEF1A2, eEF1Bα and eEF1Bδ in mouse spinal cord. A.eEF1A2 in wasted mouse 
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Figure 4.3. IF images of the expression of eEF1A2 and eEF1Bα (top panel) or eEF1Bδ (bottom panel) on mouse spinal cord. Arrows indicate cells without apparent 
eEF1Bα or eEF1Bδ expression. 
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4.2.2 PLA of eEF1A and eEF1B 
4.2.2.1 PLA on mouse spinal cord sections 
The colocalization of eEF1A2 and eEF1B subunits in motor neurons has been 
confirmed by IHC and IF; therefore the next step is to investigate whether the two 
proteins are in close proximity to form a complex. As a specific and sensitive 
technique, PLA enables a direct observation of the interacting endogenous proteins 
in cells and subcellular compartments. 
At first the experiments were performed on mouse spinal cord sections where 
the IF experiments were carried out. Spinal cord is one of the tissues that express 
eEF1A2, as well as eEF1BδL. Spinal cord sections from wasted mice where eEF1A2 
is absent could be used as a negative control. Unfortunately, despite the fact that 
spinal cord should have been an ideal object for this study, this experiment 
encountered many difficulties. As shown in Figure 4.4 B and C, the PLA experiment 
of eEF1A2 with eEF1Bα and with eEF1Bδ did show PLA signals, recognized as red 
dots, indicating that eEF1A2 is in close proximity with eEF1Bα and eEF1Bδ. 
However, and when the spinal cord sections from wasted mice were examined, the 
same combination of antibodies gave similar positive signals around many nuclei 
(Figure 4.4. D), although weaker than in wild type spinal cord. As the antibody used 
in this experiment was proved to be isoform-specific earlier, the false signals are 
likely to be a result of technical artefact. Nevertheless, the negative control omitting 
one primary antibody also gave visible positive signals, especially in the white matter. 
Similar results were observed on mouse brain sections (data not shown).  
To address the specificity of the technique became crucial and further proteins 
were then tested. The three proteins chosen, EF2, PABP and TK1 have not yet been 
reported to interact with eEF1A and thus were intended to be negative technical 
controls for PLA.  However, the three proteins all gave, to different extents, positive 
signals with eEF1A2 (Figure 4.4.E-G). Even though the three proteins have not been 




reported to be interacting with eEF1A2, it is still possible that they are doing so. The 
signals of eEF1A2/PABP are dense and in the cytoplasm of motor neurons (Figure 
4.4 F), which is similar to the signals given by eEF1A2/eEF1Bα (Figure 4.4 B) and 
eEF1A2/eEF1Bδ (Figure 4.4 C), while the signals of eEF1A2/EF2 and eEF1A2/TK1 
are mostly around nuclei and more spreading (compare Figure 4.4 E, G to B, C), with 
only a few signals concentrated on certain nuclei (indicated by white arrows). 
Therefore, it is very likely that most of the red dots are not true PLA signals from the 
cells displayed, but a general background. This caused difficulties in distinguishing 
between true PLA signals and random background signals.  
Different experimental conditions were used to reduce the false signals, 
including different combinations of concentrations of primary antibodies and probes. 
The company (OLink) have also offered technique suggestions, including an 
improved kit, Duolink II Probemaker (explained in section 2.3.7). However, the 
background signals from controls could not be removed without depriving signals on 
other sections at the same time. In a word, in spinal cord and brain sections the 
background signals could hardly be differentiated from true PLA signals. The false 
positive signals made it difficult to draw any conclusion from the results above, or to 
continue the study on spinal cord or brain tissue sections; this led to investigation of 
other possible objects. The other tissues that express eEF1A2 are heart and muscle. 
However, sections of these two tissues are difficult to maintain a native morphology 
for IHC or IF experiments under the experimental conditions in our lab, and give 
very diffuse staining for eEF1A2. Therefore the following PLA experiments were 
performed on cultured cells other than animal tissues. 
 
4.2.2.2 PLA on HeLa cells 
HeLa cells express both isoforms of eEF1A (Kim, Namkung et al. 2009). In 
some reports eEF1BδL was found in HeLa cells (Kaitsuka, Tomizawa et al. 2011), 




but under the cell culture conditions of our lab the strain used in this study expressed 
only shorter eEF1Bδ isoforms (Figure 3.1 in chapter 3). 
As in spinal cord sections, in HeLa cells eEF1A2 and all eEF1B subunits gave 
positive PLA signals (Figure 4.5.C, D and E), but with lower density. Cells with 
eEF1A2 and TK1 antibodies gave neither PLA signals nor dotty background (Figure 
4.5 F), showing that the signals given by eEF1A2/eEF1Bα, eEF1A2/eEF1Bδ and 
eEF1A2/eEF1Bγ are genuine and specific, and that eEF1A2 does co-localise with 
eEF1Bα, eEF1Bδ, and eEF1Bγ in HeLa cells, at least at the resolution that can be 
detected by PLA. 
4.2.2.3 PLA on transfected NIH-3T3 cells. 
In order to further indicate the interactions between eEF1A and eEF1B 
components, PLA of eEF1A1 with eEF1B was examined. However, due to the lack 
of an efficient and specific eEF1A1 antibody for IHC/IF and thus PLA, stable NIH-
3T3 cell lines expressing tagged eEF1A1 or eEF1A2were used instead. 
NIH-3T3 cells express only eEF1A1 and do not express eEF1A2 except in 
certain conditions, for example serum deprivation (Ann, Moutsatsos et al. 1991). V5-
tagged eEF1A1 and eEF1A2 transgenic NIH-3T3 stable cell lines were generated by 
a former member in our lab, Dr Justyna Janikiewicz. NIH-3T3 cells were transfected 
with constructs containing human eEF1A1 or eEF1A2 with V5 tag respectively, and 
were grown in selective cell culture medium containing varying concentrations of 
Geneticin®  (G418) or ZeocinTM. The cell lines with the highest protein level of V5-
tagged eEF1A1 or eEF1A2 were chosen for this study (clones A1 8.6 and A2 9.6 in 
Justyna Janikiewicz’s PhD thesis Figure 3.7). 
Unlike in HeLa cells, TK1/V5 gave positive signals in V5-eEF1A2 transgenic 
3T3 stable cells (data not shown), therefore PLA of TK1 with each of the three 
eEF1B subunit were tested to demonstrate the reliability of the experiments, and all 
turned out to be negative (Figure 4.6 and Figure 4.7 D, F, H).  




In V5-eEF1A1 transgenic NIH-3T3 cells, V5 gave positive PLA signals with 
eEF1B subunits, as eEF1A2 with eEF1B in HeLa cells. Signals of V5/eEF1Bγ 
(Figure 4.6 G) were not as dense as those of V5/eEF1Bα or V5/eEF1Bδ (Figure 4.6 
C and E), but still showed a visible difference from all the negative controls. In V5-
eEF1A2 transgenic NIH-3T3 cells similar results were observed, except the PLA 
signals from V5 with all three subunits appeared weaker than in V5-eEF1A1 
transgenic cells. 
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 Figure 4.4. PLA on mouse spinal cord. A. both primary antibodies omitted as a negative control. B. eEF1A2 and eEF1Bα. C. eEF1A2 and eEF1Bδ. D. eEF1A2 and eEF11Bδ in wasted spinal cord. E. 
eEF1A2 and EF2.  F. eEF1A2 and PABP. G. eEF1A2 and TK1. H.TK1 positive control in HeLa cells. 
Images in the squares are higher magnification of selected areas. Arrows indicate PLA signals around 
nuclei. 









Figure 4.5. PLA on HeLa cells. A. Negative control with both primary antibodies omitted.  B. 
eEF1A2 antibody only. C. PLA of eEF1A2 and eEF1Bα. D. PLA of eEF1A2 and eEF1Bδ. E. PLA 
of eEF1A2 and eEF1Bγ. F. PLA of eEF1A2 and TK1 as negative control. Images in the squares are 
higher magnification of selected areas. 




Figure 4.6. PLA on 1A1 transgenic NIH-3T3 cells. A. Negative control with both primary antibodies 
omitted.  B. V5 antibody only. C. PLA of eEF1Bα and V5. D. PLA of eEF1Bα and TK1. E. PLA of 
eEF1Bδ and V5. F. PLA of eEF1Bδ and TK1. G. PLA of eEF1Bγ and V5. H. PLA of eEF1Bγ and TK1. 
Images in the squares are higher magnification of selected areas. 
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 Figure 4.7. PLA on 1A2 transgenic NIH-3T3 cells. A. Negative control with both primary antibodies omitted.  B. V5 antibody only. C. PLA of eEF1Bα and V5. D. PLA of eEF1Bα and TK1. E. PLA of 
eEF1Bδ and V5. F. PLA of eEF1Bδ and TK1. G. PLA of eEF1Bγ and V5. H. PLA of eEF1Bγ and TK1. 
Images in the squares are higher magnification of selected areas. 
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4.3 Discussion 
As an important part of the cellular machinery that regulates protein translation 
elongation as well as being involved in other cellular functions, the structure of 
eEF1H has been broadly studied. eEF1H is composed of eEF1A and eEF1B, and 
several models have been proposed for relative placement of each component. 
However, as there is much inconsistency among these models, further studies are 
required, especially to take different isoforms of the components into account. 
Besides, while the regions containing sequence differences between eEF1A1 and 
eEF1A2 proteins do not harbour eEF1B binding sites, suggesting the two isoforms 
have similar capability of binding to eEF1B, the results from the Y2H experiments 
that found interactions of eEF1A1/eEF1B but no interactions between eEF1A2 with 
eEF1B suggest otherwise (Mansilla, Friis et al. 2002).  
In IHC and IF experiments on mouse spinal cord eEF1A2 is only observed in 
motor neurons, which is in accord with the known expression pattern of eEF1A2; 
eEF1Bα and eEF1Bδ are both expressed almost ubiquitously, with apparent stronger 
staining in motor neurons, suggesting a higher expression level in these cells. As a 
result eEF1A2 and eEF1B were found co-localized in the cytoplasm of motor 
neurons of mouse spinal cord. Both eEF1A2 and eEF1B were expressed in 
cytoplasm, which is in agreement with their roles as components of protein 
translation machinery and with previous findings. Unexpectedly, it seems some cells 
do not express eEF1Bα (indicated by white arrow in Figure 4.3), but it is yet not 
possible to tell if the absence of eEF1Bα has any specificity for certain type(s) of cell. 
Two colour immunofluoresence with an antibody that is cell type specific may help 
to understand if the expression of eEF1Bα is restricted to certain cells. Moreover, 
since no eEF1Bδ antibody that can distinguish between isoforms is available, it is not 
possible to demonstrate whether different eEF1Bδ isoforms have different 
distributions within the spinal cord, i.e. whether there are exclusive expressions 
among different isoforms, as of eEF1A. 




The relationships between eEF1A2 and eEF1B were then studied using in situ 
PLA technique. PLA has been proved to be an efficient and straightforward method 
to examine endogenous protein-protein interactions in situ, avoiding the possible 
artefacts from experimenting with isolated or exogenous proteins. For example, 
change of physiological condition may cause inactivation of the protein; techniques 
like co-Immunoprecipitation (co-IP) performed with proteins from disrupted cells 
may give false positive results of proteins that actually localize at different 
subcellular compartments; different post-transcriptional modification is also likely to 
happen when a protein is expressed in cells from different species. Since spinal cord 
expresses eEF1A2 and eEF1BδL as well as the ubiquitous isoforms, and the 
antibodies have already been tested on spinal cord by IHC and IF, mouse spinal cord 
sections became the first choice for performing PLA. Unfortunately the PLA 
experiments on mouse spinal cord encountered many problems that it proved 
impossible to solve. Although PLA signals for eEF1A2/eEF1Bα and 
eEF1A2/eEF1Bδ were indeed observed, no ideal biological negative control was 
achieved to validate the results. It was the same with brain tissue sections. In spite of 
the different experimental conditions tried the situation was not improved.  
It was not clear why such false positive signals appeared, and at the time these 
experiments were performed, no publications on the subject of doing PLA on spinal 
cord sections were found. One recent study performing PLA on mouse brain sections 
has observed nonspecific signals that exist in the controls omitting one PLA probe or 
one primary antibody and are consistent among genotypes (wild type and specific 
gene knockout mice), which is similar to the situation of our study. The same study 
also found that nonspecific signals in their study were present in fixed sections but 
absent in fresh frozen sections. It was therefore presumably caused by the deleterious 
effect of aldehydes on DNA that might benefit the binding of oligonucleotides to the 
probes during the PLA reaction (Trifilieff, Rives et al. 2011). This suggestion also 
explains why the negative control omitting both primary antibodies in our study, 
which was not present in the study referenced, did not give positive signals. However, 




PLA on cultured cells fixed using the same fixation method as for spinal cord or 
brain sections did not show nonspecific signals. Hence it is possibly because nerve 
cells are more susceptible to the effect of aldehydes on DNA, and thus showed more 
intervention in the binding of oligonucleotides to PLA probe. 
The same experiments were then carried out on the human HeLa cell line as an 
alternative, which expresses eEF1A2 (Tomlinson, Newbery et al. 2005). As on spinal 
cord sections, PLA experiments on HeLa cells have identified co-localisation, 
consistent with direct interactions of, eEF1A2/eEF1Bα and eEF1A2/eEF1Bδ. In 
addition, eEF1A2/eEF1Bγ, which was not examined in spinal cord sections, was also 
found to co-localise. Compared to the results from spinal cord sections, the PLA 
signals of eEF1A2/eEF1B from HeLa cells have lower density, which could be 
explained by the apparent higher expression of eEF1A2 in spinal cord than in HeLa 
cells. TK1, a protein that has not been reported to interact with eEF1A2, was used as 
a negative control, and no interaction of eEF1A2/TK1 was observed in HeLa cells. 
Therefore these results seemed more reliable than the ones of spinal cord sections.  
The same technique was also used to investigate the interaction between 
eEF1A1 and eEF1B subunits. However, because at the time of this study there was 
no antibody that is eEF1A1 specific and suitable for PLA, the PLA of eEF1A1 with 
eEF1B was carried out on transgenic NIH-3T3 cells instead of HeLa cells. In both 
V5-tagged 1A1-3T3 cells and 1A2-3T3 cells, PLA of V5 and all three eEF1B 
subunits gave positive PLA signals. eEF1A1 has previously been found in various 
researches to be associated with eEF1B subunits (Carvalho, Carvalho et al. 1984; 
Janssen, van Damme et al. 1994). The results in Figure 4.6 confirmed the binding of 
the eEF1A1 to eEF1B complex, in accordance with previous reports. On the other 
hand, as eEF1A2 showed same results in PLA experiments, it indicates that both 
eEF1A isoforms are likely to be associated with eEF1B in a similar way.  
Interestingly, unlike in HeLa cells, transgenic NIH-3T3 cells showed a positive 
signal suggesting a direct physical link between V5-eEF1A and TK1. This difference 




might be the result of the different characters between cell lines; on the other hand, 
the eEF1A1 and eEF1A2 proteins detected in stable NIH-3T3 cells are exogenous, 
and although the V5 tag is only 14 amino acids long, the conformation of tagged 
proteins were probably different from endogenous proteins. The results were hence 
validated by negative controls of PLA of TK1 and each eEF1B subunit.  
It should be kept in mind that neither HeLa nor transgenic NIH-3T3 cells used 
in this study express eEF1BδL. eEF1BδL is tissue-specific and expressed only in 
brain, spinal cord and testis (Kaitsuka, Tomizawa et al. 2011), which is overlapping 
with the tissues that express eEF1A2. Whereas within spinal cord and brain, the 
expression of eEF1A2 is restricted to certain types of cells, it is not clear if eEF1BδL 
has a similar pattern, because eEF1BδL has not been extensively studied yet and no 
eEF1BδL specific antibody is available. As a result, had a cell line that expresses 
eEF1BδL been used and shown PLA signals of eEF1A2/eEF1Bδ, it would have been 
impossible to determine which eEF1Bδ isoform interacts with eEF1A2. 
In both cell lines used in this study, eEF1A2 appeared to be associated with 
eEF1Bα, eEF1Bγ and at least the short isoforms of eEF1Bδ, contrary to what the 
Y2H experiment suggested. Another study of human protein-protein interactions 
based on mass spectrometry has also identified the interactions of eEF1A2/eEF1Bα 
and eEF1A2/eEF1Bδ using eEF1A2 as a bait (Ewing, Chu et al. 2007). One 
explanation for this conflict is that the fusion protein  expressed in yeast cells may 
have failed to keep the native conformation and consequently influenced protein 
interactions. With the same Y2H system eEF1A2 in fusion with GAL4 DNA-binding 
domain was competent in interaction with other eEF1A-binding proteins identified in 
an Y2H screening (Mansilla, Friis et al. 2002; Mansilla, Dominguez et al. 2008), but 
no positive control was included in the original paper, making it hard to judge the 
validity of these conclusions. Assuming the results in the follow-up paper to be valid, 
this has ruled out most potential problems that could cause a false negative result, 
such as non-functional fusion proteins, toxicity, or fail to localise to the yeast nucleus, 




but it is still possible that the fusion protein was modified in a way that masks (part 
of) the binding sites for eEF1B.  
The other major difference between the result in our study and the Y2H 
experiments is that in transgenic NIH-3T3 cells we also detected an interaction 
between V5-tagged eEF1A1 and eEF1Bγ, which was not found in the Y2H 
experiments. This is presumably because that eEF1A and eEF1Bγ are not directly 
binding each other, but form a complex bridged by another eEF1B subunit, as 
suggested in most of the eEF1H structure models proposed so far (reviewed in 
section 1.3.4). In PLA the maximum distance between the two probes that allows 
DNA hybridization and thus PLA signal is around 16nm (Trifilieff, Rives et al. 2011). 
Including the two primary antibodies and the two probes, the distance for two 
proteins to be recognized as being in proximity by PLA is estimated at roughly 30-
50nm, depending on the sizes of the antibodies used (Duolink Brochure; Soderberg, 
Gullberg et al. 2006; Ling, Albuquerque et al. 2010). The question of whether the 
interactions observed in this study are direct or indirect could be further investigated 
by complementary techniques such as co-IP. 
The two isoforms of eEF1A are 92% identical and 98% similar, and showed 
equal activity in vivo and in vitro translation assay, although with different affinities 
to GTP and GDP respectively: eEF1A1 has about equal affinity to GDP and GTP; 
eEF1A2 binds to GDP more strongly than GTP, suggesting eEF1A2 has a greater 
dependence on eEF1B (Kahns, Lund et al. 1998). It is shown herein that both 
eEF1A1 and eEF1A2 associate with eEF1B subunits, in accordance with their 
conventional roles in protein translation elongation. It is not yet clear whether 
eEF1BδL could be included as well and whether eEF1A binds to each eEF1B 
subunit directly. Based on the hypothesis that eEF1A2 interacts with eEF1B, it 
would be of much interest to investigate if eEF1A2 is functionally related to eEF1B 
as eEF1A1 is. For further investigation of the relationships between eEF1A2 and 
eEF1B, RNAi will be used to knock down the two proteins respectively in cultured 
cells. In the meantime, a mouse model, wasted mice, where eEF1A2 is abolished will 




also be used to examine the influence of absence of eEF1A2 on eEF1B. These 
questions will be addressed in detail in the next chapter. 
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Chapter 5 eEF1A2 absence affects eEF1B expression 
5.1 Introduction 
The two isoforms of eEF1A have similar translation activities, but different 
affinities for GTP and GDP. eEF1A1 binds GTP more strongly than GDP while 
eEF1A2 shows the opposite behaviour (Kahns, Lund et al. 1998). In the previous 
chapter it was found that both eEF1A1 and eEF1A2 interact with eEF1B physically 
in cells, which is contrary to the Y2H results (Mansilla, Friis et al. 2002). The aim of 
this chapter is to determine whether they are dependent on each other as well, and the 
experiments were carried out on both animal model and cultured cells. 
The expression patterns of eEF1A isoforms in different mouse tissues have 
been thoroughly studied and found to be mutually exclusive. eEF1A1 is almost 
ubiquitously expressed while eEF1A2 is expressed only in brain, spinal cord, heart 
and muscle. In mouse brain, isoform-specific antibodies picked up eEF1A1 in glial 
cells and eEF1A2 in Purkinje cells. Similarly, in spinal cord eEF1A1 is found in glial 
cells, while eEF1A2 is seen in motor neurones only (Lee, Francoeur et al. 1992; 
Khalyfa, Bourbeau et al. 2001; Newbery, Loh et al. 2007). 
Wasted is a spontaneous recessive mutation that arose in HRS/J mice in The 
Jackson Lab that leads to immuno-deficiency, neural abnormalities and progressive 
muscular wasting (Shultz, Sweet et al. 1982). The mutation is a deletion in the 
promoter and first exon of eEF1A2 (Chambers, Peters et al. 1998). In wild type mice, 
eEF1A1 declines and eEF1A2 is switched on in brain, spinal cord, heart, muscle 
postnatally. By 21 days after birth eEF1A1 is shut down in heart and muscle and 
replaced by eEF1A2. In wasted mice, the reduction of eEF1A1 in brain, spinal cord, 
heart and muscle happens on schedule, regardless of the absence of eEF1A2 in these 
tissues (Khalyfa, Bourbeau et al. 2001), and causes death to the mice by 27 days. In 
this study wasted mice are used as a model for investigation of the possible effect of 
eEF1A2 absence on the expression of eEF1B subunits. 




The effect of eEF1A2 and eEF1B absence was also examined respectively in 
NSC34 cells using RNAi. NSC34 is a hybrid cell line produced by fusion of motor 
neuron enriched, embryonic mouse spinal cord cells with mouse neuroblastoma. 
NSC34 cells have a multipolar neuron-like phenotype and express motor neuron 
properties (Cashman, Durham et al. 1992). Furthermore, NSC34 cells express both 
eEF1A isoforms, as well as the brain specific isoform of eEF1Bδ, eEF1BδL, which 
makes it an ideal cell line for this study.  
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5.2 Result 
5.2.1 Pilot study of eEF1B expression in wild type and wasted mouse tissues 
Ten tissues were taken from 24-day wild type and wasted mice to compare the 
expression of eEF1B subunits at the protein level using Western blotting. The 
experiments were performed in triplicate, i.e. on three wild type and three wasted 
mice. Figure 5.1 A shows the results from one representative group. 
All of the ten tissues tested express eEF1B subunits, and pancreas has the 
highest expression compared to other tissues (Figure 5.1 A). eEF1Bα is expressed in 
all ten tissues tested, although relatively in a lower level in brain, spinal cord, heart, 
lung and muscle. eEF1Bδ shows different variants, with a longer one expressed only 
in brain and spinal cord (about 72kD), in accord with previous findings (described in 
section 1.3.2). Other isoforms are around a similar size, between 32 to 38kD, but 
have different expression patterns (Figure 5.1 B). One of the isoforms, isoform c, is 
common to all tissues (indicated by arrow c). In heart and muscle there is a heavier 
isoform a (indicated by arrow a), while spinal cord and brain have a lighter isoform b 
(indicated by arrow b) although still heavier than isoform c. In kidney, liver, lung, 
pancreas, spleen and thymus, there is the lightest isoform d (indicated by arrow d), 
eEF1Bγ is expressed in a similar level in all the tissues tested, except for muscle, 
where it is weaker, and pancreas, where it is stronger.  
Comparing the western blot results of 24 days old mice, it seems eEF1B levels 
are different between genotypes in some tissues. For example in the tissues from the 
representative group shown in Figure 5.1 A, heart, lung and spleen appear to have 
lower level of eEF1B in wasted than in wild type mice. Yet in other groups of mice 
not all of these tissues show different levels of eEF1B between genotypes (data not 
shown). Data from quantitative analysis of all three groups show no significant 
difference (Figure 5.2), probably due to the high variability between individuals. 
Note that because the shorter isoforms of eEF1Bδ have similar electroporetic 




mobility to each other and thus appear very close in Western blot results, it is hard to 
quantify the bands separately. As a result the quantification of eEF1Bδ refers to the 
value of total eEF1Bδ. More mice of different ages were then examined for a time 
course study, in order to understand if the expression pattern of eEF1B during mouse 


































Figure 5.2. Quantitative analysis of eEF1B subunits in 24-day 
old mice. wt. wild type. wst. wasted. B.Brain. H. Heart. K. 
Kidney. Li. Liver. Lu. Lung. M. Muscle. P. Pancreas. Sc. Spinal 
cord. Sp. Spleen. Th. Thymus. B1 and Sc1. eEF1BδL. B2 and 
Sc2. eEF1Bδ shorter isoforms.  
Figure 5.1. The expression of eEF1B subunits in different tissues from wild 
type (wt) and wasted mice (wst). A. Representative group showing eEF1B 
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5.2.2 Time course of eEF1B expression in wild type and wasted mouse tissues 
In wild type mice, eEF1A2 is expressed mainly in four tissues: spinal cord, 
brain, heart and muscle. In these tissues the increase of eEF1A2 and decrease of 
eEF1A1 happen gradually after birth and by 21 days eEF1A1 is undetectable and 
eEF1A2 takes its place (Khalyfa, Bourbeau et al. 2001). Wasted mice show 
observable abnormalities from 21 days which coincides with the decline of eEF1A1 
in the above tissues, and mice die by 27 days.  
For the study of time course of eEF1B expression in mouse tissues during 
development, the above four tissues taken from 21, 23, 25 and 27 days old wild type 
and wasted mice were examined.  
5.2.2.1 eEF1B expression in mouse spinal cord and brain 
From the western blot results on mouse spinal cord, eEF1Bα is apparently 
weaker in wasted mice of all four ages, while eEF1Bδ expression is more variable. In 
21 day old mice, eEF1BδL seems lower in wasted mice spinal cord but other 
isoforms appear higher in wasted mice. In 23 and 25 day old mice, all eEF1Bδ 
isoforms are lower in wasted than in wild type mice, while in 27 day old (Figure 5.3 
A) and 24 day old (Figure 5.2) mice there is no visible difference of eEF1Bδ 
expression between wild type and wasted mouse spinal cord. The high variability 
between samples is probably because the sections were taken from different 
anatomical levels, which is discussed later in this chapter. 
However, the quantitative data show no statistically significant difference in 
eEF1Bα expression between wild type and wasted mice of all ages. For eEF1Bδ, 
only 23 day old mice show a lower expression of two isoforms than in wild type 
(19±3.4% and 46±11% of wild type respectively) (Figure 5.3 B). Unlike eEF1Bα and 
eEF1Bδ, eEF1Bγ expression in spinal cord is relatively consistent among individuals 
and between genotypes of all ages. 




Brain has the same expression pattern of eEF1A2 as spinal cord. For the 
experiments on brain mice of two different ages were examined, 21 and 27 days old. 
All three eEF1B subunits showed no difference between brain from wild type and 
wasted mice, and quantitation of the data confirmed this (Figure 5.4). 
 
5.2.2.2 eEF1B expression in mouse heart and muscle 
Heart and muscle are the two tissues where only eEF1A2 is expressed instead 
of eEF1A1 after the mice are 21 days old.  
In mouse heart eEF1Bα and eEF1Bδ have a similar pattern according to the 
Western blot results (Figure 5.5 A). In heart from 21 and 23 day old mice the protein 
is at similar level in wild type and wasted mice, but in 25 and 27 day old mice 
appears to be lower in wasted mice than in wild type. Quantitative analysis shows 
that in 27-, but not 25-, day old mice, eEF1Bα is lower in wasted mice than in wild 
type mice (40±3% of wild type), while the two variants of eEF1Bδ are significantly 
lower in wasted mice of 25 (34±0.2% and 63±3% of wild type respectively) and 27 
days old (34±1.6% and 53±1.5% of wild type respectively) as shown in Western blot 
results. eEF1Bγ, however, shows no obvious difference between genotypes 
throughout development.  
The other mouse tissue that expresses only eEF1A2 from 21 days is skeletal 
muscle. In muscle the expression pattern of eEF1B was found to be similar to heart 
(Figure 5.6 A). eEF1Bα and eEF1Bδ are similar in different genotypes of 21 and 23 
day old mice, but are much lower in wasted mice of 25 and 27 days old. eEF1Bγ is 
the same in genotypes of all ages tested. The quantitative analysis in muscle shows 
similar results as in heart, except that in muscle from 25 days old mice the expression 
of eEF1Bα and eEF1Bδ shows no significant difference between genotypes, while in 
27 days old mouse muscle, eEF1Bα is 26±5% and the two eEF1Bδ isoforms are 
26±0.2% and 18±0.6% of wild type mouse muscle respectively (Figure 5.6 B). 




















Figure 5.3. Expression of eEF1B in mouse spinal cord. A. Western blot of eEF1Bα, eEF1Bδ 
and eEF1Bγ in the spinal cord from three wild type (wt) and three wasted (wst) mice of 
different ages. B. Quantitative analysis of Western blot results normalized to GAPDH. For each 
age and genotype group the average of three animals were taken and compared between 
genotypes. The third animal sample of 21-day old wild type mice was excluded due to the lack 


































Figure 5.4. Expression of eEF1B in mouse brain. A. Western blot of eEF1Bα, eEF1Bδ and 
eEF1Bγ in the brain from three wild type (wt) and three wasted (wst) mice of different ages. B. 
Quantitative analysis of Western blot results normalized to GAPDH. For each age and 
genotype group the average of three animals were taken and compared between genotypes. 



















           
Figure 5.5. Expression of eEF1Bα and eEF1Bδ in mouse heart. A.Western blot of eEF1Bα, 
eEF1Bδ and eEF1Bγ in the heart from three wild type (wt) and three wasted (wst) mice at 
different ages. B.Quantitative analysis of Western blot results normalized to GAPDH. For each 
age and genotype group the average of three animals were taken and compared between 



























Figure 5.6. Expression of eEF1Bα and eEF1Bδ in mouse muscle. A. Western blot of 
eEF1Bα, eEF1Bδ and eEF1Bγ in the muscle from three wild type (wt) and three wasted (wst) 
mice at different ages. B. Quantitative analysis of Western blot results normalized to GAPDH. 
For each age and genotype group the average of three animals were taken and compared 
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5.2.2.5 eEF1B decreases at the mRNA level 
eEF1Bα and eEF1Bδ both declined in heart and muscle from wasted mice 
where eEF1A2 is absent. In order to examine if this downregulation happens at the 
protein level only or also at the mRNA level, cDNA from heart tissue of 27 day old 
wild type and wasted mice were collected to investigate the expression of eEF1B 
subunits at the mRNA level using quantitative PCR. 
As shown in Figure 5.7 the mRNA of both eEF1Bα and eEF1Bδ is lower in 
wasted mouse heart than in wild type mouse heart (53% of wild type), suggesting 
that the decrease of eEF1Bα and eEF1Bδ happens at the mRNA level as well as 
protein level. 
eEF1Bγ expression at the mRNA level is similar in wild type and wasted mice, 






5.2.3 eEF1Bδ in HSA-EEF1A2 transgenic mice 
Transgenic wasted mice that express eEF1A2 under the control of the human 
specific actin (HSA) promoter were generated in order to investigate the reasons for 
wasted mice pathology. The transgenic mice, namely HSA-EEF1A2, express 
eEF1A2 only in heart and muscle, although some transgenic wasted mice express 
Figure 5.7. Expression of eEF1B mRNA in 27 days mouse 
heart. Numbers represent the relative value of wst to wt, and 
each value represents the average of three individual animals 
of the same genotype. 




eEF1A2 in stomach and eyes as well, which is possibly caused by random 
integration of the transgene.  
It was found in our lab that expression of eEF1A2 in neuronal and muscle 
tissues corrects the abnormalities of wasted mice, but expression of eEF1A2 in heart 
and muscle alone, as seen in HSA-EEF1A2 transgenic wasted mice, does not, 
indicating that the wasted phenotype is caused by the loss of eEF1A2 in neurons. 
HSA-EEF1A2 transgenic wasted mice differ from the wild type mice in the same 
aspects and with the same ranges of statistic significances as non-transgenic wasted 
mice do. They have similar phenotypes to non-transgenic wasted mice, including 
lower body weight, shorter body length, gait abnormality, tremor and muscle 
pathology. There is no statistical significance in any of the above aspects between 
HSA-EEF1A2 transgenic and non-transgenic wasted mice. As a result, HSA-
EEF1A2 transgenic mice are indistinguishable from non-transgenic wasted mice in 
sensorimotor function tests and body weight and length. The only difference noticed 
is that HSA-EEF1A2 transgenic wasted mice survive for one or two days longer than 
wasted mice according to the result from a relatively small sample number 
(Permphan Dharmasaroja, PhD thesis, 2007). Unlike non-transgenic wasted mice 
where there is no eEF1A2 expression at all, the HSA-EEF1A2 transgenic mice used 
in this study express eEF1A2 in heart and muscle, but no other tissues, and therefore 
could help to answer the question of whether the downregulation of eEF1Bα and 
eEF1Bδ in certain tissues from wasted animals is a direct result of the loss of 
eEF1A2 or whether it is due to other aspects of the wasted phenotype.  
Heart tissue proteins extracted from five HSA-EEF1A2 transgenic wasted mice 
were compared to the proteins of wild type and wasted mice. Although the five 
transgenic mice were at different ages, number 3 was 25 days old, number 4 was 28 
days old, and number 5-7 were 27 days old, they all have a high level of eEF1A2 
expression in heart (Figure 5.8 A 3-7), same as or even stronger than in wild type 
mouse heart (Figure 5.8 A 1), with heart tissue from a wasted mouse used as a 
negative control (Figure 5.8 A 2).  
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The heart from the non-transgenic wasted mouse has a lower eEF1Bδ level 
than wild type, in accordance with the previous observation in section 5.2.2.2, while 
in HSA-EEF1A2 transgenic wasted mice the level of eEF1Bδ is similar to wild type 
(Figure 5.8 B). Interestingly, eEF1Bδ in all five transgenic mice is at a similar level 
















Figure 5.9. Quantification of the 
expression of eEF1A2 and eEF1Bδ 
proteins normalized to GAPDH 
and Tubulin respectively in the 
heart from a wild type mouse (1), a 
wasted mouse (2) and five HSA-
EEF1A2 transgenic wasted mice 
(3-7). 
Figure 5.8. Expression of eEF1A2 (A) and eEF1Bδ (B) 
protein in the heart of HSA-EEF1A2 mice. 1. Wild type 
mouse. 2. Wasted mouse. 3-7. Five transgenic wasted mice. 
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Figure 5.10. Knockdown of eEF1A2 using isoform specific siRNAs. 1. Cells only. 2. 
Mock. 3. Cells treated with non-targeting siRNAs. 4-6. Three individual samples treated 
with siRNAa. 7-9. Three individual samples treated with siRNAb. 
 
5.2.4 RNAi of eEF1A2 and eEF1B subunits in cells 
The effect of eEF1A2 absence on eEF1B in cells was investigated using RNAi. 
eEF1B siRNAs were validated in section 3.2.3.1, and eEF1A2 siRNAs are also 











5.2.4.1Knockdown of eEF1A2 in NSC34 cells  
The expression of eEF1B subunits was examined in eEF1A2 knockdown 
samples.  
Unlike the results in mouse tissues, knockdown of eEF1A2 in NSC34 cells did 
not decrease the level of eEF1Bα (Figure 5.11 A1). In two of the samples of eEF1A2 
knockdown, eEF1Bα protein expression was even higher than controls (Figure 5.11 
A1 8 and 9), which is possibly due to an artefact. These observations were confirmed 
when the expression of eEF1Bα was normalised to a loading control, tubulin (Figure 
5.11 A2). 
eEF1Bδ, on the other hand, showed a lower protein level in samples where 
eEF1A2 was knocked down (Figure 5.11 B1 and B2), indicating that the knockdown 
of eEF1A2 causes downregulation of eEF1Bδ in this cellular context. Interestingly in 
GAPDH  37kD 
eEF1A2  52kD
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the three samples where eEF1A2 siRNA was less efficient (Figure 5.10 A7, 8 and 9), 
the downregulation of eEF1Bδ is less significant than in the other three samples 
(Figure 5.11 B1 7, 8 and 9). In the Western blot result of eEF1BδL expression the 
bands representing controls are not clearly visible; it is therefore not possible to 
quantify eEF1BδL expression. 
 
5.2.4.2 Knockdown of eEF1B in NSC34 cells 
The expression of eEF1A2 was examined in cells where eEF1Bα and eEF1Bδ 
as well as eEF1BδL were knocked down. Surprisingly the three knockdown 
experiments gave different results.  
As shown in Figure 5.12 A1, knockdown of eEF1Bα did not reduce the 
expression of eEF1A2. In fact it appears that eEF1A2 expression was increased when 
eEF1Bα was knocked down (Figure 5.12 A2). Knockdown of eEF1Bδ slightly down 
regulated eEF1A2 expression (Figure 5.12 B1 and B2), while knock down of 
eEF1BδL showed no effect on eEF1A2 expression (Figure 5.12 C1 and C2), 
indicating that the decrease of eEF1A2 in Fig 5.12 A1 was caused by the 
downregulation of the shorter isoforms of eEF1Bδ. 








Figure 5.11. Knockdown of eEF1A2 in NSC34 cells. A1. Expression of 
eEF1Bα. A2. Quantification of eEF1Bα normalized to Tubulin. B1. 
Expression of eEF1Bδ. B2. Quantification of eEF1Bδ normalized to 
Tubulin. 1. Cells only. 2. Mock. 3. Cells treated with non-targeting 
siRNAs. 4-6. Three individual samples treated with eEF1A2 siRNAa. 7-9. 

































Figure 5.12. eEF1A2 expression in NSC34 cells when eEF1Bα (A1 and 
A2), eEF1Bδ (B1 and B2), or eEF1BδL (C1 and C2) was knocked down. 
Quantification of eEF1A2 protein expression normalised to GAPDH. 1. 
Cells only. 2. Mock. 3. Cells treated with non-targeting siRNAs. 4-6. Three 
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5.3 Discussion 
5.3.1 The absence of eEF1A2 in mice 
Following the results achieved in Chapter 4, in this chapter the relationships 
between expression of eEF1A2 and eEF1B subunits were examined in animals and 
cultured cells. 
In mammals eEF1A2 is expressed in a tissue-specific pattern.  It is found to be 
expressed only in brain, spinal cord, heart and skeletal muscle. In these tissues 
eEF1A1 expression declines and eEF1A2 increases after birth, and by the age of 21 
days eEF1A1 is shut down and taken place by eEF1A2 (Lee, Francoeur et al. 1992; 
Khalyfa, Bourbeau et al. 2001). Wasted mice do not express eEF1A2 but the decline 
of eEF1A1 in the above tissues happens on schedule (Khalyfa, Bourbeau et al. 2001). 
As a result, wasted mice show neurologic and immunologic abnormalities (reviewed 
in section 1.5) after 21 days and most of them die by 27 days after birth (Lutsep and 
Rodriguez 1989; Chambers, Peters et al. 1998; Khalyfa, Bourbeau et al. 2001). 
In the ten tissues taken from 24 day old mice, it seems that eEF1B is lower in 
some tissues from wasted mice, but the results are variable. As the decrease of 
eEF1A1 and increase of eEF1A2 level happens gradually after birth, mice of 
different ages were then examined in order to demonstrate whether it is the same in 
mice of other ages. 
Four tissues that express eEF1A2 were chosen for the time course study of 
eEF1B expression: brain, spinal cord, heart and skeletal muscle. The four tissues can 
be divided into two categories: the first one includes brain and spinal cord, which 
express both eEF1A1 and eEF1A2 but mutually exclusively in different cells; the 
second category includes heart and muscle, where only eEF1A2 is expressed instead 
of eEF1A2 after 21 days. Interestingly the time course of eEF1B expression in these 
tissues also shows two different patterns: In brain and spinal cord, the expression of 
eEF1B shows no significant difference between wild type and wasted mice of all 




ages tested, whereas in heart and muscle eEF1Bα and eEF1Bδ are much lower in 
wasted mice than in wild type mice of 25 and 27 years old (summarised in Table 5.1). 
This difference is likely to be caused by the different expression patterns of eEF1A 
in these tissues. 
In mouse heart and muscle eEF1A1 is present throughout embryonic 
development but declines postnatally and becomes undetectable by 21 days, while 
eEF1A2 increases postnatally and takes its place. In wasted mice where eEF1A2 is 
abolished, there is no eEF1A expressed in heart and muscle by 21 days after birth, 
which leads to the absence of protein translation in these tissues. However, since the 
expression level of eEF1B was normalised to a housekeeping protein, it appears that 
the failure of translation is not responsible for the downregulation of eEF1B. In fact 
the expression of eEF1Bγ seems fairly stable among genotypes and throughout 
development, suggesting the downregulation of eEF1Bα and eEF1Bδ is specific and 
not due to global downregulation. Furthermore, HSA-EEF1A2 transgenic wasted 
mouse heart expresses eEF1Bδ at a similar level to wild type, without correcting the 
wasted phenotype and the mice show neuronal and muscular abnormalities as wasted 
mice do. This result suggests that the downregulation of eEF1Bδ in heart of wasted 
mice is not a result of the phenotypic abnormalities seen in wasted mice, but is 
caused specifically by the loss of eEF1A2. 
Interestingly, it seems the level of eEF1Bδ is not in accordance with eEF1A2 
in transgenic mice, showing that although the transgenic eEF1A2 recovers the 
expression of eEF1Bδ, excess eEF1A2 does not lead to over expression of eEF1Bδ. 
The story is different in brain and spinal cord, where both eEF1A1 and 
eEF1A2 are expressed mutually exclusively, with eEF1A1 in glial cells and smaller 
neurons, and eEF1A2 in motor neurons (Khalyfa, Bourbeau et al. 2001; Newbery, 
Loh et al. 2007). So in wasted mice after 21 days, motor neurons have neither form 
of eEF1A, yet in other cells eEF1A1 still exists. As a result, while in heart and 
muscle from wasted mice there is no eEF1A expression, in brain and spinal cord 




from the same groups of animal protein translation is still ongoing in certain cells 
that have eEF1A1, therefore maintaining a relatively stable level of eEF1Bα and 
eEF1Bδ as the GTP exchange factor. In fact, IHC results on wasted spinal cord do 
show a weaker staining of eEF1B in some of the motor neurons (section 3.2.4.1). 
Since the brain and spinal cord extract examined in Western Blotting experiments 
contains protein from all cell types, further quantitative or semi-quantitative 
experiments of eEF1B expression in different cell types are needed to support this 
hypothesis.   
 
Tissue  eEF1Bα  eEF1Bδ  eEF1Bγ 
Spinal cord  Variable  Variable (lower in 23 day old wst)  No difference 
Brain  No difference  No difference  No difference 
Heart  Lower in 27 day old wst  Lower in 25 and 27 day old wst  No difference 
Muscle  Lower in 27 day old wst  Lower in 27 day old wst  No difference 
 
There are a few more points worth noting regarding eEF1B expression in the 
above four tissues. Firstly, it seems the changes of these two subunits are following 
slightly different timelines: in heart of all the ages examined the expression of 
eEF1Bα shows differences between genotype only in 27 days old mice, while for 
eEF1Bδ the decline starts from the age of 25 days. It should be pointed out that in 
muscle from 25 days old mice eEF1Bδ shows no significant difference in the 
quantitative data, which is however more likely to be a result of the variations of 
eEF1Bδ expression between individuals in wild type mice as shown in Figure 5.6 A. 
Therefore the possibility of eEF1Bδ also being lower in 25 years old wasted mouse 
muscle should not be ruled out. Apparently a larger sample size is needed before any 
conclusion can be drawn. If eEF1Bα and eEF1Bδ indeed show different timecourses 
in muscle and heart from wasted mice, then it probably means that they are related to 
eEF1A in different ways, and are affected by time differently. 
Table 5.1. Comparisons of eEF1B expression in four tissues from wild type and wasted mice. 




Secondly, in spinal cord although the overall level of eEF1B shows no 
significant difference between wild type and wasted mice, the Western blot result is 
actually highly variable among individuals. The motor neuron pathology in spinal 
cord of wasted mice varies in different parts, happening first at the cervical level and 
then progresses caudally, suggesting that eEF1A1 possibly decreases in spinal cord 
in a cascade. Haematoxylin and eosin staining showed vacuolar degeneration in 
anterior horn cells at the cervical level but not at the lumbar level of the spinal cord 
from mice over 24 days (Newbery, Gillingwater et al. 2005).  
The motor neurone pathology in wasted mouse spinal cord has added 
complicity to this study. The spines examined in this study were more or less 
destroyed when the mice were culled, especially the cervical spine which was easily 
broken. Although when the spinal cords were taken, they were taken as complete as 
possible to reduce individual differences, it was still very difficult to make sure that 
all the samples represented the same level of the spinal cord. Therefore as the 
expression of eEF1A in spinal cord varies in different samples, the expression of 
eEF1B may consequently vary between individuals. When the average of eEF1B 
expression was quantified, none of the ages examined showed statistically significant 
difference between wild type and wasted mice. Unlike eEF1Bα and eEF1Bδ, 
although showing no significant difference between wild type and wasted mice as 
well, the result for eEF1Bγ from spinal cord of different ages is consistent. 
In all tissues tested, eEF1Bγ remains at a similar level between genotype 
despite the age of the mice. Although Western blotting of eEF1Bγ in muscle from 27 
days old wasted mice shows a weaker band than in wild type mice, the band of 
GAPDH which is used as a loading control is also quite faint, probably due to muscle 
atrophy. When normalised to loading control, the expression of eEF1Bγ in wild type 
and wasted mice shows no difference. As a subunit of eEF1B, the function of 
eEF1Bγ in translation is yet not clear. It does not have GTP exchange activity and is 
considered as a structural subunit for eEF1B that directs the complex to certain 
cellular components (Janssen and Moller 1988; Le Sourd, Boulben et al. 2006). 




eEF1Bγ usually associates tightly with eEF1Bα (Motoyoshi and Iwasaki 1977; Bec, 
Kerjan et al. 1994), so it is surprising that when eEF1Bα decreases eEF1Bγ seems 
unaffected. The reason for it is unclear, perhaps related to its non canonical 
function(s), such as in RNA metabolism (Al-Maghrebi, Brule et al. 2002; Shi, Di 
Giammartino et al. 2009). 
Quantatitive PCR showed that the decline of eEF1Bα and eEF1Bδ in wasted 
mice happens not only at the protein but also at the mRNA level. However, 
compared to the differences of eEF1Bα and eEF1Bδ protein levels between wild type 
and wasted mouse heart, the differences observed at mRNA level appear less 
significant. Therefore apart from regulation at the mRNA level, the downregulation 
of eEF1B could also involve post-transcriptional regulation, and/or proteasomal 
degradation caused by the loss of one subunit of the complex, which can be 
determined by treating the cells with a proteasome inhibitor. Unfortunately the 
eEF1Bδ primers used amplify both shorter variants so it is not clear whether the two 
variants also show different mRNA levels. Besides the Real Time PCR result of 
muscle cDNA was too variable (data not shown) to compare the expression levels, 
hence only the results in heart were analysed. 
 
5.3.2 The absence of eEF1A2 in cells 
RNAi experiments (results summarized in Table 5.2) in NSC34 cells revealed 
that when eEF1A2 is knocked down, eEF1Bα stays at a similar level, which is 
apparently contradictory to the results in wasted mice where the loss of eEF1A2 
causes decrease of eEF1Bα. Nevertheless, other research on MCF-7 cells found that 
eEF1A1 and eEF1Bα siRNAs did not decrease each other’s levels (Byun, Han et al. 
2009). The MCF-7 cells in this research were harvested 6 days after RNAi, and no 
other time intervals were investigated, so it is yet unknown whether this result 
applies to a shorter time interval, for example, 72 hours after transfection as in our 
study.  





Protein  eEF1A2 siRNA  eEF1Bα siRNA  eEF1Bδ siRNA  eEF1BδL siRNA 
eEF1A2  ‐  Increase  Decrease  No change 
eEF1Bα  No change  ‐  ‐  ‐ 
eEF1Bδ  Decrease  ‐  ‐  ‐ 
 
One possible explanation for the unchanged eEF1Bα expression after eEF1A2 
knockdown is that MCF-7 cells express both eEF1A1 and eEF1A2 (Amiri, Noei et al. 
2007), and so do NSC34 cells (data not shown), which means when either eEF1A 
isoform is knocked down, the other isoform is still present, perhaps maintaining a 
certain level of translation elongation. Consequently the expression of eEF1Bα is not 
affected significantly, at least in the short term. More information should be achieved 
by knocking down both eEF1A isoforms using combined siRNAs. However, since 
eEF1A is crucial for cell growth, knockdown of both eEF1A isoforms is lethal, 
making it very difficult to optimize the knockdown conditions to carry out further 
investigations.  
Unexpectedly, when eEF1Bα was knocked down, the level of eEF1A2 was 
elevated slightly. It has been found that overexpression of eEF1A1 in a eEF1Bα-
deficient yeast strain overcomes the lethal phenotype without correcting the growth 
defect (Ozturk and Kinzy 2008). In cells with eEF1Bα knockdown, the expression of 
eEF1A1 has not yet been examined, but it is possible that eEF1A2 has similar 
behaviour to eEF1A1 to complement the loss of eEF1Bα. In this case, perhaps the 
cells attempt to correct the result of the loss of eEF1Bα, presumably temporarily, by 
over expressing eEF1A2.  
On the other hand, when eEF1A2 was knocked down, eEF1Bδ decreased to a 
certain extent, and vice versa. The observation that the expression of eEF1A2 is 
regulated in different ways in the cases of eEF1Bα and eEF1Bδ knockdown indicates 
Table 5.2. Expression of eEF1A2 and eEF1B in NSC34 cells treated with siRNAs. 




that eEF1Bα and eEF1Bδ may have different physiological functions even though 
they have similar C-terminal sequences and GDP exchange activity. This was 
demonstrated earlier in a study with eEF1Bα-deficient yeast which found that human 
eEF1Bδ failed to complement the  conditional growth defects despite the fact that it 
interacts with yeast eEF1A, as does eEF1Bα (Carr-Schmid, Valente et al. 1999). 
eEF1Bα and eEF1Bδ bind to eEF1A through different sites, and the binding of 
eEF1A to eEF1Bα, but not eEF1Bδ, causes masking of the CKII phosphorylation site 
(Sheu and Traugh 1997). It is unclear whether the CKII phosphorylation could affect 
the functions of eEF1Bα and eEF1Bδ, or whether the N-terminus difference is also 
involved, though it is the C-terminus that is considered to interact with eEF1A (van 
Damme, Amons et al. 1990).  
eEF1Bα was not affected by the knockdown of eEF1A2. Whilst eEF1Bδ 
decreased in the cells where eEF1A2 was knocked down, the decline of eEF1Bδ 
appeared less significant than in wasted mice. One possible reason is, as stated earlier 
in this section, the fact that wasted mice have no eEF1A2 and the expression of 
eEF1A1 also decreases, but the cells with eEF1A2 knockdown still have eEF1A1 
and a low level of eEF1A2. The other possibility is the different times when the 
samples were collected. In fact, the expression of eEF1Bδ in mice did not show a 
difference between wild type and wasted mice until the age of 25 days, about 4 days 
after the absence of total eEF1A started, while the RNAi samples were collected 72 
hours after transfection. Although mouse tissue and cultured cells cannot be 
compared directly, it is still possible that the expression of eEF1B changes with time. 
Hence it would be of much interest to investigate longer time intervals after RNAi, 
and/or to knock down both eEF1A subunits.  
NSC34 cells also express eEF1BδL, which seems not to be affected by changes 
in eEF1A2 since it shows no change in wasted mice or in cells where eEF1A2 was 
knocked down, and vice versa, indicating that eEF1BδL, although has a tissue-
specific expression pattern that is similar to eEF1A2’s, does not affect the expression 




of eEF1A2. Clearly a eEF1BδL specific antibody will be helpful to demonstrate 
whether it is related to eEF1A2 physically or not. 
Putting together the above results suggest that eEF1A2 and eEF1B do not only 
physically interact, but also have a certain dependence on each other, and that the 
two GEF subunits of eEF1B may have different physiological functions. For future 
studies more mice should be examined and spinal cord sections need to be processed 
with particular caution so that different anatomical levels of spinal cord can be 
investigated for the time course study. Knockdown of combination of eEF1A1 and 
eEF1A2 siRNAs should be attempted under varying experimental conditions to 
further establish the effect of eEF1A loss on eEF1B. eEF1A1 should also be 
examined in cells with eEF1B knockdown to understand whether the two isoforms 
respond in different ways to loss of eEF1B. 
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Chapter 6 General Discussion  
6.1 Summary 
eEF1B is one of the proteins that is believed to have additional functions other 
than their canonical roles (reviewed in Sasikumar, Perez et al. 2012). In this thesis 
the involvement of eEF1B in cancer and MND, as well as the relationships between 
eEF1B subunits and eEF1A were studied. 
The cell lines derived from different cancers showed an altered expression 
pattern of eEF1B subunits compared to untransformed cell lines. However, when the 
expression of eEF1B protein was examined in tissues, no significant difference was 
observed between breast cancer tissues and corresponding normal tissues, indicating 
that the previous reports of an upregulated eEF1B mRNA in breast cancer tissues 
may not necessarily reflect the expression pattern of eEF1B protein. 
A couple of reports suggest that eEF1B subunits may play a role in MND 
(Bakay, Wang et al. 2006; Wain, Pedroso et al. 2009). The results in this thesis 
showed that eEF1Bδ had a different expression pattern in the spinal cord from MND 
patients compared to the controls. Although further evidence is needed, it seems 
likely that eEF1Bδ is involved in the reactive gliosis that happens in response to CNS 
injury or diseases. Another proportion of the MND cases showed a lower expression 
of eEF1Bδ in motor neurons, the reason for which is yet to be elucidated. Unlike the 
observation in wasted mice, in the MND cases eEF1A2 seems unlikely to be the 
direct reason for the downregulation of eEF1Bδ, since the motor neurons with a 
lower expression of eEF1Bδ in MND patients did not always show a lower level of 
eEF1A2 compared to the controls, suggesting the possibility of other pathways. 
The other aspect of this thesis is to investigate the relationship between eEF1B 
and eEF1A. Previous studies of the structure of eEF1H did not take eEF1A2 into 
account, except one Y2H experiment which identified no interaction between 




eEF1A2 and any of the eEF1B subunits, which is very surprising because eEF1A2 in 
fact is likely to be more dependent on a GEF than eEF1A1 since it showed more 
affinity to GDP than GTP (Kahns, Lund et al. 1998). It is important to determine 
whether eEF1A2 uses eEF1B as its GEF or whether there exist other proteins that 
function as a GEF for eEF1A2. Using the PLA technique both eEF1A1 and eEF1A2 
were found to be associated with eEF1B subunits as a complex. Furthermore, 
experiments on wasted mice and in cells using RNAi showed that eEF1A2 and 
eEF1B are not only physically associated, but also have a certain dependence on 
each other, which supports the possibility that eEF1A2 does use eEF1B as its GEF. 
Due to the lack of isoform specific antibody, it is yet to know which eEF1Bδ isoform 
is responsible for the interaction observed between eEF1Bδ and eEF1A, and whether 
both eEF1A1 and eEF1A2 interact with the same eEF1Bδ isoform(s). 
Interestingly, the results of eEF1B expression in cells and tissues showed an 
unbalanced expression of the three subunits. In the breast cancer cell lines and spinal 
cord sections from MND patients examined, the expression of eEF1Bα and eEF1Bδ 
were not always coordinate. The cell lines that showed an altered expression pattern 
of eEF1Bα did not necessarily show a similar change of eEF1Bδ. Similarly, in 
wasted mouse spinal cord sections, the two proteins showed different expression 
patterns especially in motor neurons. The difference is more significant in the spinal 
cord sections from MND patients, as in some of the MND cases where eEF1Bδ was 
upregulated in glial cells the expression of eEF1Bα showed no apparent difference 
from controls. Moreover, the RNAi experiments in cultured cells also revealed that 
the knockdown of eEF1A2 has different effects on eEF1Bα and eEF1Bδ expression, 
and vice versa. Although the three eEF1B subunits are considered to function as a 
complex in protein translation, the observations above indicate that they are very 
likely to be regulated as individual proteins rather than an integrate complex, which 
supports the possibility of different physiological functions of eEF1Bα and eEF1Bδ, 
and could explain in part the significance of the existence of two GEFs that could not 
supplement nucleotide exchange deficient yeast. 
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6.2 Future studies 
6.2.1 eEF1B subunits expression 
As seen in the Western blot results of cell lines and mouse tissues, eEF1Bδ 
exists as different variants, and the expression of some of the variants showed a 
tissue specific pattern. These variants should be further examined at the mRNA level 
to investigate the different eEF1Bδ transcripts. Antibodies against each eEF1Bδ 
isoform should be produced to detect the sub-cellular localisation and possible cell 
type specificity of each isoform. Since the two isoforms of eEF1A have different 
expression patterns through development, it would be interesting to examine whether 
eEF1Bδ isoforms also show specific expression patterns in different developmental 
stages and different tissues of mice. 
Current studies showed certain inconsistencies regarding the effect of the loss 
of eEF1B subunits on cell viability. In this thesis an MTT essay did not detect any 
viability change in NSC34 cells 72 hours after eEF1B knockdown, which needs to be 
validated using other different methods. Other aspects of the effects of eEF1B 
knockdown on cultured cells should also be examined, including morphology, cell 
cycle and apoptosis, in order to fully understand the functions of eEF1B subunits in 
different cellular activities. Protein overexpression experiment should be used as a 
complementary approach to attempt to rescue the possible phenotype caused by the 
knockdown of eEF1B subunits.  
 
6.2.2 The involvement of eEF1B in cancer and MND 
More transformed cell lines should be examined for the expression of eEF1B 
subunits, and corresponding control cell lines would be helpful to compare the 
expression levels of eEF1B subunits. The expression of eEF1B subunits should be 
examined at both protein and mRNA levels to investigate whether the lower bands 




for eEF1Bα and eEF1Bδ observed in this thesis are caused by alternative splicing or 
merely products of protein degradation, and whether there is a change of expression 
levels in transformed cells. On the other hand, protein overexpression experiments 
coupled with transformation assays such as soft agar assay could be performed in 
untransformed cell lines to examine whether the overexpression of eEF1B subunits is 
able to cause transformation in cultured cells, in order to further understand the 
tumourigenesis potential of eEF1B subunits. 
In the breast cancer tissues investigated in this thesis, the expression of 
eEF1Bα and eEF1Bδ proteins in cancer tissues showed no significant difference 
from that in corresponding control tissues. A larger sample size of cancer specimens 
originating from different tissues, as well as suitable controls of corresponding 
normal tissues would be helpful to understand whether the upregulation of eEF1B 
subunits is common in different cancers. Furthermore, the expression levels of 
eEF1B mRNA in cancer tissues can be also examined using microarray and real-time 
quantitative PCR. 
For the study of eEF1B expression in MND, more specimens would be used 
and all the three subunits would be examined in the spinal cord from MND patients 
and the controls, for both the expression level and the distribution of eEF1B in 
different cell types of spinal cord. A relatively larger sample size and detailed 
pathological information would be necessary to demonstrate whether there is any 
correlation between the expression patterns of eEF1B and the pathological 
background as well as the age and sex of the patients.  
Nevertheless, the preliminary data in this thesis indicate a possible involvement 
of eEF1Bδ in neuronal diseases, which is worth further investigation and could be 
studied in two areas. Firstly, immunofluorescence experiments staining the spinal 
cord sections from MND patients with both eEF1Bδ and a glial marker such as 
GFAP and CD68 would be very helpful to demonstrate whether the increase of 
eEF1Bδ expression indeed happened in activated astrocytes and/or microglia to 




examine whether eEF1Bδ showed potential relevance to reactive gliosis. 
Furthermore, the previous report of the involvement of EEF1D gene in a CNV region 
associated with ALS (Wain, Pedroso et al. 2009) also needs further verification. The 
copy number of EEF1D gene in ALS cases can be determined by Real Time PCR; 
genomic DNA sequencing can be performed to identify potential gene mutation(s) in 
the EEF1D gene in ALS cases. 
The other aspect is related to the isoforms of eEF1Bδ. Since the longest 
isoform, eEF1BδL, is tissue specific, and has been found only in brain, spinal cord 
and testis, it is of great interest to determine whether it is this isoform that is involved 
in MND. If this is confirmed, the next step is to investigate whether the loss of 
eEF1BδL in neurons causes any phenotype. This can be approached in cultured 
neuronal cells using siRNAs targeting different eEF1Bδ isoforms, as well as mouse 
strains with deletion of a specific isoform.  
Knockout mice produced by inactivating a specific eEF1B subunit could also 
be used to investigate the loss of each eEF1B subunit in animals to extend the studies 
proposed in section 6.2.1. Conditional knockout mice with deletion of each eEF1B 
subunit in a tissue specific manner would be helpful to interpret the effect of eEF1B 
loss more specifically, especially if the deletion of any eEF1B subunit leads to 
embryonic lethality. For example, the inactivation of eEF1B subunits in brain and 
spinal cord can be used to investigate the loss of eEF1B in CNS and to understand its 
potential roles in neuronal disease. 
 
6.2.3 The relationship between eEF1B and eEF1A 
PLA experiments in this study have detected a physical interaction between 
eEF1B subunits and both eEF1A isoforms. Since the PLA with eEF1A1 was 
performed in stable cell lines, in the future study if a eEF1A1 antibody for PLA is 
available, the interaction of eEF1B and the endogenous eEF1A1 should be examined. 




The physical interaction between eEF1B and eEF1A should be further confirmed 
using techniques such as coIP. 
The expression of eEF1B in different tissues from wild type and wasted mice 
has established a certain expression pattern of eEF1B in the absence of eEF1A, but 
the expression of eEF1B in spinal cord needs more analysis. In the future study the 
spinal cord sections need to be processed with particular caution so that different 
anatomical levels of spinal cord can be investigated for the time course study and to 
determine whether there is any correlation between eEF1B expression change and 
the anatomical level. In addition, the Western blot experiments should be combined 
with IHC to examine whether the downregulation of protein expression happens in a 
cell type specific manner. 
From the results of wasted mouse tissues and the RNAi experiments, it seems 
that eEF1Bα and eEF1Bδ showed different dependencies on the two eEF1A isoforms. 
In order to further establish the relationships between eEF1B subunits and eEF1A, 
combinations of eEF1A1 and eEF1A2 siRNAs should be used under varying 
experimental conditions to knockdown both eEF1A isoforms at the same time, and 
cell lines expressing only eEF1A1 should be also examined for eEF1A or eEF1B 
knockdown. These experiments would be helpful to answer the question of whether 
the expression of eEF1Bα and eEF1Bδ is dependent on the existence of a specific 
eEF1A isoform or not. 
The details of how the two GEF and the two eEF1A isoforms associate are not 
clear, yet they did show dependence on each other although to different extents. The 
next step is to determine whether this dependence is functional. Protein synthesis 
assay should be combined with RNAi experiments to investigate whether the loss of 
each subunit or isoform affects the function of others in protein synthesis. 
 
 




6.2.4 The tissue specific isoform of eEF1Bδ 
So far little is known about eEF1BδL, but it is obviously of great interest to 
understand the significance of a tissue specific isoform of eEF1Bδ. As mentioned 
earlier, a eEF1BδL specific antibody would be helpful for further investigations. 
Since there is no commercial eEF1BδL antibody available at the moment, it would 
be necessary to generate a eEF1BδL specific antibody that can be used to investigate 
the whether eEF1BδL is specifically expressed in certain cell types, and whether it 
coexists with eEF1A2 in brain and spinal cord. 
eEF1BδL has an expression pattern that overlaps with that of eEF1A2, which 
leads to a hypothesis that eEF1BδL might be the GEF specifically for eEF1A2. The 
results in this thesis showed that the expression of eEF1BδL and eEF1A2 is not 
necessarily dependent on each other, but it does not exclude the possibility of 
eEF1BδL and eEF1A2 do form a complex in protein translation or that they are 
functionally related, similar to the relationship between eEF1Bγ and eEF1A2. A PLA 
experiment of eEF1A2 and eEF1BδL would be helpful to determine whether 
eEF1BδL is included in eEF1H complex to function in protein translation elongation.  
The potential involvement of eEF1BδL in the heat shock response by inducing 
the expression of HSE-containing genes in cooperation with HSF1 is also worth 
further investigation. Because there is some inconsistency between my results and  
the report of eEF1BδL in the heat shock response, different cell lines should be 
examined in further studies to establish the expression profile of eEF1BδL in cells, 
and the heat shock dependent alternative splicing of eEF1BδL needs to be confirmed 
at both protein and mRNA levels. 
Once the involvement of eEF1BδL in heat shock response is established, the 
next question would be whether it is related to the role of eEF1A as one of the co-
activators for HSF1 in response to heat shock, which, if eEF1BδL is not exclusively 
expressed in motor neurons, could be addressed by a series of knockdown 




experiment followed by heat shock in cultured cells. Since cultured cells expressing 
eEF1BδL usually express both eEF1A1 and eEF1A2, it is worth performing the 
above knockdown experiments both in cells with endogenous eEF1δL and in cells 
that do not express eEF1A2 but are transfected with exogenous eEF1BδL, even 
though eEF1A2 is likely not able to complement the loss of eEF1A1 in heat shock.
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6.3 Conclusion 
The data presented in this thesis demonstrated the involvement of eEF1B in 
diseases and its relationship with eEF1A in vivo and further supports the theory that 
the eEF1B subunits can be regulated separately from the complex, providing insight 
into the non-canonical functions of eEF1B subunits and the composition of the 
eEF1H complex. Further studies are needed to investigate of the roles of each eEF1B 
subunit other than in protein translation, such as tumourigenesis, motor neuron 
diseases, cell cycle regulation and stress response, and the underlying mechanisms, 
as well as to understand in detail the structure of eEF1H and the significance of 
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Appendix 3. Comparision of eEF1A2 (Left panel) and eEF1D (Right panel) expression in spinal cord 
from control (B and M) and MND cases (A5, E1, F2 and G1). Scale bar, 200µm. 
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